



## PREHOSPITAL TREATMENT – 100.1

### Principle

- The objective of prehospital treatment is to provide timely, equitable, high-quality, and patient-centered care.

### Standards

- All treatments shall be administered per protocol unless the patient declines, there is a contraindication, such as an allergy, or a Base Hospital Physician Order to withhold a required treatment.
- When clinically indicated, more than one protocol may be applied for patient treatment.
- All protocol treatments may be performed by the Emergency Medical Technician (EMT), Advanced Emergency Medical Technician (AEMT), and/or Paramedic via standing orders except for those stating Base Hospital Order (BHO) or Base Hospital Physician Order (BHPO). Standing orders may be continued after Base Hospital contact unless the Base Hospital directs otherwise.
- Mobile Intensive Care Nurses (MICNs) may relay BHPOs.
- These protocol standards do not apply when a physician on scene assumes responsibility for patient care (see S-403 Physician on Scene).
- Base Hospital Physician<sup>1</sup> consultation is encouraged for unclear or complex situations.

#### Base Hospital Physicians are authorized to:

- Order additional doses or boluses of a protocolized treatment
- Order the withholding of a protocolized treatment

#### Base Hospital Physicians are not authorized to:

- Order medications, routes, or procedures that are outside EMT, AEMT, or Paramedic scopes of practice<sup>2</sup>
- Modify Local Optional Scope of Practice (LOSOP) protocols
- Order treatments specifically prohibited by local CoSD EMS protocols

#### Under extraordinary circumstances, Base Hospital Physicians may order an Emergency Protocol Exception (EPE) when the following conditions are met:

- Immediate/imminent risk of serious morbidity or mortality
- S-104 or P-115 do not explicitly prohibit use<sup>3</sup>
- Complies with the above criteria for non-authorized orders

The Base Hospital shall report every EPE to CoSD EMS as an “unusual event” within 24 hours

<sup>1</sup> Refer to S-403 Physician on Scene when a physician on scene assumes patient care

<sup>2</sup> EMS clinicians are only permitted to follow orders within their respective local scopes of practice (B-450, B-451, P-401)

<sup>3</sup> Per P-115, EPEs are not authorized for administration of ketamine in dissociative doses or naloxone in cardiac arrest

## BLS/ALS TRANSPORT CRITERIA – 100.2

### Principle

- All patients should receive the most suitable level of transport to optimize clinical outcomes, efficient use of resources, and overall patient care.

### Standards

- Patients meeting the following criteria shall be transported by ALS\*

#### Decompensating Patient

- Provider impression of extremis, including new onset of altered mental status, poor appearance, airway issues, severe respiratory distress/failure, signs and symptoms of shock/poor perfusion, or imminent cardiac respiratory arrest

#### Airway

- Current or anticipated need for airway management

#### Breathing

- Respiratory failure or distress
- Hypoxia (SpO<sub>2</sub> <94%) despite NRB or PPV (including CPAP)

#### Circulation

- Cardiac chest pain or anginal equivalent
- ECG with ischemia or infarct
- ECG with new or concerning dysrhythmia
- Current or anticipated need for IV fluids, vasopressors, or other IV medication
- Unstable bradycardia/tachycardia
- Hypotension

#### Disability


- Acute change in mental status (GCS <13)
- New neurologic deficit (e.g., positive BE-FAST)
- Seizure not returned to baseline or multiple seizures
- Syncope
- Acute agitation
- Severe intoxication or overdose


#### Miscellaneous

- Meets T-460A criteria (including special considerations designated for transport to a trauma center)
- ALS medication administered (except single therapeutic treatment of naloxone, ondansetron, glucagon, dextrose, or acetaminophen and are not anticipated to require repeat doses)
- Hypoglycemia with persistent altered mental status
- Hyperglycemia with persistent altered mental status
- Pediatric patients with a high-risk complaint (e.g., BRUE) or complex medical history
- EMT provider has a clinical concern
- ALS procedure performed (excluding IV placement or 12-lead ECG interpretation)

### \*Exceptions

- BLS transport may be considered under the following conditions:
  - MCI/Annex D activation
  - ALS resources not available within a reasonable timeframe
  - Hospital-to-hospital interfacility transfers meeting criteria in Policy B-450 EMT Scope of Practice and Protocol S-135 Existing Devices and Medications



 <b>COUNTY OF SAN DIEGO</b> EMERGENCY MEDICAL SERVICES	TREATMENT PROTOCOL		<b>S-101</b>
	<b>GLOSSARY OF TERMS</b>		
	Date: 7/1/2023		Page 1 of 2

**BE-FAST** - Prehospital Stroke Screening Scale in assessment of possible TIA or stroke patients and **FAST-ED**, Prehospital Stroke Severity Scale, for patients with a positive BE-FAST.

**B** = Balance: Unsteadiness, ataxia  
**E** = Eyes: Blurred/double or loss of vision  
**F** = Face: Unilateral face droop  
**A** = Arms and/or legs: Unilateral weakness exhibited by a drift or drop  
**S** = Speech: Slurred, inability to find words, absent  
**T** = Time: Accurate last known well time

**F** = Facial Palsy  
**A** = Arm Weakness  
**S** = Speech Changes  
**T** = Time  
**E** = Eye Deviation  
**D** = Denial/Neglect

**Brief, Resolved, Unexplained Event (BRUE):** An episode involving an infant younger than 12 months where an observer reports a sudden, brief, yet resolved episode of one or more of the following:

- 1) Absent, decreased, or irregular breathing
- 2) Color change (cyanosis or pallor)
- 3) Marked change in muscle tone (hypertonia or hypotonia)
- 4) Altered level of responsiveness

**Definitive Therapy:** Immediate or anticipated immediate need for administration of a fluid bolus or medications.

**End-Tidal CO<sub>2</sub> (EtCO<sub>2</sub>) (quantitative capnography):** Quantitative capnometer to continuously monitor end-tidal CO<sub>2</sub> is mandatory for use in the intubated patient. See Skills List (S-104) for exceptions.

**LEADSD:** Acronym for the steps to be performed in the assessment and documentation of endotracheal intubation attempts:

1. Lung Sounds
2. End-Tidal CO<sub>2</sub> Detection Device
3. Absence of Abdominal Sounds
4. Depth
5. Size
6. Documentation

**Nebulizer:** O<sub>2</sub>-powered delivery system for administration of normal saline or medications.

**Opioid:** Any derivative, natural or synthetic, of opium, morphine or any substance that has effects on opioid receptors (e.g., analgesia, somnolence, respiratory depression).

## San Diego County Emergency Medical Services Office

### Policy / Procedure / Protocol

**Opioid-Dependent Pain Management Patient:** An individual who is taking prescribed opioids for chronic pain management, particularly those with opioid infusion devices.

**Opioid Overdose (Symptomatic):** Decreased level of consciousness and/or respiratory depression (e.g., respiratory rate of  $<12$  or  $\text{EtCO}_2 \geq 40$  mmHg).

**Pediatric Patient:** Children known or appearing to be 14 years or younger.  
A pediatric trauma patient is determined by age, regardless of weight.

**Neonate:** From birth to 30 days.

**Infant:** One month to one year.

### Perilaryngeal Airway Adjunct (PAA) Options

1. **Supraglottic airway (SGA):** The “i-gel” is the only such airway approved for prehospital use in San Diego County.
2. **Retroglottic airway:** The “King Airway” is the only such airway approved for prehospital use in San Diego County.

### Unstable

A patient who meets the following criteria:

1. 15 years or older (known or apparent age)  
SBP  $<90$  mmHg and exhibiting any of the following signs/symptoms of inadequate perfusion, e.g.,
  - Altered mental status (decreased LOC, confusion, agitation)
  - Pallor
  - Diaphoresis
  - Significant chest pain of suspected cardiac origin
  - Severe dyspnea
2. 14 years or younger (known or apparent age)  
Exhibiting any of the following signs/symptoms of inadequate perfusion, e.g.,
  - Altered mental status (decreased LOC, confusion, agitation)
  - Pallor, mottling, or cyanosis
  - Diaphoresis
  - Difference in peripheral vs. central pulses
  - Delayed capillary refill
  - Hypotension by age
    - $<1$  month: SBP  $<60$  mmHg
    - 1 month – 1 year: SBP  $<70$  mmHg
    - 1 year – 10 years: SBP  $<70\text{mm Hg} + (2 \times \text{age in years})$
    - $\geq 10$  years: SBP  $<90$  mmHg



**ABBREVIATION LIST**

Date: 7/1/2025

Page 1 of 3

AAA	Abdominal Aortic Aneurysm
AED	Automated External Defibrillator
AEMT	Advanced Emergency Medical Technician
AHA	American Heart Association
AICD	Automatic Implanted Cardiac Defibrillator
ALS	Advanced Life Support
AV	Arteriovenous (Fistula)
BEF	Basic Emergency Facility
BH	Base Hospital
BHO	Base Hospital Order
BHPO	Base Hospital Physician Order
BLS	Basic Life Support
BP	Blood Pressure
BPM	Beats Per Minute
BRUE	Brief, Resolved, Unexplained Event
BS	Blood Sugar (Blood Glucose)
BSA	Body Surface Area
BVM	Bag-Valve-Mask
CaCl <sub>2</sub>	Calcium Chloride
C/C	Chief Complaint
CHF	Congestive Heart Failure
CNS	Central Nervous System
CO	Carbon Monoxide
CO <sub>2</sub>	Carbon Dioxide
CPAP	Continuous Positive Airway Pressure
CPR	Cardiopulmonary Resuscitation
CVA	Cerebrovascular Accident
d/c	Discontinue
DCI	Decompression Illness
dL	Deciliter
D <sub>10</sub>	10% Dextrose
D <sub>50</sub>	50% Dextrose
ECPR	Extracorporeal Cardiopulmonary Resuscitation
EJ	External Jugular
ECG	Electrocardiogram
EMSA	California Emergency Medical Services Authority
ePCR	Electronic Patient Care Record
EpiPen <sup>®</sup>	Brand name for Epinephrine Auto-Injector
ET	Endotracheal Tube
EtCO <sub>2</sub>	End-Tidal CO <sub>2</sub>
GI	Gastrointestinal
gm	Gram
GU	Genitourinary
HR	Heart Rate
ICS	Intercostal Space
IM	Intramuscular
IN	Intranasal

**San Diego County Emergency Medical Services Office**  
**Policy / Procedure / Protocol**

in	Inches
IO	Intraosseous
IV	Intravenous
J	Joule
kg	Kilogram
L	Liter
LBBB	Left Bundle Branch Block
LBRT	Length-Based Resuscitation Tape
LEMSA	Local Emergency Medical Services Agency
LT Airway	Laryngeal-Tracheal Airway
LOC	Level of Consciousness or Loss of Consciousness
LOSOP	Local Optional Scope of Practice
LVAD	Left Ventricular Assist Device
mA	Milliampere
MAD	Mucosal Atomizer Device
max	Maximum
mcg	Microgram
MCI	Mass Casualty Incident
MDI	Metered-Dose Inhaler
mEq	Milliequivalent
mg	Milligram
MICN	Mobile Intensive Care Nurse
min	Minute
mL	Milliliter
MOI	Mechanism of Injury
MPI	Multiple Patient Incident
MR	May Repeat
MS	Morphine Sulfate
MTV	Major Trauma Victim
NaHCO <sub>3</sub>	Sodium Bicarbonate
NC	Nasal Cannula
NG	Nasogastric
NPO	Nothing by Mouth ( <i>Nil Per Os</i> )
NS	Normal Saline
NTG	Nitroglycerin
O <sub>2</sub>	Oxygen
OD	Overdose
ODT	Oral Dissolving Tablet
OG	Orogastric
OPP	Organophosphate Poisoning
PAA	Perilaryngeal Airway Adjunct
PCR	Patient Care Record
PEA	Pulseless Electrical Activity
PO	By Mouth ( <i>Per Os</i> )
POLST	Physician Orders for Life-Sustaining Treatment
PRN	As Needed ( <i>Pro Re Nata</i> )
PVC	Premature Ventricular Complex
q	Every ( <i>Quaque</i> )
RBBB	Right Bundle Branch Block
ROSC	Return of Spontaneous Circulation
SGA	Supraglottic Airway
SL	Sublingual
SLUDGE/BBB	Salivation, Lacrimation, Urination, Defecation, Gastric Emesis, Bronchorrhea, Bronchospasm, Bradycardia

**ABBREVIATION LIST**

Protocol: S-102

DISCLAIMER: PRINTED COPIES ARE FOR REFERENCE ONLY. PLEASE REFER TO THE ELECTRONIC COPY FOR THE LATEST VERSION.


7/1/2025

Page 2 of 3

**San Diego County Emergency Medical Services Office**  
**Policy / Procedure / Protocol**

SMR	Spinal Motion Restriction
SO	Standing Order
SOB	Shortness of Breath
STEMI	ST-Elevation Myocardial Infarction
SVT	Supraventricular Tachycardia
TAH	Total Artificial Heart
TdP	Torsades de Pointes
TIA	Transient Ischemic Attack
TKO	To Keep Open
TOP	Topical
TOR	Termination of Resuscitation
VAD	Ventricular Assist Device
VF	Ventricular Fibrillation
VSM	Valsalva Maneuver
VT	Ventricular Tachycardia
?	Possible, Questionable, or Suspected
<	Less Than
≥	Greater Than or Equal To
★	Regulatory Reference
Ⓐ	Advanced Emergency Medical Technician (AEMT) Scope of Practice



 <b>COUNTY OF SAN DIEGO</b> EMERGENCY MEDICAL SERVICES	INVENTORY / MEDICATION LISTS AND CHARTS / SKILLS LIST		<b>S-103</b>
	<b>BLS/ALS AMBULANCE INVENTORY</b>		
	Date: 7/1/2025		Page 1 of 6

## I. PURPOSE

To identify a standardized inventory on all Basic Life Support (BLS) and Advanced Life Support (ALS) Transport Units.

## II. AUTHORITY

Health and Safety Code, Division 2.5, Section 1797.204.

## III. POLICY/PROCEDURE

Essential equipment and supplies are required by California Code of Regulations, Title 13, Section 1103.2(a)1-2 (for vehicle requirements, refer to County of San Diego, Emergency Medical Services (CoSD EMS) Policy B-833 "Ground Ambulance Vehicle Requirements"). Any equipment or supplies carried for use in providing emergency medical care must be maintained in good working order. Each BLS or ALS transporting unit in San Diego County shall carry the following:

BLS Requirements	Minimum Requirements
Automated External Defibrillator (Automated External Defibrillator not required for ALS)	1
Ambulance cot and collapsible stretcher – clean, mattress intact, and in good working order	1 each
Straps to secure the patient to the cot or stretcher	1 set
Ankle and wrist restraints	1 set
Linens (sheets, pillow, pillowcase, blanket, towels)	2 sets
Personal protective equipment (masks, gloves, gowns, shields)	2 sets
Oropharyngeal airways	-
• Adult	2
• Pediatric 0-5	1 each
• Neonate	1
• Premature	1
Pneumatic or rigid splints	4
Bag-valve-mask w/reservoir and clear resuscitation mask	-
• Adult	1
• Pediatric	1
• Neonate	1
• Premature	1
Oxygen cylinder w/wall outlet (H or M)	1
Oxygen tubing	1
Oxygen cylinder – portable (D or E)	2
Oxygen administration mask	-
• Adult	4

**San Diego County Emergency Medical Services Office**  
**Policy / Procedure / Protocol**

• <i>Pediatric</i>	2
• <i>Infant</i>	1
Nasal cannulas (Adult)	4
Nasal airways (assorted sizes)	1 set
Nebulizer for use w/sterile H <sub>2</sub> O or saline	2
Blood glucose monitoring device & supplies	1
Glucose paste/tablets	1 15 gm tube <b>OR</b> 3 tabs
Naloxone intranasal	1
Epinephrine auto-injector adult 0.3 mg (Auto-injector not required for ALS)	1
Epinephrine auto-injector pediatric 0.15 mg (Auto-injector not required for ALS)	1
Bandaging supplies	-
• 4-inch sterile bandage compresses	12
• 3x3 gauze pads	4
• 2-, 3-, 4-, or 6-inch roller bandages	6
• 1-, 2-, or 3-inch adhesive tape rolls	2
• Bandage shears	1
• 10-inch x30-inch <b>or</b> larger universal dressing	2
• Hemostatic gauze <sup>1</sup>	2
Emesis basin ( <b>or</b> disposable bags)	1
Covered waste container	1
Portable suction equipment (30 L/min, 300 mmHg)	1
Suction device – fixed (30 L/min, 300 mmHg)	1
Suction catheter – tonsil tip	3
<i>Pediatric suction catheter (5, 6, 10)</i>	1 each
Adult suction catheter (8, 12, 18)	1 each
Spinal immobilization devices w/straps	1
Head immobilization device	2
Cervical collars – rigid	-
• Adult	3
• <i>Pediatric (small, medium, large)</i>	2 each
• <i>Infant</i>	2
Thermometer	1
Traction splint*	-
• Adult <b>or</b> equivalent	1
• <i>Pediatric or equivalent</i>	1
Tourniquet (County-approved type <sup>2</sup> )	2
Blood pressure manometer and cuff	-
• Adult	1
• <i>Pediatric</i>	1
• <i>Infant</i>	1
Stethoscope	1
Obstetrical supplies to include:	1 kit
• Sterile gloves, umbilical tape <b>or</b> clamps, dressings, head coverings,	-

<sup>1</sup> The active hemostatic agent must be incorporated into the gauze (loose granules or granules delivered in an applicator, or particles sprinkled into the wound, are not authorized). The active hemostatic agent must not be exothermic (heat producing) upon contact with the wound.

<sup>2</sup> San Diego County EMS Office approves the [Committee for Tactical Combat Casualty Care \(CoTCCC\) list of recommended tourniquets \(limb non-pneumatic/limb pneumatic\)](#).

**San Diego County Emergency Medical Services Office**  
**Policy / Procedure / Protocol**

ID bands, towels, bulb syringe, sterile scissors <b>or</b> scalpel, clean	-
plastic bags	-
Potable water (1 gallon) <b>or</b> saline (2 liters)	1
Bedpan	1
Urinal	1
Disposable gloves – non-sterile	1 box
Disposable gloves – sterile	4 pairs
Cold packs	2
Warming packs (not to exceed 110 degrees F) <b>or</b> warming device with blanket	2
Sharps container (OSHA approved)	1
Agency radio	1
EMS radio	1
Metronome ( <b>or audible</b> equivalent device for chest compressions)	1
<b>Optional items<sup>3</sup>:</b>	
• Burn sheets	
• Automated cardiac compression device	
• Chest seals	
• Oxygen saturation monitoring device	
○ Adult probe	
○ <i>Pediatric/Infant</i>	
• Mark 1 kit(s) <b>or</b> equivalent	

**ALS Requirements:** All supplies and equipment in BLS Requirements in addition to the following:

<b>A. Airway Adjuncts</b>	<b>Minimum Requirements</b>
Quantitative end tidal CO <sub>2</sub> monitor	1
<i>Pediatric end tidal CO<sub>2</sub> detection device (if capnography not equipped to read EtCO<sub>2</sub> in patients weighing &lt;15kgs)</i>	2
CPAP equipment	1
Endotracheal tubes	-
• 5.0, 5.5, 6.0, 6.5, 7.0, 7.5, 8.0 (cuffed)	1 each
Supraglottic airway (i-gel: sizes 3, 4, 5)	1 each
<b>OR</b>	-
Retroglottic airway (King Airway: sizes 3, 4, 5)	1 each
ET adapter (nebulizer)	1 setup
Laryngoscope – handle	2
Laryngoscope – blade	-
• <i>Straight sizes 0-4</i>	1 each
• <i>Curved sizes 2-4</i>	1 each
Magill tonsil forceps – small and large	1 each
Stylet – 6 and 14 french, Adult	1 each

<sup>3</sup> Any patient care inventory not listed in this protocol must have LEMSA approval prior to use. Agencies must validate training, education, and QA reporting processes for all approved optional inventory items.

**San Diego County Emergency Medical Services Office**  
**Policy / Procedure / Protocol**

Bougie	1 each
HEPA/viral filter (for BVM, CPAP, nebulizer)	6
Positive end-expiratory pressure (PEEP) valve	1

<b>B. Vascular Access/Monitoring Equipment</b>	<b>Minimum Requirements</b>
IV administration sets	-
• Macro drip (2 must be vented if using acetaminophen vials)	4
• Micro drip <b>or</b>	2
• Multi-drip chambers	6
IV tourniquets	4
Needles:	-
• IV cannula – 14 gauge	8
• IV cannula – 16 gauge	8
• IV cannula – 18 gauge	8
• IV cannula – 20 gauge	6
• <i>IV cannula – 22 gauge</i>	4
• <i>IV cannula – 24 gauge</i>	4
• IM – 21 gauge x 1 inch	6
• Filter needles	2
• Angiocath for needle decompression- 14 gauge, 3.25 inches	2
• IO – jamshidi-type ( <b>or</b> approved device) needle – 18 gauge	2
• IO – jamshidi-type ( <b>or</b> approved device) needle – 15 gauge	2
<b>OR</b>	-
• IO power driver w/appropriate IO needles:	-
o 15 mm (3-39 kg)	2
o 25 mm (40 kg and greater)	2
Syringes: 1 mL, 3 mL, 10 mL, 20 mL	3 each
<b>C. Monitoring</b>	<b>Minimum Requirements</b>
Capnography cannula	2
Defibrillator pads	1 adult, 1 <i>pediatric</i>
Electrodes	1 box
Electrode cables	1 set
Monitor/defibrillator w/12-lead ECG and pacing capability	1
Oxygen saturation monitoring device	1
• Adult probe	1
• <i>Pediatric/Infant probe</i>	1
<b>D. Other Equipment</b>	<b>Minimum Requirements</b>
Automated cardiac compression device	1
<i>Length Based Resuscitation Tape (LBRT)</i>	1
Mucosal Atomizer Device (MAD)	2
Metronome ( <b>or</b> equivalent device)	1
Nasogastric tubes (8, 10, 12, 14, 18)	1 each
60mL syringe for nasogastric tube confirmation and placement	1
Water soluble lubricant	1

**San Diego County Emergency Medical Services Office**  
**Policy / Procedure / Protocol**

<b>E. Laminated Items</b>	<b>Minimum Requirements</b>
<i>Pediatric Drug Chart (Policy P-117 "ALS Pediatric Drug Chart")</i>	1
<b>F. Replaceable Medications</b>	<b>Minimum Requirements</b>
Acetaminophen IV 1,000 mg/100 mL (vials require vented tubing)	2000 mg
Adenosine – 6 mg/2 mL <b>and</b> 12 mg/4 mL	30 mg total
Albuterol – 2.5 mg/3 mL <b>or</b> 0.083%	6 vials
ASA, chewable – 81 mg each	6 units
Atropine sulfate – 1 mg/10 mL	2
Atropine sulfate – 8 mg/20 mL (0.4 mg/mL)	1
Calcium chloride – 1 gm/10 mL	1
Charcoal, activated (no sorbitol) – 50 gm	1
Dextrose, 10% – 25 gm/250 mL	4
Diphenhydramine hydrochloride – 50 mg/1 mL	2
Epinephrine 1:1,000 – 1 mg/1 mL	6
Epinephrine 1:10,000 – 1 mg/10 mL	6
Glucagon – 1 unit (mg)/1 mL	1
Ipratropium bromide – 0.5 mg/2.5 mL	2
Ketamine – 500 mg/10 mL (50 mg/mL)	1
Lidocaine hydrochloride (preservative-free) – 100 mg/5 mL (2%)	4
Midazolam – 5 mg/1 mL	20 mg total
Morphine sulfate (injectable) – 10 mg/1 mL	20 mg total
<b>OR</b> (units may carry morphine <u>or</u> fentanyl, but <u>not</u> both)	
Fentanyl citrate – 100 mcg/2 mL	200 mcg total
Naloxone hydrochloride – 2 mg/2 mL	6 mg total
Nitroglycerin – 0.4 mg	1 container
Ondansetron (injectable) – 4 mg/2 mL	2
Ondansetron (PO/ODT) – 4 mg	4
Sodium bicarbonate – 50 mEq/50 mL	3
Tranexamic acid – 1 gm/10 mL	1
<u>IV Solutions:</u>	
• Normal Saline – 1,000 mL bag	4
• Normal Saline – 250 mL bag	2
• Normal Saline – 50 mL bag <b>or</b> 100 mL bag	2
<b>G. Optional Items<sup>4</sup></b>	
Albuterol MDI	
Amiodarone – 150 mg/3 mL with 100 mL normal saline bag	
Armboard – long	
Armboard – short	
Buprenorphine-naloxone (Suboxone®) (for agencies participating in the buprenorphine LOSOP)	
Carboxyhemoglobin monitor	
Chest seals	
<i>Colorimetric carbon dioxide detector (if capnography not equipped to read EtCO<sub>2</sub> in patients weighing &lt;15kgs)</i>	
Curved laryngoscope blades – size 0, 1	
Dextrose, 50% – 25 gm/50 mL	

<sup>4</sup> Any patient care inventory not listed in this protocol must have LEMSA approval prior to use. Agencies must validate training, education, and QA reporting processes for all approved optional inventory items.

**San Diego County Emergency Medical Services Office**  
**Policy / Procedure / Protocol**

IO power drive needle 45 mm (40kg and greater w/excessive tissue)
IV extension tubing
Levalbuterol – 1.25 mg/3 mL (adults and pediatrics ≥12 years) <b>and</b> 0.31 mg/3 mL ( <i>pediatrics ≥6 and &lt;12 years</i> )
Lidocaine 2% jelly – 5 mL tube
Mesh hood (spit sock <b>or</b> similar) – light color only (beige/white)
Leave Behind Naloxone kit(s)
Ringer's lactate solution <sup>5</sup>
Saline lock
Three-way stopcock w/extension tubing
Video laryngoscope (recording capabilities preferred)

Note: Pediatric required supplies denoted by italics

\*One splint may be used for both adult and pediatric (e.g., Sager Splint)

---

<sup>5</sup> With the exception of amiodarone and ketamine, medications listed in P-401 may be infused with Ringer's lactate solution during periods when normal saline fluid is in shortage. This substitution shall be on a one-for-one basis, i.e., a protocol treatment of 250 mL normal saline fluid bolus may be replaced with a 250 mL Ringer's lactate fluid bolus.

**COUNTY OF SAN DIEGO EMERGENCY MEDICAL SERVICES**  
**POLICY/PROCEDURE/PROTOCOL**  
**SUBJECT: TREATMENT PROTOCOL – SKILLS LIST**

**No. S-104**  
**Page: 1 of 13**  
**Date: 07/01/2025**

Color code identifies the level of EMS clinician authorized to perform each skill.

Red	Not authorized
Yellow	Authorized by LEMS Medical Director per <a href="#">22 CCR § 100063 (b)</a> <sup>1</sup> or by California EMSA-approved LOSOP <sup>5</sup>
Green	Authorized by state regulation and local protocol

SKILL	EMS CLINICIAN	INDICATION	CONTRAINDICATION	COMMENTS
Bougie	EMT	Assist with intubations		Should be used routinely during intubations.  After attempting to view with laryngoscope, may use to assist ET placement if unable to fully visualize vocal cords.
	AEMT			
	Paramedic			
Carboxyhemoglobin monitor	EMT	Suspected or known carbon monoxide exposure	None	Consider transport to facility with hyperbaric chamber for suspected carbon monoxide poisoning in the unconscious or pregnant patient.
	AEMT			
	Paramedic			
Synchronized cardioversion	EMT	Unstable VT	Pediatric: If defibrillator unable to deliver <5 J or biphasic equivalent	Remove chest transdermal medication patches prior to cardioversion.
	AEMT	Unstable SVT		
	Paramedic	Unstable Atrial Fibrillation/Flutter with HR $\geq$ 180		
Chest seal	EMT	Occlusive dressing designed for treating open chest wound	None	
	AEMT			
	Paramedic			
CPAP	EMT	Respiratory Distress: Suspected CHF/ cardiac origin  Respiratory Distress: Suspected non-cardiac origin.  Drowning with respiratory distress	Unconscious	CPAP may be used only in patients alert enough to follow direction and cooperate with the assistance. BVM-assisted ventilation is the appropriate alternative.  CPAP should be used cautiously for patients with suspected COPD or pulmonary fibrosis. Start low and titrate pressure.  HEPA filters should be applied with aerosol-generated procedures
	AEMT		Non-verbal patients with poor head/neck tone may be too obtunded for CPAP	
	Paramedic		CPR	
			SBP <90 mmHg	
			Vomiting	
			Age <15	
			Possible pneumothorax	
			Facial trauma	
			Unable to maintain airway	

**COUNTY OF SAN DIEGO EMERGENCY MEDICAL SERVICES**  
**POLICY/PROCEDURE/PROTOCOL**  
**SUBJECT: TREATMENT PROTOCOL – SKILLS LIST**

**No. S-104**  
**Page: 2 of 13**  
**Date: 07/01/2025**

Color code identifies the level of EMS clinician authorized to perform each skill.

Red	Not authorized
Yellow	Authorized by LEMS Medical Director per <a href="#">22 CCR § 100063 (b)</a> <sup>1</sup> or by California EMSA-approved LOSOP <sup>5</sup>
Green	Authorized by state regulation and local protocol

SKILL	EMS CLINICIAN	INDICATION	CONTRAINDICATION	COMMENTS
Manual defibrillation	EMT	VT (pulseless) VF	None	Remove chest transdermal medication patches prior to defibrillation.
	AEMT			
	Paramedic			
ECG monitoring	EMT	Any situation where there is a potential for cardiac arrhythmia	None	Apply monitor before moving patient with chest pain, syncope, or in arrest.  Continuous monitoring for unstable/STEMI/CPR patients required.  Document findings on PCR and leave strip with patient.
	AEMT			
	Paramedic			
12-lead ECG	EMT	Chest discomfort/pain and/or signs and symptoms suggestive of myocardial infarction (e.g., dyspnea, upper abdominal pain, fatigue)  Signs and symptoms of arrhythmia (e.g., syncope, near syncope, palpitations)  Suspected hyperkalemia  ROSC after cardiac arrest  To identify a rhythm	None	Transmit 12-lead ECGs to receiving hospital.  If STEMI suspected, immediately notify BH, transmit 12-lead ECG to appropriate STEMI receiving center and transport.  Report LBBB, RBBB, or poor-quality ECG for consideration of a false positive reading STEMI.  Repeat 12-lead ECG after arrhythmia conversion or any change in patient condition.  Do not delay transport for a repeat 12-lead ECG.  Attach ECG(s) or printout photo(s) to PCR.  Document findings on the PCR and leave ECG printout with patient.  EMT/AEMT: May assist with placement of 12-lead ECG leads.
	AEMT			
	Paramedic			
End tidal CO <sub>2</sub> Detection Device (Qualitative)	EMT	All intubated patients <15 kg - unless quantitative end tidal CO <sub>2</sub> available for patient <15 kg.	None	Continuous monitoring after ET/PAA insertion required.
	AEMT			
	Paramedic			
End tidal CO <sub>2</sub> Detection Device – Capnography (Quantitative)	EMT	All intubated patients  Respiratory distress or cardiovascular impairment	None	Continuous monitoring after ET/PAA insertion required.  Use early in cardiac arrest.
	AEMT			
	Paramedic			



**COUNTY OF SAN DIEGO EMERGENCY MEDICAL SERVICES**  
**POLICY/PROCEDURE/PROTOCOL**  
**SUBJECT: TREATMENT PROTOCOL – SKILLS LIST**

**No. S-104**  
**Page: 3 of 13**  
**Date: 07/01/2025**

Color code identifies the level of EMS clinician authorized to perform each skill.

Red	Not authorized
Yellow	Authorized by LEMS Medical Director per <a href="#">22 CCR § 100063 (b)</a> <sup>L</sup> or by California EMSA-approved LOSOP <sup>S</sup>
Green	Authorized by state regulation and local protocol

SKILL	EMS CLINICIAN	INDICATION	CONTRAINDICATION	COMMENTS
End tidal CO <sub>2</sub> Detection Device – Capnography (Quantitative) (continued)		Trauma		For EtCO <sub>2</sub> > 0 mmHg, may place ET/PAA without interrupting compressions.  If EtCO <sub>2</sub> rises rapidly during CPR, pause CPR and check for pulse.  If quantitative is unavailable due to special circumstances, then use qualitative (optional equipment)
External cardiac pacing	EMT	Unstable bradycardia unresponsive to atropine	None	Document rate setting, milliamps and capture  External cardiac pacing: <ul style="list-style-type: none"> <li>Set rate and energy per manufacturer's recommendations</li> <li>Increase energy setting until capture occurs, usually between 50 mA and 100 mA</li> <li>After electrical and mechanical capture achieved, increase energy by 10%</li> <li>If patient remains hypotensive, increase rate in 5 bpm increments (not to exceed 100 bpm) to achieve and maintain adequate perfusion</li> </ul>
	AEMT			
	Paramedic			
Glucose monitoring	EMT <sup>L</sup>	Hypoglycemia (suspected)	None	Repeat BS not indicated enroute if patient is improving.  Repeat BS must be done if patient left on scene and initial was abnormal (AMA/Release).
	AEMT	Hyperglycemia		
	Paramedic	Altered neurologic function		
Hemostatic gauze	EMT	Life-threatening hemorrhage in the trauma patient when tourniquet cannot be used or to supplement tourniquet or bleeding unable to be controlled with direct pressure.	Bleeding controlled with direct pressure with standard gauze.	Should be applied with minimum 3 minutes of direct pressure.
	AEMT			
	Paramedic			
Intranasal (IN)	EMT <sup>L</sup>	When IN route indicated	None	Volumes over 1 mL per nostril are likely too large and may result in runoff out of the nostril.  If using a mucosal atomization device, see manufacturer's guidance on accounting for dead space.
	AEMT			
	Paramedic			
Injection (IM)	EMT <sup>L</sup>	When IM route indicated	None	Pediatric preferred site: <ul style="list-style-type: none"> <li>Vastus lateralis in patients less than 3 years of age. (Maximum of 2 mL volume)</li> </ul>
	AEMT			
	Paramedic			

**COUNTY OF SAN DIEGO EMERGENCY MEDICAL SERVICES**  
**POLICY/PROCEDURE/PROTOCOL**  
**SUBJECT: TREATMENT PROTOCOL – SKILLS LIST**

**No. S-104**  
**Page: 4 of 13**  
**Date: 07/01/2025**

Color code identifies the level of EMS clinician authorized to perform each skill.

Red	Not authorized
Yellow	Authorized by LEMS Medical Director per <a href="#">22 CCR § 100063 (b)</a> <sup>1</sup> or by California EMSA-approved LOSOP <sup>5</sup>
Green	Authorized by state regulation and local protocol

SKILL	EMS CLINICIAN	INDICATION	CONTRAINDICATION	COMMENTS
				Adults: <ul style="list-style-type: none"> <li>Deltoid in patients ≥3 years of age. (Maximum of 2 mL volume). Use vastus lateralis as secondary site (Maximum of 5 mL volume)</li> </ul>
Injection (IV)	EMT	When IV route indicated	None	
	AEMT			
	Paramedic			
Intubation: ET/Stomal	EMT	To facilitate ventilation and/or oxygenation in a patient who is unable to protect his/her own airway or maintain spontaneous respiration.  Ineffective ventilations for unconscious adult patient or decreasing LOC.	Suspected opioid OD prior to naloxone  Gag reflex present  Infants and pediatric patients  <15 years of age that fit on the LBRT	If able to maintain adequate ventilation, may attempt to insert ET tube up to 3 times. After 3 unsuccessful attempts, ventilate with BVM or SGA.  An ET attempt is defined as insertion of a laryngoscope into the oropharynx with intent to intubate.  Document and report <b>LEADSD</b> Lung Sounds EtCO <sub>2</sub> Absent Abdominal Sounds Depth Size Document presence of EtCO <sub>2</sub> waveform and EtCO <sub>2</sub> numeric value at Transfer of Care  <b>Establishment of EtCO<sub>2</sub> prior to intubation:</b>  The presence of EtCO <sub>2</sub> greater than zero is required prior to ET tube/PAA placement. <ul style="list-style-type: none"> <li>If assessment rules out airway obstruction, but EtCO<sub>2</sub> remains zero despite effective BVM ventilation (including OPA/NPA placement), a PAA may be placed.</li> <li>For patients with intractable vomiting or airway bleeding, initial management should focus on clearing the airway with patient positioning (i.e., logrolling), and mouth and oropharynx suctioning.</li> <li>Immediately following insertion of an advanced airway, persistent EtCO<sub>2</sub> waveform and reading (other than zero) must be maintained or the ET tube/PAA must be removed.</li> </ul>
	AEMT			
	Paramedic			

**COUNTY OF SAN DIEGO EMERGENCY MEDICAL SERVICES**  
**POLICY/PROCEDURE/PROTOCOL**  
**SUBJECT: TREATMENT PROTOCOL – SKILLS LIST**

**No. S-104**  
**Page: 5 of 13**  
**Date: 07/01/2025**

Color code identifies the level of EMS clinician authorized to perform each skill.

Red	Not authorized
Yellow	Authorized by LEMSA Medical Director per <a href="#">22 CCR § 100063 (b)</a> <sup>1</sup> or by California EMSA-approved LOSOP <sup>5</sup>
Green	Authorized by state regulation and local protocol

SKILL	EMS CLINICIAN	INDICATION	CONTRAINDICATION	COMMENTS
Intubation: ET/Stomal  (continued)				<p>If EtCO<sub>2</sub> drops to zero and does not increase with immediate troubleshooting, extubate, and manually ventilate the patient via BVM.</p> <p>Continuous capnography monitoring after ET/PAA insertion is required.</p> <p>Report and document at a minimum:</p> <ul style="list-style-type: none"> <li>• capnography value, presence of waveform, abdominal sounds, and lung sounds before and after advanced airway placement;</li> <li>• at each patient movement, and;</li> <li>• at the transfer of care.</li> </ul> <p>When moving an intubated patient, apply C-collar prior to moving to minimize head movement and potential ET dislodgement.</p>
Intubation: Perilaryngeal airway adjuncts <ul style="list-style-type: none"> <li>• Supraglottic airway (i-gel)</li> <li>• Retroglottic airway (King Airway)</li> </ul>	<div>EMT</div> <div>AEMT</div> <div>Paramedic</div>	Apnea or ineffective respirations for unconscious patient or decreasing LOC	Gag reflex present  For King Airway, patient <4 feet tall  Ingestion of caustic substances  Known esophageal disease  Laryngectomy/stoma  Suspected opioid OD prior to naloxone  Infants and pediatric patients  <15 years of age that fit on the LBRT	<p>Extubate if placement issue.</p> <p><u>i-gel:</u>            Use Size 3 (yellow) for small adult – 36-60kg. Use 12 french OG tube            Use Size 4 (green) for medium adult – 50-90kg. Use 12 french OG tube            Use Size 5 (orange) for large adult – 90+kg. Use 14 french OG tube</p> <p><u>King Airway:</u>            Use Size 3 (yellow) for patients 4 feet – 5 feet tall            Use Size 4 (red) for patients 5 feet – 6 feet tall            Use Size 5 (purple) for patients ≥6 feet tall</p> <p>Document and report <b>LEADSD</b>:            Lung Sounds            EtCO<sub>2</sub>            Absent Abdominal Sounds            Depth            Size            Document presence of EtCO<sub>2</sub> waveform and EtCO<sub>2</sub> numeric value at Transfer of Care</p>

**COUNTY OF SAN DIEGO EMERGENCY MEDICAL SERVICES**  
**POLICY/PROCEDURE/PROTOCOL**  
**SUBJECT: TREATMENT PROTOCOL – SKILLS LIST**

**No. S-104**  
**Page: 6 of 13**  
**Date: 07/01/2025**

Color code identifies the level of EMS clinician authorized to perform each skill.

Red	Not authorized
Yellow	Authorized by LEMSA Medical Director per <a href="#">22 CCR § 100063 (b)</a> <sup>1</sup> or by California EMSA-approved LOSOP <sup>5</sup>
Green	Authorized by state regulation and local protocol

SKILL	EMS CLINICIAN	INDICATION	CONTRAINDICATION	COMMENTS
Intubation: Perilaryngeal airway adjuncts <ul style="list-style-type: none"> <li>• Supraglottic airway (i-gel)</li> <li>• Retroglottic airway (King Airway)</li> </ul> (continued)				<b>Establishment of EtCO<sub>2</sub> prior to intubation:</b>  The presence of EtCO <sub>2</sub> greater than zero is required prior to ET tube/PAA placement. <ul style="list-style-type: none"> <li>• If assessment rules out airway obstruction, but EtCO<sub>2</sub> remains zero despite effective BVM ventilation (including OPA/NPA placement), a PAA may be placed.</li> <li>• For patients with intractable vomiting or airway bleeding, initial management should focus on clearing the airway with patient positioning (i.e., logrolling), and mouth and oropharynx suctioning.</li> <li>• Immediately following insertion of an advanced airway, persistent EtCO<sub>2</sub> waveform and reading (other than zero) must be maintained or the ET tube/PAA must be removed.</li> </ul> If EtCO <sub>2</sub> drops to zero and does not increase with immediate troubleshooting, extubate, and manually ventilate the patient via BVM.  Continuous capnography monitoring after ET/PAA insertion is required.  Report and document at a minimum: <ul style="list-style-type: none"> <li>• capnography value, presence of waveform, abdominal sounds, and lung sounds before and after advanced airway placement;</li> <li>• at each patient movement, and;</li> <li>• at the transfer of care.</li> </ul> When moving an intubated patient, apply C-collar prior to moving to minimize head movement and potential ET dislodgement.
Length-Based Resuscitation Tape (LBRT)	EMT AEMT Paramedic	Determination of length for calculation of pediatric drug dosages and equipment sizes.	None	Base dosage calculation on length of child.  Refer to pediatric chart for dosages (P-117).

**COUNTY OF SAN DIEGO EMERGENCY MEDICAL SERVICES**  
**POLICY/PROCEDURE/PROTOCOL**  
**SUBJECT: TREATMENT PROTOCOL – SKILLS LIST**

**No. S-104**  
**Page: 7 of 13**  
**Date: 07/01/2025**

Color code identifies the level of EMS clinician authorized to perform each skill.

Red	Not authorized
Yellow	Authorized by LEMS Medical Director per <a href="#">22 CCR § 100063 (b)</a> <sup>1</sup> or by California EMSA-approved LOSOP <sup>5</sup>
Green	Authorized by state regulation and local protocol

SKILL	EMS CLINICIAN	INDICATION	CONTRAINDICATION	COMMENTS
Magill forceps	EMT	Airway obstruction from foreign body with decreasing LOC/unconscious	None	
	AEMT			
	Paramedic			
Nasogastric / Orogastric tube	EMT	Gastric distention interfering w/ ventilations	Severe facial trauma  Known esophageal disease	If NG tube needed in a patient with a King Airway/i-gel, insertion should be via the suction/gastric port, if available.
	AEMT			
	Paramedic			
Nebulizer, oxygen powered	EMT	Respiratory distress with: • Bronchospasm • Wheezing • Croup-like cough • Stridor	None	Flow rate 4-6 L/min via mouthpiece; 6-10 L/min via mask/ET.  If concerned about aerosolized infectious exposure, substitute with MDI, if available.  Consider applying HEPA filters with aerosol-generating procedures for in-line nebulizer treatments.
	AEMT			
	Paramedic			
Needle thoracostomy	EMT	Severe respiratory distress with diminished or absent breath sounds (unilaterally or bilaterally), and SBP <90 mmHg, and suspected pneumothorax (Adult)  Severe respiratory distress with diminished or absent breath sounds (unilaterally or bilaterally), and hypotensive for age, and suspected pneumothorax (Pediatric)	None	Use 14-gauge, 3.25-inch IV catheter.  Anterior axillary line needle thoracostomy placement is preferred as it has a lower failure rate than midclavicular line placement.  Insert the catheter into the anterior axillary line 4 <sup>th</sup> /5 <sup>th</sup> ICS on the involved side (roughly nipple level / inframammary fold: preferred position) <b>OR</b> Insert the catheter into the midclavicular line 2 <sup>nd</sup> /3 <sup>rd</sup> ICS on the involved side (non-preferred position)  Tape catheter securely to chest wall and leave open to air.
	AEMT			
	Paramedic			
Obstetrical maneuvers	EMT	Difficult deliveries	None	Nuchal cord (cord wrapped around neck): • Slip cord over the head and off neck. • Clamp and cut cord, if wrapped too tightly.  Prolapsed cord: • Place mother with her hips elevated on pillows. • Insert a gloved hand into vagina and gently push presenting part off cord.
	AEMT			
	Paramedic			

**COUNTY OF SAN DIEGO EMERGENCY MEDICAL SERVICES**  
**POLICY/PROCEDURE/PROTOCOL**  
**SUBJECT: TREATMENT PROTOCOL – SKILLS LIST**

**No. S-104**  
**Page: 8 of 13**  
**Date: 07/01/2025**

Color code identifies the level of EMS clinician authorized to perform each skill.

Red	Not authorized
Yellow	Authorized by LEMS Medical Director per <a href="#">22 CCR § 100063 (b)</a> <sup>1</sup> or by California EMSA-approved LOSOP <sup>5</sup>
Green	Authorized by state regulation and local protocol

SKILL	EMS CLINICIAN	INDICATION	CONTRAINDICATION	COMMENTS
				<ul style="list-style-type: none"> <li>• Transport immediately while retaining this position. Do not remove hand until relieved by hospital personnel.</li> <li>• Cover exposed cord with saline-soaked gauze.</li> </ul> <p>Shoulder dystocia:</p> <ul style="list-style-type: none"> <li>• Hyperflex mother's knees to her chest.</li> </ul>
Positive end-expiratory pressure (PEEP) valve	EMT	BVM ventilation	Adult: CPR  SBP <90 mmHg  Possible pneumothorax  Pediatric: CPR  Hypotensive for age  Possible pneumothorax	Adult: PEEP should be increased slowly by 2-3 cmH2O and titrated from 5 cmH2O (initial setting) to a max of 15 cmH2O closely monitoring response and vital sign changes.  Pediatric: PEEP should be increased slowly by 2-3 cmH2O and titrated from 5 cmH2O (initial setting) to a max of 10 cmH2O closely monitoring response and vital sign changes.  EMT/AEMT: May perform BVM ventilations with PEEP valve in place, but may not adjust settings.
	AEMT			
	Paramedic			
Prehospital pain scale	EMT	All patients with a traumatic or pain-associated chief complaint	None	Assess for presence and intensity of pain.
	AEMT			
	Paramedic			
Pulse oximetry	EMT	Assess oxygenation	None	Obtain room air saturation prior to O <sub>2</sub> administration, if possible.
	AEMT			
	Paramedic			
Prehospital stroke screening and severity scales	EMT	All patients with suspected Stroke/TIA	None	Bring witness to ED to verify time of symptom onset and provide consent for interventions. If witness unable to ride in ambulance, obtain accurate contact phone number.  Use <b>BE-FAST</b> Prehospital Stroke Screening Scale in assessment of possible TIA or stroke patients: <b>B</b> = Balance: Unsteadiness, ataxia <b>E</b> = Eyes: Blurred/double or loss of vision <b>F</b> = Face: Unilateral face droop <b>A</b> = Arms and/or legs: Unilateral weakness exhibited by a drift or drop
	AEMT			
	Paramedic			

**COUNTY OF SAN DIEGO EMERGENCY MEDICAL SERVICES**  
**POLICY/PROCEDURE/PROTOCOL**  
**SUBJECT: TREATMENT PROTOCOL – SKILLS LIST**

**No. S-104**  
**Page: 9 of 13**  
**Date: 07/01/2025**

Color code identifies the level of EMS clinician authorized to perform each skill.

Red	Not authorized
Yellow	Authorized by LEMSA Medical Director per <a href="#">22 CCR § 100063 (b)</a> <sup>1</sup> or by California EMSA-approved LOSOP <sup>5</sup>
Green	Authorized by state regulation and local protocol

SKILL	EMS CLINICIAN	INDICATION	CONTRAINDICATION	COMMENTS
				<p><b>S</b> = Speech: Slurred, inability to find words, absent  <b>T</b> = Time: Accurate Last Known Well time</p> <p>Get specific Last Known Well time in military time (hours: minutes).</p> <p>If <b>BE-FAST</b> is positive, calculate and report the FAST-ED Prehospital Stroke Severity Scale value:  <b>F</b> = Facial palsy  <b>A</b> = Arm weakness  <b>S</b> = Speech changes  <b>T</b> = Time  <b>E</b> = Eye deviation  <b>D</b> = Denial/neglect</p>
Re-alignment of fracture	<div>EMT</div> <div>AEMT</div> <div>Paramedic</div>	Grossly angulated long bone fracture	None	Use unidirectional traction. Check for distal pulses prior to realignment and every 15 min thereafter.
Removal of impaled object obstructing airway	<div>EMT</div> <div>AEMT</div> <div>Paramedic</div>	Impaled object in face, cheek or neck causing total airway obstruction	None	Impaled objects not causing total airway obstruction should be immobilized and left in place.
Spinal motion restriction	<div>EMT</div> <div>AEMT</div> <div>Paramedic</div>	<p>Spinal pain of possible traumatic cause</p> <p>MOI suggests potential spinal injury consider:</p> <p>≥65 years and older</p> <p>Acute neurological deficit following injury</p> <p>Penetrating trauma with neurological deficit</p> <p>Victims of penetrating trauma (stabbing, gunshot wound) to the head, neck, and/or torso should not receive spinal stabilization unless there is one or more of the following:</p> <ul style="list-style-type: none"> <li>Neurologic deficit</li> <li>Priapism</li> <li>Anatomic deformity to the spine secondary to injury</li> </ul>	None	<p>Pregnant patients (&gt;6 mo) tilt 30° left lateral decubitus.</p> <p>See S-104 Attachment for “<b>Spinal Motion Restriction Algorithm</b>”</p> <p><b>The Acronym “NSAIDS” Should Be Used to Remember the Steps in Algorithm:</b>  <b>N</b>- Neurologic exam  <b>S</b>- Sixty-five  <b>A</b>- Altered (including language barrier)  <b>I</b>- Intoxication  <b>D</b>- Distracting injury  <b>S</b>- Spine exam</p> <p>Spinal Motion Restriction is <b>not</b> required if <b>ALL of the following are present and documented:</b></p> <ol style="list-style-type: none"> <li>No neuro complaints/ no abnormal exam</li> <li>Not altered / no language barrier</li> <li>Not intoxicated by drugs and/or alcohol</li> <li>No significant competing, distracting pain</li> <li>No spine pain or tenderness</li> </ol>

COUNTY OF SAN DIEGO EMERGENCY MEDICAL SERVICES  
POLICY/PROCEDURE/PROTOCOL  
SUBJECT: TREATMENT PROTOCOL – SKILLS LIST

No. S-104  
Page: 10 of 13  
Date: 07/01/2025

Color code identifies the level of EMS clinician authorized to perform each skill.

Red	Not authorized
Yellow	Authorized by LEMS Medical Director per <a href="#">22 CCR § 100063 (b)</a> <sup>1</sup> or by California EMSA-approved LOSOP <sup>5</sup>
Green	Authorized by state regulation and local protocol

SKILL	EMS CLINICIAN	INDICATION	CONTRAINDICATION	COMMENTS
Spinal Motion Restriction  (continued)				<p><b>Spinal Motion Restriction:</b>            -The use of an appropriately sized cervical collar on a stretcher while limiting the movement of the spine and maintaining "neutral" in-line position.</p> <p>-Backboards should be limited to extrication whenever possible. In-line stabilization should be maintained with the patient supine and neutral on the gurney during transport.</p> <p>-If a patient is not able to tolerate the supine position during transport, document the reason and communicate to receiving hospital staff.</p> <p><u>Sports Injury Patient</u>            If a patient is helmeted and/or shoulder padded, patient helmet and pads should be removed while on scene.</p> <p><b>Document a neurological examination including:</b></p> <ul style="list-style-type: none"> <li>• Test of sensation and abnormal sensation (paresthesia) in all 4 extremities</li> <li>• Test of motor skills in all 4 extremities with active movements by the patient (avoid just reflexive movements like hand grasp to include:               <ul style="list-style-type: none"> <li>- Wrist/finger extension and flexion</li> <li>- Foot plantar and dorsiflexion</li> </ul> </li> </ul> <p><u>Pediatric Patient</u>  <b>N</b>-no altered LOC  <b>E</b>-evidence of obvious injury absent  <b>C</b>-complete spontaneous ROM without pain  <b>K</b>-kinematic (mechanism) negative</p> <p><u>Pediatrics Patients and Car Seats</u>  <b>Infants restrained in a rear-facing car seat</b> may be immobilized and extricated in the car seat. The child may remain in the car seat if the immobilization is secure and his/her condition allows (no signs of respiratory distress or shock).</p> <p><b>Children restrained in a car seat</b> (with a high back) may be immobilized and extricated in the car seat; however, once removed from the vehicle, the child should be placed in spinal immobilization.</p> <p><b>Children restrained in a booster seat</b> (without a back) need to be extricated and immobilized following standard spinal immobilization procedures.</p>



**COUNTY OF SAN DIEGO EMERGENCY MEDICAL SERVICES**  
**POLICY/PROCEDURE/PROTOCOL**  
**SUBJECT: TREATMENT PROTOCOL – SKILLS LIST**

**No. S-104**  
**Page: 11 of 13**  
**Date: 07/01/2025**

Color code identifies the level of EMS clinician authorized to perform each skill.

Red	Not authorized
Yellow	Authorized by LEMS Medical Director per <a href="#">22 CCR § 100063 (b)</a> <sup>1</sup> or by California EMSA-approved LOSOP <sup>5</sup>
Green	Authorized by state regulation and local protocol

SKILL	EMS CLINICIAN	INDICATION	CONTRAINDICATION	COMMENTS
Saline lock	EMT	Used to provide IV access in patients who do not require continuous infusion of intravenous solutions	None	Patient presentations which may require IV fluid replacement.
	AEMT			
	Paramedic			
Tourniquet	EMT	Severely injured extremity when direct pressure or pressure dressing fails to control life-threatening hemorrhage	None	In MCI, direct pressure not required prior to tourniquet application.  Tourniquet must be tight enough to occlude arterial flow/distal pulses. Assess and document distal pulses, time placed, and any subsequent adjustments.
	AEMT			
	Paramedic			
Valsalva maneuver	EMT	Stable SVT	None	Most effective with adequate BP.  D/C after 5-10 sec if no conversion.
	AEMT			
	Paramedic			
Video laryngoscope	EMT	To assist with endotracheal intubation using video laryngoscopy	None	Optional inventory item (recording capabilities preferred).  See Intubation ET for comments.
	AEMT			
	Paramedic			
VASCULAR ACCESS External jugular	EMT	When unable to establish other peripheral IV and IV is needed for definitive therapy ONLY	None	
	AEMT			
	Paramedic			
Extremity	EMT	Whenever IV line is needed or anticipated for definitive therapy	None	Lower extremities remain standing order in the pediatric patient.
	AEMT			
	Paramedic			
Indwelling Devices	EMT	Primary access site for patients with indwelling catheters if needed for definitive therapy	Devices without external port (i.e., port-a-cath)	Clean site for minimum of 15 seconds prior to accessing.  Infuse at a rate to support continuous flow and prevent backflow into IV line.  Needleless systems may require adaptor.  Examples include Groshong, Hickman, and PICC lines.
	AEMT			
	Paramedic			

**COUNTY OF SAN DIEGO EMERGENCY MEDICAL SERVICES**  
**POLICY/PROCEDURE/PROTOCOL**  
**SUBJECT: TREATMENT PROTOCOL – SKILLS LIST**

**No. S-104**  
**Page: 12 of 13**  
**Date: 07/01/2025**


Color code identifies the level of EMS clinician authorized to perform each skill.

Red	Not authorized
Yellow	Authorized by LEMS Medical Director per <a href="#">22 CCR § 100063 (b)</a> <sup>1</sup> or by California EMSA-approved LOSOP <sup>5</sup>
Green	Authorized by state regulation and local protocol

SKILL	EMS CLINICIAN	INDICATION	CONTRAINDICATION	COMMENTS
Intraosseous	EMT	Fluid/medication administration in patient when needed for definitive therapy and unable to establish venous access  Pediatric patient: unconscious	Tibial fracture  Vascular Disruption  Prior attempt to place in target bone  Humeral fracture (for humeral placement) Local infection at insertion site	Splint extremity after placement.
	AEMT			Observe carefully for signs of extravasation.
	Paramedic			Do not infuse into fracture site.
				Attempts to initiate tibial IO should be the priority when peripheral access is unavailable; however humeral IO insertion may be utilized when unable to access other sites.  Avoid placement if potential fracture is on target bone.  In conscious adult patients, slowly infuse lidocaine 40 mg IO prior to fluid/medication administration.  <b>AEMT: Authorized to establish and maintain IO access in a pediatric patient only.</b>
Percutaneous Dialysis Catheter Access (e.g., Vascath)	EMT	If unable to gain other IV access and for immediate life threat only	None	Vascath contains concentrated dose of heparin which must be aspirated PRIOR to infusion.
	AEMT			Infuse at a rate to support continuous flow and prevent backflow into IV line. Needleless systems may require adaptor.
	Paramedic			Annual training required.
Shunt/graft – AV (Dialysis)	EMT	If unable to gain other IV access and for immediate life threat only	None	Prior to access, check site for bruits and thrills.
	AEMT			Access fistula on venous side (weaker thrill). Inflate BP cuff around IV bag to just above patient's systolic BP to maintain flow of IV. If unsuccessful, hold direct pressure over site for 10 min to stop bleeding.
	Paramedic			
				Do not apply pressure dressing.

EMT/AEMT/Paramedics or supervised EMT/AEMT/Paramedic students are authorized to perform these skills when on-duty as part of the organized EMS system, while at the scene of a medical emergency or during transport, or during interfacility transfer.

## Spinal Motion Restriction Algorithm: NSAIDS



## The Acronym “NSAIDS” Should Be Used to Remember the Steps in Algorithm

**N- Neurologic exam-** Are there any abnormal sensory or motor findings? Weakness/numbness or complaints of paresthesia? Look for focal deficit, such as tingling, reduced strength, numbness in an extremity.

**S-Sixty five-** Greater than or equal to 65 years of age?

**A- Altered-** Is the patient oriented to person, place, time and situation? Is the patient altered in any way? Is there a language barrier? Is the patient cooperative?


**I-Intoxication-** Is there any indication that the person is impaired by drugs or alcohol?

**D-Distracting injury-** Is there any other injury which is capable of producing significant pain in this patient?

**S-Spine exam-** Does the patient complain of neck or back pain? Assess entire spine for point tenderness or spinal process tenderness.

## **SPECIAL CONSIDERATIONS**

- Prehospital provider assessment will determine what method is needed. Every patient with trauma must receive an assessment. If any assessment component is positive, the patient requires spinal motion restriction.
- Patients with severe kyphosis or other anatomical or medical conditions (e.g., ankylosing spondylitis or rheumatoid arthritis) may be stabilized using a combination of pillow, blanket, or other devices.
- Spinal motion restriction should be accomplished using the most appropriate tool for the specific circumstance. May include, but are not limited to, vacuum splints, pneumatic splints, cervical collars, soft collars, straps, tape, as well as soft materials, such as pillows and blanket to minimize movement, compression, or distraction of the spine.
- Patients with acute or chronic difficulty breathing: Use spinal motion restriction with caution in patients presenting with dyspnea and place patient in position best suited to protect the airway.

 <b>COUNTY OF SAN DIEGO</b> EMERGENCY MEDICAL SERVICES	TREATMENT PROTOCOL		<b>P-115</b>
	<b>MEDICATION LIST</b>		
	Date: 7/1/2025		Page 1 of 27

<b>RED</b>	Not authorized
<b>YELLOW</b>	Authorized by LEMSAs Medical Director per Title 22, Division 9, Chapter 3.1, § 100066.02 <sup>L</sup> or by California EMSA-approved LOSOP <sup>S</sup>
<b>GREEN</b>	Authorized by state regulation and local protocol

This document contains the authorized medications for EMT/AEMT/Paramedics to administer when on-duty as part of the organized EMS system, while at the scene of a medical emergency or during transport, or during interfacility transfer.

## ACETAMINOPHEN (IV)

EMT	AEMT	PARAMEDIC
<b>Class</b> <ul style="list-style-type: none"> <li>Analgesic, antipyretic</li> </ul>		
<b>Mechanism of Action</b> <ul style="list-style-type: none"> <li>Mechanism of action unclear; may work peripherally to block pain impulse generation; may also inhibit prostaglandin synthesis in CNS.</li> </ul>		
<b>Indications</b> <ul style="list-style-type: none"> <li>Management of acute pain</li> <li>Protocols: S-141, S-173</li> </ul>		<b>Contraindications</b> <ul style="list-style-type: none"> <li>Severe acute liver disease</li> <li>Known or suspected total dose exceeding 4,000 mg in a 24-hour period</li> <li>&lt;2 years of age</li> <li>Pregnancy with pain from active labor</li> </ul>
<b>Adult Dose</b> <ul style="list-style-type: none"> <li>Acetaminophen 1,000 mg IV over 15 min</li> </ul>		<b>Pediatric Dose</b> <ul style="list-style-type: none"> <li>Acetaminophen IV per drug chart in 100 ml of NS over 15 min</li> </ul>
<b>Adverse Effects</b> <ul style="list-style-type: none"> <li>Nausea/vomiting</li> <li>Skin rash</li> <li>Itching</li> <li>Overdose can cause hepatotoxicity</li> </ul>		
<b>Notes</b> <ul style="list-style-type: none"> <li>Remember to consider non-pharmacologic pain treatments, e.g., place in position of comfort, apply ice packs/splints PRN, and verbal reassurance.</li> <li>If patient refuses or has contraindications to acetaminophen, may treat as moderate pain with fentanyl or morphine.</li> </ul>		

## ACTIVATED CHARCOAL

EMT	AEMT	PARAMEDIC
<b>Class</b> <ul style="list-style-type: none"> <li>Antidote</li> </ul>		
<b>Mechanism of Action</b> <ul style="list-style-type: none"> <li>Adsorbs a variety of drugs and chemicals (e.g., physical binding of a molecule to the surface of charcoal particles); desorption of bound particles may occur unless the ratio of charcoal to toxin is extremely high.</li> </ul>		
<b>Indications</b> <ul style="list-style-type: none"> <li>Management of overdose and poisoning</li> <li>Protocols: S-134, S-165</li> </ul>		<b>Contraindications</b> <ul style="list-style-type: none"> <li>Caustic agents, hydrocarbons, or liquid ingestions (e.g., alcohols)</li> </ul>
<b>Adult Dose</b> <ul style="list-style-type: none"> <li>Activated charcoal 50 gm PO</li> </ul>		<b>Pediatric Dose</b> <ul style="list-style-type: none"> <li>Activated charcoal per drug chart PO</li> </ul>
<b>Adverse Effects</b> <ul style="list-style-type: none"> <li>Nausea/vomiting</li> </ul>		
<b>Notes</b> <ul style="list-style-type: none"> <li>Due to risk of charcoal aspiration, do not administer activated charcoal to a patient anticipated to have a decline in mental status over the next 30-60 minutes.</li> <li>Does not effectively bind to or adsorb certain ions like metals (iron, lithium, sodium), electrolytes (potassium, magnesium), and acids/alkalis.</li> <li>Authorized to administer activated charcoal on standing order, if recommended by Poison Control Center.</li> <li>The 24-hour toll-free telephone number to Poison Control Center is (800) 222-1222.</li> <li>Shake vigorously before use because separation occurs while it is stored.</li> </ul>		

## ADENOSINE

EMT	AEMT	PARAMEDIC
<b>Classification</b> <ul style="list-style-type: none"> <li>• Antidysrhythmic</li> </ul>		
<b>Mechanism of Action</b> <ul style="list-style-type: none"> <li>• Slows conduction through the AV node and interrupts AV reentry pathways as well as conduction through the SA nodes.</li> </ul>		
<b>Indications</b> <ul style="list-style-type: none"> <li>• Management of supraventricular tachycardia (SVT)</li> <li>• Protocols: S-127, S-163</li> </ul>		<b>Contraindications</b> <ul style="list-style-type: none"> <li>• Second- or third-degree AV block (without pacemaker)</li> <li>• Sick sinus syndrome</li> </ul>
<b>Adult Dose</b> <ul style="list-style-type: none"> <li>• Adenosine 6 mg rapid IV/IO followed by 20 mL NS rapid IV/IO</li> <li>• If no conversion, adenosine 12 mg rapid IV/IO followed by 20 mL NS rapid IV/IO, MR x1</li> </ul>		<b>Pediatric Dose</b> <ul style="list-style-type: none"> <li>• Adenosine per drug chart rapid IV/IO, followed with 20 mL NS rapid IV/IO, MR x2</li> </ul>
<b>Adverse Effects</b> <ul style="list-style-type: none"> <li>• Flushing</li> <li>• Sweating</li> <li>• Dizziness</li> <li>• Nervousness</li> <li>• Hypotension</li> <li>• Feeling of impending doom</li> <li>• Severe bronchospasm in patients with asthma</li> <li>• Paresthesia</li> </ul>		
<b>Notes</b> <ul style="list-style-type: none"> <li>• For stable patients, use Valsalva maneuver prior to administration. Discontinue Valsalva maneuver after 5-10 seconds if no conversion.</li> <li>• Ideally, cannulate a proximal vein with an 18-20g catheter. Use the IV port closest to the patient and rapidly flush with 20mL normal saline immediately.</li> <li>• Run a 6-second ECG strip before, during, and after drug administration.</li> <li>• Patients frequently have a brief period of escape beats or asystole before the sinus node starts up again. This may be perceived as a feeling of impending death and can be extremely frightening for patients.</li> <li>• If the wide-complex tachycardia is ventricular in origin, adenosine is highly unlikely to result in cardioversion.</li> <li>• Bronchospasm may occur in patients with a history of airway disease, such as asthma or COPD.</li> </ul>		



## ALBUTEROL / LEVALBUTEROL

EMT	AEMT	PARAMEDIC
<b>Classification</b> <ul style="list-style-type: none"><li>Beta-2 receptor agonist</li></ul>		
<b>Mechanism of Action</b> <ul style="list-style-type: none"><li>Albuterol: Selective beta-2 adrenergic agonist that causes relaxation of smooth muscles in the bronchial tree, decreasing airway resistance, facilitating mucous drainage and increasing vital capacity; shifts potassium intracellular; has mild beta-1 activity that may increase heart rate.</li><li>Levalbuterol: Relaxes bronchial smooth muscle by action on beta-2 receptors; less likely to cause tachycardia than albuterol.</li></ul>		
<b>Indications</b> <ul style="list-style-type: none"><li>Management of respiratory distress (non-cardiac, anaphylaxis, and burns), suspected hyperkalemia, and specific crush injuries</li><li>Protocols: S-122, S-124, S-127, S-131, S-136, S-139, S-162, S-163, S-167, S-169, S-170</li></ul>		<b>Contraindications</b> <ul style="list-style-type: none"><li>&lt;6 years of age (levalbuterol only)</li></ul>
<b>Adult Dose</b> <ul style="list-style-type: none"><li>For respiratory distress (non-cardiac, anaphylaxis, and burns), albuterol/levalbuterol 6 mL via nebulizer, MR</li><li>For suspected hyperkalemia and specific crush injuries, continuous albuterol/levalbuterol 6 mL via nebulizer</li></ul>		<b>Pediatric Dose</b> <ul style="list-style-type: none"><li>For respiratory distress (non-cardiac, anaphylaxis, and burns), albuterol/levalbuterol per drug chart via nebulizer, MR</li><li>For suspected hyperkalemia and specific crush injuries, continuous albuterol/levalbuterol per drug chart via nebulizer</li></ul>
<b>Adverse Effects</b> <ul style="list-style-type: none"><li>Tremors</li><li>Headache</li><li>Nervousness</li><li>Dizziness</li><li>Dry mouth</li><li>Dysrhythmias</li><li>Chest discomfort</li><li>Palpitations</li><li>Nausea/vomiting</li></ul>		
<b>Notes</b> <ul style="list-style-type: none"><li>Ineffective in croup and should be avoided.</li><li>Pediatric patients between 2-6 years of age may be more prone to adverse effects.</li><li>Do not assume patients have administered their own drug properly. Do not include home doses of albuterol/levalbuterol in your total drug administration consideration.</li><li>If concerned about aerosolized infectious exposure, substitute with MDI, if available.</li><li>Patients may need to be instructed on proper use of the MDI.</li><li>Levalbuterol may be substituted for albuterol and can be combined with ipratropium bromide. This substitution option applies to patients ≥6 years of age.</li></ul>		

## AMIODARONE

EMT	AEMT	PARAMEDIC
<b>Classification</b> <ul style="list-style-type: none"> <li>Antidysrhythmic</li> </ul>		
<b>Mechanism of Action</b> <ul style="list-style-type: none"> <li>Class III antidysrhythmic agent that inhibits adrenergic stimulation; affects sodium, potassium, and calcium channels; markedly prolongs action potential and repolarization; decreases AV conduction and sinus node function.</li> </ul>		
<b>Indications</b> <ul style="list-style-type: none"> <li>Management of ventricular tachycardia and ventricular fibrillation</li> <li>Protocols: S-127, S-163</li> </ul>		<b>Contraindications</b>
<b>Adult Dose</b> <ul style="list-style-type: none"> <li>For stable VT, amiodarone 150 mg in 100 mL of NS over 10 min IV/IO, MR x1 in 10 min</li> <li>For persistent VF/pulseless VT after 3 defibrillation attempts, amiodarone 300 mg IV/IO, MR 150 mg q3-5 min (max 450 mg)</li> <li>For reported/witnessed AICD firing <math>\geq 2</math>, amiodarone 150 mg in 100 mL of NS over 10 min IV/IO, MR x1 in 10 min</li> </ul>		<b>Pediatric Dose</b> <ul style="list-style-type: none"> <li>For stable VT, amiodarone per drug chart BHPO</li> <li>For persistent VF/pulseless VT after 3 defibrillation attempts, amiodarone per drug chart IV/IO, MR per drug chart x2</li> <li>For reported/witnessed AICD firing <math>\geq 2</math>, amiodarone per drug chart, MR BHPO</li> </ul>
<b>Adverse Effects</b> <ul style="list-style-type: none"> <li>Hypotension</li> <li>Worsening of dysrhythmias</li> <li>Prolonged QT interval</li> <li>Bradycardia</li> <li>AV block</li> <li>Dizziness</li> <li>Nausea/vomiting</li> <li>Burning at the IV site</li> </ul>		
<b>Notes</b> <ul style="list-style-type: none"> <li>If patient is in unstable ventricular tachycardia, synchronized cardioversion should be performed first.</li> <li>Monitor the patient for hypotension and increasing PR and QT intervals.</li> <li>Risk factors for acute hypotension are patients <math>&gt;65</math> years of age with a history of myocardial infarction.</li> <li>Closely monitor heart rate, blood pressure, and cardiac rhythm during and after administration.</li> <li>Do not infuse with Ringer's lactate solution.</li> </ul>		

## ASPIRIN

EMT <sup>L</sup>	AEMT	PARAMEDIC
<b>Classification</b> <ul style="list-style-type: none"> <li>• Antiplatelet agent, non-steroidal anti-inflammatory drug (NSAID)</li> </ul>		
<b>Mechanism of Action</b> <ul style="list-style-type: none"> <li>• Inhibits platelet aggregation and inhibits synthesis of prostaglandin by cyclooxygenase; has antipyretic and analgesic activity.</li> </ul>		
<b>Indications</b> <ul style="list-style-type: none"> <li>• Antiplatelet agent for the care of patients suspected of suffering from an acute coronary syndrome</li> <li>• Protocols: S-126</li> </ul>		<b>Contraindications</b>
<b>Adult Dose</b> <ul style="list-style-type: none"> <li>• Aspirin 324 mg chewable PO</li> </ul>		<b>Pediatric Dose</b> <ul style="list-style-type: none"> <li>• Not indicated for use in pediatrics</li> </ul>
<b>Adverse Effects</b> <ul style="list-style-type: none"> <li>• GI bleeding</li> <li>• Epigastric pain</li> <li>• Nausea/vomiting</li> </ul>		
<b>Notes</b> <ul style="list-style-type: none"> <li>• <b>EMT: Authorized to assist patient to self-medicate own prescribed aspirin up to a maximum dose of 325 mg.</b></li> <li>• Administer aspirin even if discomfort/pain has resolved. If aspirin is not given, document the reason.</li> <li>• Aspirin may be withheld if an equivalent dose has been administered by a healthcare professional.</li> </ul>		

# ATROPINE

EMT	AEMT	PARAMEDIC
<b>Classification</b> <ul style="list-style-type: none"> <li>Anticholinergic, toxicity antidote</li> </ul>		
<b>Mechanism of Action</b> <ul style="list-style-type: none"> <li>Blocks the action of acetylcholine at parasympathetic sites in smooth muscle, secretory glands, and the CNS; increases cardiac output, dries secretions; reverses the muscarinic effects of cholinergic poisoning.</li> </ul>		
<b>Indications</b> <ul style="list-style-type: none"> <li>Management of unstable bradycardia and symptomatic organophosphate poisoning</li> <li>Protocols: S-127, S-134, S-163, S-165</li> </ul>		<b>Contraindications</b>
<b>Adult Dose</b> <ul style="list-style-type: none"> <li>For unstable bradycardia, atropine 1 mg IV/IO, MR q3-5 min to max 3 mg</li> <li>For symptomatic organophosphate poisoning, atropine 2 mg IV/IO. For continued signs/symptoms of SLUDGE/BBB, double prior atropine dose IV/IO q3-5 min</li> </ul>		<b>Pediatric Dose</b> <ul style="list-style-type: none"> <li>For unstable bradycardia after 3 doses of epinephrine, atropine per drug chart IV/IO, MR x1 in 5 min</li> <li>For symptomatic organophosphate poisoning, atropine per drug chart IV/IO. For continued signs/symptoms of SLUDGE/BBB, double prior atropine dose IV/IO q3-5 min</li> </ul>
<b>Adverse Effects</b> <ul style="list-style-type: none"> <li>Drowsiness</li> <li>Confusion</li> <li>Headache</li> <li>Palpitations</li> <li>Dysrhythmias</li> <li>Nausea/vomiting</li> <li>Pupil dilation</li> <li>Dry mouth/nose/skin</li> <li>Blurred vision</li> <li>Urinary retention</li> <li>Flushed, hot, dry skin</li> </ul>		
<b>Notes</b> <ul style="list-style-type: none"> <li>May omit atropine in bradycardic patients unlikely to have clinical benefit (e.g., heart transplant patients, second-degree type II, or third-degree heart block).</li> <li>Use cautiously if myocardial infarction or ischemia is suspected, as atropine will increase myocardial oxygen demand, which may worsen the infarct.</li> <li>In organophosphate poisoning, titrate atropine to SLUDGE/BBB signs/symptoms, not to tachycardia. Cardiac monitoring should be considered in all cases of severe organophosphate poisoning.</li> </ul>		

## BUPRENORPHINE-NALOXONE

EMT	AEMT	PARAMEDIC <sup>S</sup>
<b>Classification</b> <ul style="list-style-type: none"><li>• Buprenorphine: analgesic, opioid antagonist, opioid partial agonist</li><li>• Naloxone: opioid reversal agent</li></ul>		
<b>Mechanism of Action</b> <ul style="list-style-type: none"><li>• Exerts its analgesic effect via high affinity binding to mu-opioid receptors in the CNS; displays partial mu agonist and weak kappa antagonist activity. Naloxone is a competitive opioid antagonist.</li></ul>		
<b>Indications</b> <ul style="list-style-type: none"><li>• Management of opioid withdrawal and opioid use disorder</li><li>• Protocols: S-145</li></ul>		<b>Contraindications</b> <ul style="list-style-type: none"><li>• Any methadone use within the last 10 days</li><li>• Lack of opioid withdrawal signs or symptoms</li><li>• Severe medical illness (e.g., sepsis, respiratory distress)</li><li>• Altered mental status</li><li>• &lt;16 years of age</li></ul>
<b>Adult Dose</b> <ul style="list-style-type: none"><li>• Buprenorphine-naloxone (Suboxone®) 16 mg/4 mg SL BHO (opioid withdrawal base)</li><li>• For continued symptoms, repeat with buprenorphine-naloxone (Suboxone®) 8 mg/2 mg SL to a max of 24 mg/6 mg</li></ul>		<b>Pediatric Dose</b> <ul style="list-style-type: none"><li>• Not indicated for use in pediatrics</li></ul>
<b>Adverse Effects</b> <ul style="list-style-type: none"><li>• Diaphoresis</li><li>• Abdominal pain</li><li>• Nausea</li><li>• Headache</li><li>• Withdrawal syndrome</li><li>• Palpitations</li></ul>		
<b>Notes</b> <ul style="list-style-type: none"><li>• Use of buprenorphine-naloxone is only authorized for agencies participating in the Buprenorphine Pilot Program.</li><li>• Sharp Grossmont Hospital and Palomar Medical Center – Escondido are approved opioid withdrawal bases.</li><li>• For patients with overdoses reversed by naloxone, calculate a COWS score and consider administration.</li><li>• Calculate a COWS score before and after administration.</li></ul>		

## CALCIUM CHLORIDE

EMT	AEMT	PARAMEDIC
<b>Classification</b> <ul style="list-style-type: none"> <li>Electrolyte, antidote</li> </ul>		
<b>Mechanism of Action</b> <ul style="list-style-type: none"> <li>Essential regulator for the excitation threshold of nerves and muscles; causes significant increase in myocardial contractility and ventricular automaticity. Antidote for some electrolyte imbalances and calcium channel and/or beta blocker toxicity.</li> </ul>		
<b>Indications</b> <ul style="list-style-type: none"> <li>Management of suspected hyperkalemia, calcium channel blocker overdose, and specific crush injuries</li> <li>Protocols: S-127, S-131, S-134, S-139, S-163, S-169</li> </ul>		<b>Contraindications</b>
<b>Adult Dose</b> <ul style="list-style-type: none"> <li>For PEA with suspected hyperkalemia, CaCl<sub>2</sub> 1 gm IV/IO</li> <li>For suspected hyperkalemia, if widened QRS complex, immediately administer CaCl<sub>2</sub> 1 gm IV/IO</li> <li>For suspected calcium channel blocker OD, CaCl<sub>2</sub> 1 gm IV/IO</li> <li>For specific crush injuries, CaCl<sub>2</sub> 1 gm IV/IO over 30 sec</li> </ul>		<b>Pediatric Dose</b> <ul style="list-style-type: none"> <li>For PEA with suspected hyperkalemia, CaCl<sub>2</sub> per drug chart IV/IO, MR x1 in 5 min for continued ECG findings consistent with hyperkalemia</li> <li>For specific crush injuries, CaCl<sub>2</sub> IV/IO over 30 sec per drug chart, MR x1 in 5 min for continued ECG findings consistent with hyperkalemia</li> </ul>
<b>Adverse Effects</b> <ul style="list-style-type: none"> <li>Syncope</li> <li>Bradycardia</li> <li>Asystole</li> <li>Hypotension</li> <li>Nausea/vomiting</li> <li>Metallic taste with rapid injection</li> <li>Tissue necrosis at injection site</li> </ul>		
<b>Notes</b> <ul style="list-style-type: none"> <li>Confirm IV is patent prior to administration, as extravasation causes severe tissue necrosis. Avoid use in small veins (feet/hands) for this reason.</li> <li>Precipitates to form calcium carbonate (chalk) when used with sodium bicarbonate. Administer calcium chloride and sodium bicarbonate in separate IV/IO or thoroughly flush in between administrations using at least 10 mL of normal saline.</li> <li>Calcium chloride contains three times more elemental calcium than calcium gluconate does. Constant ECG and vital sign monitoring are essential.</li> <li>Contact base hospital if dose exceeds par level.</li> </ul>		

## DEXTROSE

EMT	AEMT	PARAMEDIC
<b>Classification</b> <ul style="list-style-type: none"> <li>Glucose-elevating agent</li> </ul>		
<b>Mechanism of Action</b> <ul style="list-style-type: none"> <li>Main form of glucose used by the body to create energy; elevates serum blood glucose levels.</li> </ul>		
<b>Indications</b> <ul style="list-style-type: none"> <li>Management of hypoglycemia</li> <li>Protocols: S-123, S-161</li> </ul>		<b>Contraindications</b>
<b>Adult Dose</b> <ul style="list-style-type: none"> <li>Dextrose 25 gm IV if BS &lt;60 mg/dL</li> <li>If patient remains symptomatic and BS remains &lt;60 mg/dL, MR</li> </ul>		<b>Pediatric Dose</b> <ul style="list-style-type: none"> <li>D<sub>10</sub> per drug chart IV if BS &lt;60 mg/dL (&lt;45 mg/dL for neonate)</li> <li>If patient remains symptomatic and BS remains &lt;60 mg/dL (&lt;45 mg/dL for neonate), MR</li> </ul>
<b>Adverse Effects</b> <ul style="list-style-type: none"> <li>Warmth, pain, burning, or phlebitis from IV infusion</li> </ul>		
<b>Notes</b> <ul style="list-style-type: none"> <li>Confirm IV is patent prior to administration, as extravasation causes severe tissue necrosis. Use a large vein for administration and monitor the site closely.</li> <li>Immediately stop administration if extravasation occurs; document it and notify the receiving facility staff.</li> <li>Do not administer to patients with stroke unless hypoglycemia is documented.</li> <li>Repeat blood glucose level is required if patient remains on scene (AMA or release) and initial blood glucose level was abnormal.</li> <li>Repeat blood glucose is not indicated enroute if patient status is improving.</li> </ul>		

## DIPHENHYDRAMINE

EMT	AEMT	PARAMEDIC
<b>Classification</b> <ul style="list-style-type: none"> <li>Antihistamine</li> </ul>		
<b>Mechanism of Action</b> <ul style="list-style-type: none"> <li>H<sub>1</sub> (histamine) receptor antagonist; works on effector cells in respiratory tract, blood vessels, and GI smooth muscle; also has anticholinergic properties.</li> </ul>		
<b>Indications</b> <ul style="list-style-type: none"> <li>Management of allergic reactions and extrapyramidal reactions</li> <li>Protocols: S-122, S-134, S-162, S-165</li> </ul>		<b>Contraindications</b>
<b>Adult Dose</b> <ul style="list-style-type: none"> <li>Diphenhydramine 50 mg IV/IM</li> </ul>		<b>Pediatric Dose</b> <ul style="list-style-type: none"> <li>Diphenhydramine per drug chart IV/IM</li> </ul>
<b>Adverse Effects</b> <ul style="list-style-type: none"> <li>Drowsiness</li> <li>Sedation</li> <li>Seizures</li> <li>Dizziness</li> <li>Headache</li> <li>Blurred vision</li> <li>Wheezing</li> <li>Thickening of bronchial secretions</li> <li>Palpitations</li> <li>Hypotension</li> <li>Dysrhythmias</li> <li>Dry mouth</li> <li>Nausea/vomiting</li> <li>Hallucinations, confusion, and paradoxical CNS excitation can occur in children</li> </ul>		
<b>Notes</b> <ul style="list-style-type: none"> <li>Administer slow IV.</li> <li>Epinephrine is the most important immediate treatment for anaphylaxis and should be administered as soon as anaphylaxis is recognized. The pharmacologic actions address the pathophysiological changes that occur in anaphylaxis better than any other medication. <b>Delayed epinephrine injection is associated with fatalities.</b></li> <li>May be administered between epinephrine doses in anaphylaxis.</li> </ul>		



## EPINEPHRINE (1:1,000)

EMT <sup>L</sup>	AEMT	PARAMEDIC
<b>Classification</b> <ul style="list-style-type: none"> <li>Alpha/beta adrenergic agonist</li> </ul>		
<b>Mechanism of Action</b> <ul style="list-style-type: none"> <li>A naturally occurring catecholamine that acts directly on alpha- and beta-adrenergic receptors. It is the most potent activator of alpha receptors, vasoconstricting the aorta and peripheral vasculature. Beta-1 stimulation increases inotropy, chronotropy, and AV conduction. Beta-2 stimulation causes bronchial smooth muscle relaxation and vasodilation to internal organs and skeletal muscles.</li> </ul>		
<b>Indications</b> <ul style="list-style-type: none"> <li>Management of anaphylaxis, severe respiratory distress/failure, and stridor in pediatrics</li> <li>Protocols: S-122, S-136, S-162, S-167, S-170</li> </ul>		<b>Contraindications</b>
<b>Adult Dose</b> <ul style="list-style-type: none"> <li>Epinephrine 1:1,000 (1 mg/mL) 0.5 mg IM, MR x2 q5 min</li> </ul>		<b>Pediatric Dose</b> <ul style="list-style-type: none"> <li>IM: 1:1,000 per drug chart IM, MR x2 q5 min</li> <li>Nebulized: 1:1,000 per drug chart (combined with 3 mL normal saline) via nebulizer, MR x1</li> </ul>
<b>Adverse Effects</b> <ul style="list-style-type: none"> <li>Nervousness/restlessness</li> <li>Headache</li> <li>Chest pain</li> <li>Tremors</li> <li>Dysrhythmias</li> <li>Nausea/vomiting</li> <li>Hypertension</li> <li>Palpitations</li> </ul>		
<b>Notes</b> <ul style="list-style-type: none"> <li><b>EMT: Authorized to administer via auto-injector only.</b></li> <li>Epinephrine is the most important immediate treatment for anaphylaxis and should be administered as soon as anaphylaxis is recognized. The pharmacologic actions address the pathophysiologic changes that occur in anaphylaxis better than any other medication. <b>Delayed epinephrine injection is associated with fatalities.</b></li> <li>Inadvertent IV injection of usual IM formulation and dose constitutes a 10-fold overdose that can result in sudden and severe hypertension and cerebral hemorrhage.</li> <li>In patients who remain hypotensive after initial IM epinephrine, administer IV fluids. Have push-dose epinephrine ready for patients unresponsive to repeated IM epinephrine and IV fluids.</li> </ul>		

## EPINEPHRINE (1:10,000)

EMT	AEMT	PARAMEDIC
<b>Classification</b> <ul style="list-style-type: none"> <li>Alpha/beta adrenergic agonist</li> </ul>		
<b>Mechanism of Action</b> <ul style="list-style-type: none"> <li>A naturally occurring catecholamine that acts directly on alpha- and beta-adrenergic receptors. It is the most potent activator of alpha receptors, vasoconstricting the aorta and peripheral vasculature. Beta-1 stimulation increases inotropy, chronotropy, and AV conduction. Beta-2 stimulation causes bronchial smooth muscle relaxation and vasodilation to internal organs and skeletal muscles.</li> </ul>		
<b>Indications</b> <ul style="list-style-type: none"> <li>Management of cardiac arrest and bradycardia in pediatric patients</li> <li>Protocols: S-127, S-130, S-133, S-163, S-166, S-176</li> </ul>		<b>Contraindications</b>
<b>Adult Dose</b> <ul style="list-style-type: none"> <li>For cardiac arrest, epinephrine 1:10,000 1 mg IV/IO q3-5 min</li> <li>For VF and pulseless VT, epinephrine 1:10,000 1 mg IV/IO q3-5 min, begin after second defibrillation</li> <li>For cardiac arrest with hypothermia, epinephrine 1:10,000 1 mg IV/IO x1</li> </ul>		<b>Pediatric Dose</b> <ul style="list-style-type: none"> <li>For cardiac arrest or newborn with HR &lt;60, epinephrine 1:10,000 per drug chart IV/IO q3-5 min</li> <li>For VF and pulseless VT, epinephrine 1:10,000 per drug chart IV/IO q3-5 min, begin after second defibrillation</li> <li>For cardiac arrest with hypothermia, epinephrine 1:10,000 per drug chart IV/IO x1</li> <li>For unstable bradycardia, epinephrine 1:10,000 per drug chart IV/IO, MR x2 q3-5 minutes. MR q3-5 minutes BHO</li> </ul>
<b>Adverse Effects</b> <ul style="list-style-type: none"> <li>Nervousness/restlessness</li> <li>Headache</li> <li>Chest pain</li> <li>Tremors</li> <li>Dysrhythmias</li> <li>Nausea/vomiting</li> <li>Hypertension</li> <li>Palpitations</li> </ul>		
<b>Notes</b> <ul style="list-style-type: none"> <li>During CPR, epinephrine is administered to increase systemic vasomotor tone, thereby increasing diastolic blood pressure and coronary perfusion pressure.</li> </ul>		

## EPINEPHRINE (1:100,000)

EMT	AEMT	PARAMEDIC
<b>Classification</b> <ul style="list-style-type: none"> <li>Alpha/beta adrenergic agonist</li> </ul>		
<b>Mechanism of Action</b> <ul style="list-style-type: none"> <li>A naturally occurring catecholamine that acts directly on alpha- and beta-adrenergic receptors. It is the most potent activator of alpha receptors, vasoconstricting the aorta and peripheral vasculature. Beta-1 stimulation increases inotropy, chronotropy, and AV conduction. Beta-2 stimulation causes bronchial smooth muscle relaxation and vasodilation to internal organs and skeletal muscles.</li> </ul>		
<b>Indications</b> <ul style="list-style-type: none"> <li>Management of severe anaphylaxis and shock</li> <li>Protocols: S-122, S-126, S-127, S-138, S-143, S-162, S-163, S-168, S-177</li> </ul>		<b>Contraindications</b>
<b>Adult Dose</b> <ul style="list-style-type: none"> <li>Push-dose epinephrine 1:100,000 (0.01 mg/mL) 1 mL IV/IO, MR q3 min, titrate to SBP <math>\geq</math>90 mmHg</li> </ul>		<b>Pediatric Dose</b> <ul style="list-style-type: none"> <li>Push-dose epinephrine 1:100,000 (0.01 mg/mL) per drug chart IV/IO, MR q3 min, titrate to adequate perfusion</li> </ul>
<b>Adverse Effects</b> <ul style="list-style-type: none"> <li>Nervousness/restlessness</li> <li>Headache</li> <li>Chest pain</li> <li>Tremors</li> <li>Dysrhythmias</li> <li>Nausea/vomiting</li> <li>Hypertension</li> <li>Palpitations</li> </ul>		
<b>Notes</b> <ul style="list-style-type: none"> <li>Administer slowly via IV and titrate to adequate perfusion.</li> <li>Patients with anaphylaxis unresponsive to IM epinephrine and aggressive fluid resuscitation may benefit from push-dose epinephrine.</li> </ul>		
<b>Mixing Instructions</b> <ul style="list-style-type: none"> <li>Remove 1 mL normal saline (NS) from the 10 mL NS syringe</li> <li>Add 1 mL of epinephrine 1:10,000 (0.1 mg/mL) to 9 mL NS syringe</li> <li>The mixture now has 10 mL of epinephrine at 0.01 mg/mL (10 mcg/mL) concentration</li> </ul>		

## FENTANYL

EMT	AEMT	PARAMEDIC
<b>Classification</b> <ul style="list-style-type: none"> <li>Synthetic opioid, opioid analgesic</li> </ul>		
<b>Mechanism of Action</b> <ul style="list-style-type: none"> <li>Opioid agonist-analgesic; inhibits ascending pain pathways, thus altering pain perception; increases pain threshold; produces analgesia, respiratory depression, and sedation.</li> </ul>		
<b>Indications</b> <ul style="list-style-type: none"> <li>Management of acute pain</li> <li>Protocols: S-141, S-173</li> </ul>		<b>Contraindications</b> <ul style="list-style-type: none"> <li>Pregnancy with pain from active labor</li> </ul>
<b>Adult Dose</b> <ul style="list-style-type: none"> <li>IV: Fentanyl up to 100 mcg IV. MR up to 50 mcg IV q5 min x2. Maximum total dose 200 mcg IV</li> <li>IN: Up to 50 mcg IN q15 min x2. 3<sup>rd</sup> dose fentanyl up to 50 mcg IN</li> </ul>		<b>Pediatric Dose</b> <ul style="list-style-type: none"> <li>IV: <ul style="list-style-type: none"> <li>&lt;10 kg: Fentanyl IV per drug chart. MR at half initial IV dose BHO</li> <li>≥10 kg: Fentanyl IV per drug chart. MR at half initial IV dose</li> </ul> </li> <li>IN: <ul style="list-style-type: none"> <li>&lt;10 kg: Fentanyl IN per drug chart. MR at initial IN dose BHO</li> <li>≥10 kg: Fentanyl IN per drug chart. MR at initial IN dose</li> </ul> </li> </ul>
<b>Adverse Effects</b> <ul style="list-style-type: none"> <li>Confusion</li> <li>Paradoxical excitation</li> <li>Delirium</li> <li>Sedation/drowsiness</li> <li>CNS depression</li> <li>Respiratory depression</li> <li>Apnea</li> <li>Dyspnea</li> <li>Dysrhythmias</li> <li>Hypotension</li> <li>Syncope</li> <li>Nausea/vomiting</li> <li>Abdominal pain</li> </ul>		
<b>Notes</b> <ul style="list-style-type: none"> <li>Remember to consider non-pharmacologic pain treatments, e.g., place in position of comfort, apply ice packs/splints PRN, and verbal reassurance.</li> <li>Closely monitor respiratory status (including capnography) after administration.</li> <li>An initial dose of 100 mcg IV or 50 mcg IN is well tolerated in most adults.</li> <li>In opioid-naive or elderly patients, start with a lower dose. For elderly patients not taking opioids, 25 mcg is frequently sufficient for pain relief. Consider beginning with 25 mcg and titrating up in increments of 25 mcg to achieve pain relief without respiratory depression.</li> <li>For pediatric patients &gt;36 kg or longer than the LBRT, rather than administering the maximum dose, use weight-based dosing for both initial and repeat doses. It is acceptable to round doses (up or down) to the nearest 5 mcg.</li> </ul>		

# GLUCAGON

EMT	AEMT	PARAMEDIC
<b>Classification</b> <ul style="list-style-type: none"> <li>Glucose-elevating agent, antidote</li> </ul>		
<b>Mechanism of Action</b> <ul style="list-style-type: none"> <li>A hormone naturally produced by pancreatic alpha cells of the islets of Langerhans. Causes breakdown of glycogen (stored in the liver) to glucose and inhibits the synthesis of glycogen from glucose. These combined actions increase blood glucose levels.</li> </ul>		
<b>Indications</b> <ul style="list-style-type: none"> <li>Management of hypoglycemia and beta blocker overdose with cardiac effects</li> <li>Protocols: S-123, S-134, S-161</li> </ul>		<b>Contraindications</b>
<b>Adult Dose</b> <ul style="list-style-type: none"> <li>For hypoglycemia, glucagon 1 mL IM</li> <li>For beta blocker overdose, glucagon 1-5 mg IV, MR 5-10 min, for a total of 10 mg</li> </ul>		<b>Pediatric Dose</b> <ul style="list-style-type: none"> <li>Glucagon per drug chart IM</li> </ul>
<b>Adverse Effects</b> <ul style="list-style-type: none"> <li>Dizziness</li> <li>Headache</li> <li>Hypotension</li> <li>Tachycardia</li> <li>Nausea/vomiting</li> <li>Rebound hypoglycemia</li> </ul>		
<b>Notes</b> <ul style="list-style-type: none"> <li><b>AEMT: Authorized to administer via IM only.</b></li> <li>Use mixture immediately after reconstitution of dry powder.</li> <li>Patient usually awakens from hypoglycemic coma in 5-20 minutes after glucagon injection. PO carbohydrates should be given as soon as possible after patient regains consciousness and is able to maintain airway.</li> <li>Anticipate nausea/vomiting following administration of glucagon.</li> </ul>		

## IPRATROPIUM BROMIDE

EMT	AEMT	PARAMEDIC
<b>Classification</b> <ul style="list-style-type: none"> <li>Anticholinergic</li> </ul>		
<b>Mechanism of Action</b> <ul style="list-style-type: none"> <li>Anticholinergic (parasympatholytic) agent; inhibits vagally mediated reflexes by antagonizing acetylcholine action; prevents increase in intracellular calcium concentration that is caused by interaction of acetylcholine with muscarinic receptors on bronchial smooth muscle.</li> </ul>		
<b>Indications</b> <ul style="list-style-type: none"> <li>Management of respiratory distress (non-cardiac)</li> <li>Protocols: S-122, S-136, S-162, S-167</li> </ul>		<b>Contraindications</b>
<b>Adult Dose</b> <ul style="list-style-type: none"> <li>Ipratropium bromide 2.5 mL 0.02% via nebulizer added to first dose of albuterol/levalbuterol</li> </ul>		<b>Pediatric Dose</b> <ul style="list-style-type: none"> <li>Ipratropium bromide per drug chart via nebulizer added to first dose of albuterol/levalbuterol</li> </ul>
<b>Adverse Effects</b> <ul style="list-style-type: none"> <li>Headache</li> <li>Dizziness</li> <li>Nervousness</li> <li>Tremors</li> <li>Dyspnea</li> <li>Worsening COPD symptoms</li> <li>Hypertension</li> <li>Tachycardia</li> <li>Palpitations</li> <li>Flushing</li> <li>Dry mouth</li> <li>Nausea/vomiting</li> <li>GI discomfort</li> </ul>		
<b>Notes</b> <ul style="list-style-type: none"> <li>If concerned about aerosolized infectious exposure, substitute with MDI, if available.</li> <li>Patients may need to be instructed on proper use of the MDI.</li> </ul>		

# KETAMINE

EMT	AEMT	PARAMEDIC
<b>Classification</b> <ul style="list-style-type: none"> <li>Analgesic (in sub-dissociative doses)</li> </ul>		
<b>Mechanism of Action</b> <ul style="list-style-type: none"> <li>Dissociative anesthetic; produces a cataleptic-like state in which the patient is dissociated from the surrounding environment by direct action on the cortex and limbic system; noncompetitive NMDA receptor antagonist that blocks glutamate; low (sub-dissociative) doses produce analgesia.</li> </ul>		
<b>Indications</b> <ul style="list-style-type: none"> <li>Management of acute pain</li> <li>Protocols: S-141</li> </ul>		<b>Contraindications</b> <ul style="list-style-type: none"> <li>Sedation</li> <li>Use of dissociative dose ranges</li> <li>Pregnancy with pain from active labor</li> </ul>
<b>Adult Dose</b> <ul style="list-style-type: none"> <li>IV: 0.3 mg/kg in 100 mL of NS over 10 min IV. Maximum for any IV dose is 30 mg. MR x1 in 15 min if pain remains moderate or severe.</li> <li>IN: 0.5 mg/kg IN (50 mg/mL concentration). Maximum for any IN dose is 50 mg. MR x1 in 15 min if pain remains moderate or severe.</li> </ul>		<b>Pediatric Dose</b> <ul style="list-style-type: none"> <li>Not indicated for use in pediatrics</li> </ul>
<b>Adverse Effects</b> <ul style="list-style-type: none"> <li>Hypertension</li> <li>Hallucinations</li> <li>Nausea/vomiting</li> <li>Nystagmus</li> <li>Bronchodilation</li> <li>Tachycardia</li> <li>Increased secretions</li> <li>Hypersalivation</li> <li>Laryngospasm</li> </ul>		
<b>Notes</b> <ul style="list-style-type: none"> <li>Not authorized for sedation.</li> <li>Not authorized for use in dissociative dose ranges. To reduce the risk for dissociative states, maximum dose is not to exceed 60 mg IV or 100 mg IN.</li> <li>Administration results in elevated heart rate and blood pressure.</li> <li>Do not administer to patients who cannot tolerate these changes in vital signs.</li> <li>Rapid administration can result in respiratory and potentially cardiac arrest. Administer slowly.</li> <li>Do not infuse with Ringer's lactate solution.</li> </ul>		

# LIDOCAINE

EMT	AEMT	PARAMEDIC
<b>Classification</b> <ul style="list-style-type: none"> <li>Antidysrhythmic, anesthetic</li> </ul>		
<b>Mechanism of Action</b> <ul style="list-style-type: none"> <li>Class 1b antidysrhythmic; combines with fast sodium channels and thereby inhibits recovery after repolarization, resulting in decreasing myocardial excitability and conduction velocity.</li> </ul>		
<b>Indications</b> <ul style="list-style-type: none"> <li>Management of ventricular tachycardia and ventricular fibrillation, and as a local anesthetic for the IO procedure in conscious adults</li> <li>Protocols: S-104, S-127, S-163</li> </ul>		<b>Contraindications</b> <ul style="list-style-type: none"> <li>Cardiac pre-excitation syndromes, e.g., Wolff-Parkinson-White (WPW) syndrome, Lown-Ganong-Levine (LGL) syndrome</li> </ul>
<b>Adult Dose</b> <ul style="list-style-type: none"> <li>For stable VT, persistent VF/pulseless VT after 3 defibrillation attempts, and reported/witnessed AICD firing <math>\geq 2</math>, lidocaine 1.5 mg/kg IV/IO, MR at 0.5 mg/kg IV/IO q5 min to max 3 mg/kg</li> <li>For IO procedure in conscious adult patients, slowly infuse lidocaine 40 mg IO prior to fluid/medication administration</li> </ul>		<b>Pediatric Dose</b> <ul style="list-style-type: none"> <li>For stable VT, lidocaine per drug chart BHPO</li> <li>For persistent VF/pulseless VT after 3 defibrillation attempts, lidocaine per drug chart IV/IO, MR per drug chart x1 q5 min</li> <li>For reported/witnessed AICD firing <math>\geq 2</math>, lidocaine per drug chart, MR BHPO</li> </ul>
<b>Adverse Effects</b> <ul style="list-style-type: none"> <li>Drowsiness</li> <li>Confusion</li> <li>Seizures</li> <li>Slurred speech</li> <li>Hypotension</li> <li>Dysrhythmias</li> <li>Cardiac arrest</li> <li>Nausea/vomiting</li> </ul>		
<b>Notes</b> <ul style="list-style-type: none"> <li>If patient is in unstable ventricular tachycardia, synchronized cardioversion should be performed first.</li> <li>Adult doses should be given in increments rounded (up or down) to the nearest 20 mg amount.</li> <li>Lidocaine jelly may be applied to an ET tube for intubation or on a nasopharyngeal airway.</li> </ul>		



# MIDAZOLAM

EMT	AEMT	PARAMEDIC
<b>Classification</b> <ul style="list-style-type: none"> <li>Anticonvulsant, antianxiety agent, anxiolytics, benzodiazepines</li> </ul>		
<b>Mechanism of Action</b> <ul style="list-style-type: none"> <li>Binds to receptors at multiple sites within the CNS; potentiates GABA receptor system which produces anxiolytic, anticonvulsant, muscle relaxant, and amnesic effects.</li> </ul>		
<b>Indications</b> <ul style="list-style-type: none"> <li>Management of seizures and eclampsia, sedation pre-cardioversion/pre-pacing, unable to tolerate CPAP, intubated patients with agitation, and agitated/combatative patients</li> <li>Protocols: S-123, S-127, S-133, S-135, S-136, S-142, S-161, S-163, S-166, S-175</li> </ul>		<b>Contraindications</b>
<b>Adult Dose</b> <ul style="list-style-type: none"> <li>Seizure <ul style="list-style-type: none"> <li>Patients <math>\geq 40</math> kg: midazolam 10 mg IM</li> <li>Patients <math>&lt; 40</math> kg: midazolam 0.2 mg/kg IM</li> <li>If vascular access present, midazolam 0.2 mg/kg IV/IO to max dose of 5 mg, MR x1 in 10 min. Max 10 mg total, d/c if seizure stops</li> </ul> </li> <li>Eclampsia <ul style="list-style-type: none"> <li>Midazolam IN/IM/IV/IO to a max dose of 5 mg (d/c if seizure stops), MR x1 in 10 min. Max 10 mg total</li> </ul> </li> <li>Sedation pre-cardioversion/pre-pacing <ul style="list-style-type: none"> <li>Midazolam 1-5 mg IV/IO</li> </ul> </li> <li>Unable to tolerate CPAP <ul style="list-style-type: none"> <li>Midazolam 0.5-1 mg IM/IN/IV</li> </ul> </li> <li>Intubated with agitation <ul style="list-style-type: none"> <li>Midazolam 2-5 mg IM/IN/IV/IO, MR x1 in 5-10 min</li> </ul> </li> <li>Behavioral <ul style="list-style-type: none"> <li>Midazolam 5 mg IM/IN/IV, MR x1 in 5-10 min</li> </ul> </li> </ul>		<b>Pediatric Dose</b> <ul style="list-style-type: none"> <li>Seizure <ul style="list-style-type: none"> <li>Midazolam IM per drug chart</li> <li>If vascular access present, midazolam IV/IO per drug chart, MR x1 in 10 min</li> </ul> </li> <li>Sedation pre-cardioversion/pre-pacing <ul style="list-style-type: none"> <li>Midazolam per drug chart IV/IO</li> </ul> </li> <li>Behavioral <ul style="list-style-type: none"> <li>Midazolam per drug chart IM/IN/IV, MR x1 in 10 min</li> </ul> </li> </ul>
<b>Adverse Effects</b> <ul style="list-style-type: none"> <li>Respiratory depression or apnea</li> <li>Nausea/vomiting</li> <li>Hypotension</li> <li>Headache</li> </ul>		
<b>Notes</b> <ul style="list-style-type: none"> <li>Closely monitor respiratory status (including capnography) and cardiac function after administration.</li> <li>Sedation prior to cardioversion is recommended. Consider a lower dose with attention to age and hydration status.</li> <li>For severely agitated or combative patients, IN or IM administration is the preferred route to decrease risk of injury to the patient and personnel.</li> <li>Administration in patients with alcohol intoxication can cause respiratory depression. Consider a lower dose or avoiding use.</li> </ul>		

# MORPHINE

EMT	AEMT	PARAMEDIC
<b>Classification</b> <ul style="list-style-type: none"> <li>Opioid analgesic</li> </ul>		
<b>Mechanism of Action</b> <ul style="list-style-type: none"> <li>Opioid agonist-analgesic; inhibits ascending pain pathways, thus altering pain perception; increases pain threshold; produces analgesia, respiratory depression, and sedation.</li> </ul>		
<b>Indications</b> <ul style="list-style-type: none"> <li>Management of acute pain</li> <li>Protocols: S-141, S-173</li> </ul>		<b>Contraindications</b> <ul style="list-style-type: none"> <li>Pregnancy with pain from active labor</li> </ul>
<b>Adult Dose</b> <ul style="list-style-type: none"> <li>IV: Up to 0.1 mg/kg IV. MR in 5 min at half initial IV dose. MR in additional 5 min at half initial IV dose</li> <li>IM: Up to 0.1 mg/kg IM. MR in 15 min at half initial IM dose. MR in additional 15 min at half initial IM dose</li> </ul>		<b>Pediatric Dose</b> <ul style="list-style-type: none"> <li>Morphine IV/IM per drug chart</li> </ul>
<b>Adverse Effects</b> <ul style="list-style-type: none"> <li>Confusion</li> <li>Sedation</li> <li>Headache</li> <li>CNS depression</li> <li>Respiratory depression or apnea</li> <li>Bronchospasm</li> <li>Dyspnea</li> <li>Hypotension/orthostatic hypotension</li> <li>Syncope</li> <li>Bradycardia</li> <li>Tachycardia</li> <li>Nausea/vomiting</li> </ul>		
<b>Notes</b> <ul style="list-style-type: none"> <li>Remember to consider non-pharmacologic pain treatments, e.g., place in position of comfort, apply ice packs/splints PRN, and verbal reassurance.</li> <li>Closely monitor respiratory status (including capnography) after administration.</li> </ul>		

# NALOXONE

EMT <sup>L</sup>	AEMT	PARAMEDIC
<b>Classification</b> <ul style="list-style-type: none"> <li>Opioid reversal agent</li> </ul>		
<b>Mechanism of Action</b> <ul style="list-style-type: none"> <li>Competitive inhibitor of opioid receptors in the brain. Reverses the respiratory depression associated with opioid overdose.</li> </ul>		
<b>Indications</b> <ul style="list-style-type: none"> <li>Reversal of acute opioid toxicity</li> <li>Protocols: S-123, S-134, S-161, S-165</li> </ul>		<b>Contraindications</b>
<b>Adult Dose</b> <ul style="list-style-type: none"> <li>Naloxone 2 mg IN/IM/IV, MR <b>OR</b> naloxone 4 mg via nasal spray preloaded single-dose device</li> <li>If patient refuses transport, give additional naloxone 2 mg IM <b>OR</b> naloxone 4 mg via nasal spray preloaded single-dose device. Administer full dose in one nostril, MR</li> </ul>		<b>Pediatric Dose</b> <ul style="list-style-type: none"> <li>Naloxone per drug chart IN/IV/IM, MR</li> <li>For opioid-dependent patients, dilute and titrate slowly per drug chart.</li> </ul>
<b>Adverse Effects</b> <ul style="list-style-type: none"> <li>Restlessness</li> <li>Seizures</li> <li>Dyspnea</li> <li>Pulmonary edema</li> <li>Hypotension with rapid administration</li> <li>Hypertension</li> <li>Dysrhythmias</li> <li>Diaphoresis</li> <li>Nausea/vomiting</li> <li>Withdrawal symptoms in opioid-dependent patients</li> </ul>		
<b>Notes</b> <ul style="list-style-type: none"> <li>EMT: Authorized to administer via IN only.</li> <li>AEMT: Authorized to administer via IN/IM only.</li> <li>Not authorized in cardiac arrest.</li> <li>Titrate IV dose to maintain adequate respiratory drive; use only enough to reverse respiratory depression.</li> <li>Duration of opioid effects may exceed that of naloxone; closely monitor patient's respiratory status.</li> <li>Naloxone may precipitate acute withdrawal symptoms or acute pulmonary edema when given to patients with opioid use disorder.</li> <li>Administration can result in the sudden onset of opiate withdrawal (agitation, tachycardia, pulmonary edema, nausea, vomiting, and, in neonates, seizures)</li> </ul>		

## NITROGLYCERIN

EMT	AEMT	PARAMEDIC
<b>Classification</b> <ul style="list-style-type: none"> <li>Nitrate, anti-anginal</li> </ul>		
<b>Mechanism of Action</b> <ul style="list-style-type: none"> <li>Nitrate enters vascular smooth muscle and is converted to nitric oxide leading to vasodilation. Relaxes smooth muscle via dose-dependent dilation of arterial and venous beds: reduces both preload, afterload, and myocardial oxygen demand. Also improves coronary collateral circulation. Lowers blood pressure, increases heart rate and occasionally causes paradoxical bradycardia.</li> </ul>		
<b>Indications</b> <ul style="list-style-type: none"> <li>Management of discomfort/pain of cardiac origin and acute pulmonary edema</li> <li>Protocols: S-126, S-136</li> </ul>		<b>Contraindications</b> <ul style="list-style-type: none"> <li>Use of erectile dysfunction or pulmonary hypertension medications within last 48 hours</li> <li>Suspected intracranial bleed</li> </ul>
<b>Adult Dose</b> <ul style="list-style-type: none"> <li>For discomfort/pain of cardiac origin if SBP <math>\geq 100</math> mmHg, NTG 0.4 mg SL, MR q3-5 min</li> <li>For CHF                             <ul style="list-style-type: none"> <li>If systolic BP <math>\geq 100</math> but <math>&lt; 150</math>: NTG 0.4 mg SL, MR q3-5 min</li> <li>If systolic BP <math>\geq 150</math>: NTG 0.8 mg SL, MR q3-5 min</li> </ul> </li> </ul>		<b>Pediatric Dose</b> <ul style="list-style-type: none"> <li>Not indicated for use in pediatrics</li> </ul>
<b>Adverse Effects</b> <ul style="list-style-type: none"> <li>Headache</li> <li>Dizziness</li> <li>Weakness</li> <li>Reflex tachycardia</li> <li>Syncope</li> <li>Hypotension</li> <li>Nausea/vomiting</li> </ul>		
<b>Notes</b> <ul style="list-style-type: none"> <li><b>EMT: Authorized to assist patient to self-medicate own prescribed NTG only.</b></li> <li>Examples of erectile dysfunction medications include sildenafil (Viagra), tadalafil (Cialis) and vardenafil (Levitra).</li> <li>Examples of pulmonary hypertension medications include sildenafil (Revatio) and epoprostenol sodium (Flolan, Veletri).</li> <li>Nitroglycerin is used primarily to provide pain relief from anginal chest discomfort.</li> <li>Assess the patient and document vital signs, including pain scale, before and after each administration.</li> </ul>		

## ONDANSETRON

EMT	AEMT	PARAMEDIC
<b>Classification</b> <ul style="list-style-type: none"> <li>• Antiemetic, selective 5-HT3 antagonist</li> </ul>		
<b>Mechanism of Action</b> <ul style="list-style-type: none"> <li>• Mechanism of action unclear; believed to function via serotonin antagonism at central and/or peripheral receptors. Serotonin receptors of the 5-HT3 type are present both peripherally on vagal nerve terminals and centrally in the chemoreceptor trigger zone of the area of the medullary structure that controls vomiting. May cause prolongation of the QT interval.</li> </ul>		
<b>Indications</b> <ul style="list-style-type: none"> <li>• Management of nausea or vomiting</li> <li>• Protocols: S-120, S-139, S-169, S-174</li> </ul>		<b>Contraindications</b> <ul style="list-style-type: none"> <li>• Known or suspected long QT syndrome</li> <li>• &lt;6 months of age</li> </ul>
<b>Adult Dose</b> <ul style="list-style-type: none"> <li>• Ondansetron 4 mg IV/IM/ODT, MR x1 in 10 min</li> </ul>		<b>Pediatric Dose</b> <ul style="list-style-type: none"> <li>• Ondansetron IV/IM/ODT per drug chart</li> </ul>
<b>Adverse Effects</b> <ul style="list-style-type: none"> <li>• Headache</li> <li>• Syncope</li> <li>• Wheezing</li> <li>• Bronchospasm</li> <li>• Dysrhythmias</li> <li>• ECG changes</li> <li>• Palpitations</li> <li>• Hives</li> <li>• Skin rash</li> </ul>		
<b>Notes</b> <ul style="list-style-type: none"> <li>• ECG changes include dose-dependent QT prolongation and ST-segment depression.</li> <li>• May cause serotonin syndrome if co-administered with selective serotonin reuptake inhibitors (SSRIs), e.g., fluoxetine, sertraline, citalopram, escitalopram, paroxetine.</li> </ul>		

## SODIUM BICARBONATE

EMT	AEMT	PARAMEDIC
<b>Classification</b> <ul style="list-style-type: none"> <li>Alkalizing agent, antidote</li> </ul>		
<b>Mechanism of Action</b> <ul style="list-style-type: none"> <li>Increases blood and urinary pH by neutralizing hydrogen ion concentration.</li> </ul>		
<b>Indications</b> <ul style="list-style-type: none"> <li>Management of hyperkalemia, tricyclic antidepressant overdose, and specific crush injuries</li> <li>Protocols: S-127, S-131, S-134, S-139, S-163, S-165, S-169</li> </ul>		<b>Contraindications</b>
<b>Adult Dose</b> <ul style="list-style-type: none"> <li>NaHCO<sub>3</sub> 1 mEq/kg IV/IO</li> </ul>		<b>Pediatric Dose</b> <ul style="list-style-type: none"> <li>NaHCO<sub>3</sub> per drug chart IV/IO</li> </ul>
<b>Adverse Effects</b> <ul style="list-style-type: none"> <li>Electrolyte imbalance</li> <li>Pulmonary edema (secondary to sodium overload)</li> <li>Tremors</li> <li>Twitching</li> <li>Seizures (caused by alkalosis)</li> </ul>		
<b>Notes</b> <ul style="list-style-type: none"> <li>Monitor the patient closely for signs and symptoms of fluid overload. Because the buffering action produces carbon dioxide, ensure the patient has adequate airway and ventilatory support.</li> <li>May precipitate or inactivate other medications; flush the IV line well before and after administering sodium bicarbonate. For example, precipitates to form calcium carbonate (chalk) when used with calcium chloride. Administer calcium chloride and sodium bicarbonate in separate IV/IO or thoroughly flush in between administrations using at least 10 mL of normal saline.</li> </ul>		

## TRANEXAMIC ACID

EMT	AEMT	PARAMEDIC
<b>Classification</b> <ul style="list-style-type: none"> <li>Hemostatic agent, antifibrinolytic agent, plasminogen inhibitor</li> </ul>		
<b>Mechanism of Action</b> <ul style="list-style-type: none"> <li>Prevents clot breakdown by inhibiting the activation of plasminogen, which reduces the conversion of plasminogen to plasmin (enzyme that halts the clotting process). Increases fibrin formation, which impedes blood flow for the formation of a clot.</li> </ul>		
<b>Indications</b> <ul style="list-style-type: none"> <li>Management of trauma-associated hemorrhage and postpartum hemorrhage</li> <li>Protocols: S-133, S-139, S-166</li> </ul>		<b>Contraindications</b> <ul style="list-style-type: none"> <li>Isolated, severe head injury</li> <li>Thromboembolic event within 24 hours (e.g., stroke, MI, DVT, PE)</li> <li>Potential need for reimplantation</li> <li>Mechanism of injury or delivery more than 3 hours prior to EMS care</li> </ul>
<b>Adult Dose</b> <ul style="list-style-type: none"> <li>Tranexamic acid 1 gm/10 mL IV/IO, in 50-100 mL NS, over 10 min</li> </ul>		<b>Pediatric Dose</b> <ul style="list-style-type: none"> <li>Not indicated for use in pediatrics</li> </ul>
<b>Adverse Effects</b> <ul style="list-style-type: none"> <li>Headache</li> <li>Dizziness</li> </ul>		
<b>Notes</b> <ul style="list-style-type: none"> <li>Rapid infusion may cause hypotension; administer over 10 minutes.</li> <li>Slow infusion rate if nausea, vomiting, or near syncope occurs.</li> <li>May increase the risk of thromboembolic disorders.</li> </ul>		

SUBJECT: TREATMENT PROTOCOL -  
PEDIATRIC WEIGHT-BASED DOSAGE STANDARDS

Date: 07/1/2024

MEDICATION	DOSE	MAXIMUM SINGLE DOSE
Acetaminophen IV (<2 years)	contraindicated	-
Acetaminophen IV (≥2 years)	15 mg/kg	1 gm
Adenosine IV 1st	0.1 mg/kg	6 mg
Adenosine IV 2nd/3rd	0.2 mg/kg	12 mg
Albuterol Nebulized	5 mg (6 mL)	5 mg
Amiodarone IV/IO	5 mg/kg	150 mg
Atropine (Bradycardia) IV/IO	0.02 mg/kg	0.5 mg
Atropine (Organophosphate) IV/IO	0.02 mg/kg	2 mg
Calcium Chloride IV/IO	20 mg/kg	500 mg
Charcoal PO	1 gm/kg	50 gm
Dextrose 10% IV	0.5 gm/kg	25 gm
Diphenhydramine IV/IM	1 mg/kg	50 mg
Epinephrine IM (1:1,000)	0.01 mg/kg	0.3 mg
Epinephrine IV/IO Cardiac Arrest (1:10,000)	0.01 mg/kg	1 mg
Epinephrine IV/IO Push-Dose (1:100,000)	0.001 mg/kg	0.01 mg (10 mcg)
Epinephrine Nebulized (1:1,000)	2.5 mg - 5 mg	5 mg
Fentanyl Citrate IN <10 kg	1 mcg/kg	10 mcg
Fentanyl Citrate IV <10 kg	1 mcg/kg	10 mcg
Fentanyl Citrate IN ≥10 kg	1.5 mcg/kg	50 mcg
Fentanyl Citrate IV ≥10 kg	1 mcg/kg	100 mcg
Glucagon IM	0.05 mg/kg	1 mg
Ipratropium Bromide Nebulized	0.5 mg (2.5 mL)	0.5 mg (2.5 mL)
Levalbuterol Nebulized (<6 years)	contraindicated	-
Levalbuterol Nebulized (≥6 years – <12 years)	0.62 mg (6 mL)	0.62 mg (6 mL)
Levalbuterol Nebulized (≥12 years)	2.5 mg (6 mL)	2.5 mg (6 mL)
Lidocaine 2% IV/IO	1 mg/kg	not applicable
Midazolam IN/IM	0.2 mg/kg	5 mg
Midazolam IV slow	0.1 mg/kg	5 mg
Morphine Sulfate IV/IM	0.1 mg/kg	4 mg
Naloxone IN/IM/IV	0.1 mg/kg	2 mg
Normal Saline Fluid Bolus	20 mL/kg	500 mL
Ondansetron (<6 months)	contraindicated	-
Ondansetron IM/IV/ODT (6 months - 3 years)	2 mg	2 mg
Ondansetron IM/IV/ODT (>3 years)	4 mg	4 mg
Sodium Bicarbonate IV	1 mEq/kg	50 mEq





**COUNTY OF SAN DIEGO**  
EMERGENCY MEDICAL SERVICES

TREATMENT PROTOCOL

**S-120**

**ABDOMINAL DISCOMFORT / GI / GU  
(NON-TRAUMATIC)**

Date: 7/1/2024

Page 1 of 1

**BLS**

- Ensure patent airway
- O<sub>2</sub> saturation PRN
- O<sub>2</sub> and/or ventilate PRN
- NPO
- Transport suspected symptomatic AAA to facility with surgical resources immediately available

**ALS**

- Monitor/ECG
- IV/IO <sup>Ⓐ</sup>
- Treat per Pain Management Protocol (S-141)

**Suspected volume depletion**

- 500 mL fluid bolus IV/IO, MR x1 <sup>Ⓐ</sup>

**Suspected AAA**

- 500 mL fluid bolus IV/IO to maintain SBP ≥80 mmHg, MR x1 <sup>Ⓐ</sup>

**For nausea or vomiting**

- Ondansetron 4 mg IV/IM/ODT, MR x1 in 10 min



**COUNTY OF SAN DIEGO**  
EMERGENCY MEDICAL SERVICES

TREATMENT PROTOCOL

**S-121**

**AIRWAY OBSTRUCTION**

Date: 7/1/2025

Page 1 of 1

**BLS**

**ALS**

**For conscious patient**

- Reassure, encourage coughing
- O<sub>2</sub> PRN

**For inadequate air exchange**

Airway maneuvers (AHA)

- Abdominal thrusts
- Use chest thrusts in obese or pregnant patients

**If patient becomes unconscious or is found unconscious**

- Begin CPR

**Once obstruction is removed**

- Ventilate with high-flow O<sub>2</sub> PRN
- O<sub>2</sub> saturation

**Treat per Respiratory Distress Protocol (S-136)**

**If patient becomes unconscious or has decreasing LOC**

- Direct or video laryngoscopy and Magill forceps, MR PRN
- Capnography

**Once obstruction is removed**

- Monitor/ECG
- IV/IO <sup>(A)</sup>

**Note:** If unable to ventilate effectively, transport immediately while continuing CPR (unconscious patient)



ALLERGIC REACTION / ANAPHYLAXIS

Date: 7/1/2025

Page 1 of 1

BLS

ALS

- Ensure patent airway
  - O<sub>2</sub> saturation PRN
  - O<sub>2</sub> and/or ventilate PRN
  - Attempt to identify allergen and route (injected, ingested, absorbed, or inhaled)
  - Remove allergen (e.g., stinger, injection mechanism), if possible
  - Epinephrine auto-injector 0.3 mg IM x1
- OR**
- Assist patient to self-medicate own prescribed epinephrine auto-injector or albuterol MDI **once only**. BH contact required for additional dose(s)

- Monitor/ECG
- IV/IO <sup>Ⓐ</sup>
- Capnography

**Allergic reaction (skin signs only)**

- Urticaria (hives, rash)
- Erythema (flushing)
- Pruritus (itching)

**Allergic reaction treatment**

- Diphenhydramine 50 mg IV/IM

**Suspected anaphylaxis reaction**

- Respiratory: throat tightness, hoarse voice, wheezing/stridor, cough, SOB
- Cardiovascular: fainting, dizziness, tachycardia, low BP
- GI: nausea, vomiting, abdominal cramping
- Tissues: angioedema of eyelids, lips, tongue, face

**Anaphylaxis treatment**

- Epinephrine 1:1,000 (1 mg/mL) 0.5 mg IM, MR x2 q5 min <sup>Ⓐ</sup>  
**then**
- Diphenhydramine 50 mg IV/IM

**If respiratory involvement<sup>1</sup>**

- Albuterol/Levalbuterol 6 mL via nebulizer, MR <sup>Ⓐ</sup>
- Ipratropium bromide 2.5 mL 0.02% via nebulizer added to first dose of albuterol/levalbuterol

**Severe anaphylaxis or inadequate response to treatment**

- 500 mL fluid bolus IV/IO MR to maintain SBP ≥90 mmHg <sup>Ⓐ</sup>
- Push-dose epinephrine 1:100,000 (0.01 mg/mL)  
1 mL IV/IO, MR q3 min, titrate to SBP ≥90 mmHg or improvement in status

**Push-dose epinephrine mixing instructions**

1. Remove 1 mL normal saline (NS) from the 10 mL NS syringe
  2. Add 1 mL of epinephrine 1:10,000 (0.1 mg/mL) to 9 mL NS syringe
- The mixture now has 10 mL of epinephrine at 0.01 mg/mL (10 mcg/mL) concentration.



COUNTY OF SAN DIEGO  
EMERGENCY MEDICAL SERVICES

TREATMENT PROTOCOL

S-123

ALTERED NEUROLOGIC FUNCTION  
(NON-TRAUMATIC)

Date: 7/1/2025

Page 1 of 1

BLS

ALS

- Ensure patent airway
- O<sub>2</sub> saturation, O<sub>2</sub> and/or ventilate PRN
- Spinal motion restriction PRN
- Position on affected side if difficulty managing secretions
- Do not allow patient to walk
- Restrain PRN
- Monitor blood glucose

**Symptomatic suspected opioid OD with RR <12. Use with caution in opioid-dependent, pain-management patients<sup>ⓐ</sup>**

- Naloxone 4 mg via nasal spray preloaded single-dose device. Administer full dose in one nostril
- OR**
- Naloxone 2 mg via atomizer and syringe. Administer 1 mg into each nostril

EMTs may assist family or friend to medicate with patient's prescribed naloxone in **symptomatic suspected opioid OD**

**Suspected hypoglycemia or patient's blood sugar is <60 mg/dL**

- If patient is awake and able to manage oral secretions, give 3 oral glucose tabs or paste (15 gm total)
- Patient may eat or drink, if able
- If patient is unconscious, NPO

**Stroke/TIA**

- Treat per Stroke and Transient Ischemic Attack (S-144)
- Pediatric patients presenting with stroke symptoms should be transported to Rady Children's Hospital

**Seizures**

- Protect airway and protect from injury
- Treat associated injuries

- Monitor/ECG
- Capnography
- IV/IO <sup>Ⓐ</sup>

**Symptomatic suspected opioid OD with respiratory depression (RR<12, SpO<sub>2</sub><96%, or EtCO<sub>2</sub>≥40 mmHg). Titrate slowly in opioid-dependent patients**

- Naloxone 2 mg IN/IM/IV, MR <sup>Ⓐ</sup>. Titrate IV dose to effect, **to drive the respiratory effort**
- OR**
- Naloxone 4 mg via nasal spray preloaded single-dose device. Administer full dose in one nostril, MR <sup>Ⓐ</sup>
- If patient refuses transport, give additional naloxone 2 mg IM <sup>Ⓐ</sup>
- OR**
- Naloxone 4 mg via nasal spray preloaded single-dose device. Administer full dose in one nostril, MR <sup>Ⓐ</sup>

**Symptomatic hypoglycemia with altered LOC or unresponsive to oral glucose agents**

- Dextrose 25 gm IV if BS <60 mg/dL <sup>Ⓐ</sup>
- If patient remains symptomatic and BS remains <60 mg/dL, MR <sup>Ⓐ</sup>
- If no IV, glucagon 1 mL IM if BS <60 mg/dL <sup>Ⓐ</sup>

**Symptomatic hyperglycemia**

- 500 mL fluid bolus IV/IO if BS ≥350 mg/dL or reads "high," if no rales MR x1 <sup>Ⓐ</sup>

**Status epilepticus (generalized, ongoing, and recurrent seizures without lucid interval)**

- Patients ≥40 kg: midazolam 10 mg IM
- Patients <40 kg: midazolam 0.2 mg/kg IM

**If vascular access present**

- Midazolam 0.2 mg/kg IV/IO to max dose of 5 mg, MR x1 in 10 min. Max 10 mg total, d/c if seizure stops

**Partial seizure lasting ≥5 min (includes seizure time prior to arrival of prehospital provider)**

- Midazolam 0.2 mg/kg IN/IM/IV/IO to max dose of 5 mg, MR x1 in 10 min. Max 10 mg total, d/c if seizure stops

**Eclamptic seizure of any duration**

- Treat per Obstetrical Emergencies / Newborn Deliveries (S-133)

<sup>ⓐ</sup> Per Title 22, Division 9, Chapter 2.3, § 100027.03 public safety personnel may administer nasal naloxone when authorized by the County of San Diego EMS Medical Director



BURNS

Date: 7/1/2025

Page 1 of 1

BLS

ALS

- Move patient to safe environment
- Break contact with causative agent
- Ensure patent airway, O<sub>2</sub>, and/or ventilate PRN
- O<sub>2</sub> saturation PRN
- Treat other life-threatening injuries
- Carboxyhemoglobin monitor PRN, if available

**Thermal burns**

- For burns <10% BSA, stop burning with non-chilled water or saline
- For burns >10% BSA, cover with dry dressing and keep patient warm
- Do not allow patient to become hypothermic

**Toxic inhalation (e.g., CO exposure, smoke, gas)**

- Move patient to safe environment
- 100% O<sub>2</sub> via mask
- Consider transport to facility with hyperbaric chamber for suspected CO poisoning, particularly in unconscious or pregnant patients

**Chemical burns**

- Brush off dry chemicals
- Flush with copious amounts of water

**Tar burns**

- Do not remove tar
- Cool with water, then transport

- Monitor/ECG
- IV/IO <sup>Ⓐ</sup>
- Capnography
- Treat pain per Pain Management Protocol (S-141)

**For patients with >20% partial-thickness or >5% full-thickness burns and ≥15 years**

- 500 mL fluid bolus IV/IO <sup>Ⓐ</sup>

**Respiratory distress with bronchospasm<sup>1</sup>**

- Albuterol/Levalbuterol 6 mL via nebulizer, MR <sup>Ⓐ</sup>

Contact UCSD Base Hospital for patients meeting burn center criteria<sup>†</sup>  
See Base Hospital Contact/Patient Transportation and Report (S-415)

**<sup>†</sup>Burn center criteria**

Patients with burns involving

- >20% partial-thickness or >5% full-thickness burns over BSA
- Suspected respiratory involvement or significant smoke inhalation
- Circumferential burn or burn to face, hands, feet, or perineum
- Electrical injury due to high voltage (≥1,000 volts)

<sup>1</sup> **Infection control:** If concerned about aerosolized infectious exposure, substitute with MDI, if available



DISCOMFORT / PAIN OF SUSPECTED  
CARDIAC ORIGIN

Date: 7/1/2025

Page 1 of 1

BLS

ALS

- Ensure patent airway
- O<sub>2</sub> saturation PRN
- Use supplemental O<sub>2</sub> to maintain saturation at 94-98%
- O<sub>2</sub> and/or ventilate PRN
- Minimize patient exertion, including walking, when possible
- If SBP  $\geq$  100 mmHg, may assist patient to self-medicate own prescribed NTG<sup>1</sup> SL (**maximum 3 doses, including those the patient has taken**)
- May assist with placement of 12-lead ECG leads
- May assist patient to self-medicate own prescribed aspirin up to a max dose of 325 mg

- Monitor/ECG
- IV <sup>A</sup>
- Obtain 12-lead ECG
- Repeat 12-lead ECG after arrhythmia conversion or any change in patient condition<sup>2</sup>
- If STEMI suspected, immediately notify BH, transmit 12-lead ECG to appropriate STEMI receiving center and transport<sup>3</sup>
- Report LBBB, RBBB or poor-quality ECG
- Aspirin 324 mg chewable PO<sup>4,5</sup> <sup>A</sup>

**If SBP  $\geq$  100 mmHg**

- NTG<sup>1</sup> 0.4 mg SL, MR q3-5 min <sup>A</sup>
- Treat pain with opioids per Pain Management Protocol (S-141)

**Discomfort/pain of suspected cardiac origin with associated shock**

- 250 mL fluid bolus IV/IO with no rales, MR to maintain SBP  $\geq$  90 mmHg <sup>A</sup>

**If BP refractory to second fluid bolus**

- Push-dose epinephrine 1:100,000 (0.01 mg/mL) 1 mL IV/IO, MR q3 min, titrate to SBP  $\geq$  90 mmHg

**Push-dose epinephrine mixing instructions**

1. Remove 1 mL normal saline (NS) from the 10 mL NS syringe
2. Add 1 mL of epinephrine 1:10,000 (0.1 mg/mL) to 9 mL NS syringe

The mixture now has 10 mL of epinephrine at 0.01 mg/mL (10 mcg/mL) concentration.

<sup>1</sup> NTG is contraindicated in patients who have taken erectile dysfunction medications such as sildenafil (Viagra®), tadalafil (Cialis®), and vardenafil (Levitra®) within 48 hours; and pulmonary hypertension medications such as sildenafil (Revatio®), and epoprostenol sodium (Flolan®) and (Veletri®)

<sup>2</sup> Do not delay transport for a repeat 12-lead ECG

<sup>3</sup> Immediately transmit 12-lead ECG to receiving hospital for suspected STEMI patients regardless of patient presentation

<sup>4</sup> Administer aspirin even if discomfort/pain has resolved. If aspirin is not given, document the reason

<sup>5</sup> Aspirin may be withheld if an equivalent dose has been administered by a healthcare professional



**BLS**

- Continuous compressions of 100-120/min with ventilation rate of 10-12/min
- Use metronome or other real-time audiovisual feedback device
- Rotate compressor at least every 2 min
- Use mechanical compression device (unless contraindicated)
- O<sub>2</sub> and/or ventilate with BVM
- Monitor O<sub>2</sub> saturation
- Apply AED during CPR and analyze as soon as ready

**VAD**

- Perform CPR
- Contact BH for additional instructions

**TAH**

- Contact BH for instructions

**ALS**

- Apply defibrillator pads during CPR. Defibrillate immediately for VF/pulseless VT.
- IV/IO <sup>®</sup>
- Capnography with waveform and value
- ET/PAA without interrupting compressions
- NG/OG tube PRN
- Provide cardiac monitor data to agency QA/QI department

**Team leader priorities**

- Monitor CPR quality, rate, depth, full chest recoil, and capnography value and waveform
- Minimize interruption of compressions (<5 sec) during ECG rhythm checks
- Charge monitor prior to rhythm checks. Do not interrupt CPR while charging.

**VAD/TAH**

- See Adjunct Cardiac Devices section

**Capnography**

- For EtCO<sub>2</sub> >0 mmHg, may place ET/PAA without interrupting compressions
- If EtCO<sub>2</sub> rises rapidly during CPR, pause CPR and check for pulse

**Specific protocols (see below)**

- Arrhythmias
  - Unstable bradycardia
  - Supraventricular tachycardia
  - Atrial fibrillation / flutter
  - Ventricular tachycardia
  - Ventricular fibrillation / pulseless VT
  - Pulseless electrical activity / asystole
- Return of Spontaneous Circulation
- Adjunct Cardiac Devices
- Termination of Resuscitation
- Extracorporeal Cardiopulmonary Resuscitation (ECPR) Criteria

## UNSTABLE‡ BRADYCARDIA

- Obtain 12-lead ECG
- Atropine 1 mg IV/IO, MR q3-5 min to max 3 mg\*
- If SBP <90 mmHg and rales not present, 250 mL fluid bolus IV/IO, MR <sup>Ⓐ</sup>

### Rhythm unresponsive to atropine

- Midazolam 1-5 mg IV/IO PRN pre-pacing
- External cardiac pacing<sup>†</sup>
- If capture occurs and SBP ≥100 mmHg, treat per Pain Management Protocol (S-141)

### If SBP <90 mmHg after atropine or initiation of pacing

- 250 mL fluid bolus IV/IO, MR x1
- Push-dose epinephrine 1:100,000 (0.01 mg/mL) 1 mL IV/IO. MR q3 min, titrate to SBP ≥90 mmHg.

#### Push-dose epinephrine mixing instructions

1. Remove 1 mL normal saline (NS) from the 10 mL NS syringe
2. Add 1 mL of epinephrine 1:10,000 (0.1 mg/mL) to 9 mL NS syringe

The mixture now has 10 mL of epinephrine at 0.01 mg/mL (10 mcg/mL) concentration.

\* May omit atropine in patients unlikely to have clinical benefit (e.g., heart transplant patients, 2nd degree type II, or 3rd degree heart block)

‡SBP <90 mmHg and exhibiting any of the following signs/symptoms of inadequate perfusion, e.g.,

- Altered mental status (decreased LOC, confusion, agitation)
- Pallor
- Diaphoresis
- Significant chest pain of suspected cardiac origin
- Severe dyspnea

†External cardiac pacing

- Set rate and energy per manufacturer's recommendations
- Increase energy setting until capture occurs, usually between 50 mA and 100 mA
- After electrical and mechanical capture achieved, increase energy by 10%
- If patient remains hypotensive, increase rate in 5 bpm increments (not to exceed 100 bpm) to achieve and maintain adequate perfusion



## SUPRAVENTRICULAR TACHYCARDIA

- Obtain 12-lead ECG

### Stable (symptomatic)

- If SBP <90 mmHg and rales not present, 250 mL fluid bolus IV/IO, MR <sup>Ⓐ</sup>
- VSM
- Adenosine 6 mg rapid IV/IO followed by 20 mL NS rapid IV/IO
- Adenosine 12 mg rapid IV/IO followed by 20 mL NS rapid IV/IO, MR x1

### Unstable<sup>‡</sup>

- Consider midazolam 1-5 mg IV/IO pre-cardioversion
- Synchronized cardioversion at manufacturer's recommended energy dose, MR x2, MR BHO
- After successful cardioversion
  - Check BP. If SBP <90 mmHg and rales not present, 250 mL fluid bolus IV/IO, MR
  - Obtain 12-lead ECG

<sup>‡</sup>SBP <90 mmHg and exhibiting any of the following signs/symptoms of inadequate perfusion, e.g.,

- Altered mental status (decreased LOC, confusion, agitation)
- Pallor
- Diaphoresis
- Significant chest pain of suspected cardiac origin
- Severe dyspnea

## ATRIAL FIBRILLATION / FLUTTER

- Obtain 12-lead ECG
- If SBP <90 mmHg and rales not present, 250 mL fluid bolus IV/IO, MR <sup>Ⓐ</sup>

### **Rate $\geq$ 180 and unstable<sup>‡</sup>**

- Consider midazolam 1-5 mg IV/IO pre-cardioversion
- Synchronized cardioversion at manufacturer's recommended energy dose, MR x2, MR BHO
- After successful cardioversion
  - Check BP. If SBP <90 mmHg and rales not present, 250 mL fluid bolus IV/IO, MR
  - Obtain 12-lead ECG

<sup>‡</sup>SBP <90 mmHg and exhibiting any of the following signs/symptoms of inadequate perfusion, e.g.,

- Altered mental status (decreased LOC, confusion, agitation)
- Pallor
- Diaphoresis
- Significant chest pain of suspected cardiac origin
- Severe dyspnea

## VENTRICULAR TACHYCARDIA

- Obtain 12-lead ECG

### Stable

- If SBP <90 mmHg and rales not present, 250 mL fluid bolus IV/IO, MR <sup>Ⓐ</sup>
- Amiodarone 150 mg in 100 mL of NS over 10 min IV/IO, MR x1 in 10 min

### OR

- Lidocaine 1.5 mg/kg IV/IO, MR at 0.5 mg/kg IV/IO q5 min to max 3 mg/kg

### Unstable<sup>‡</sup>

- Consider midazolam 1-5 mg IV/IO pre-cardioversion
- Synchronized cardioversion at manufacturer's recommended energy dose, MR x2, MR BHO
- After successful cardioversion
  - Check BP. If SBP <90 mmHg and rales not present, 250 mL fluid bolus IV/IO, MR
  - Obtain 12-lead ECG

<sup>‡</sup>SBP <90 mmHg and exhibiting any of the following signs/symptoms of inadequate perfusion, e.g.,

- Altered mental status (decreased LOC, confusion, agitation)
- Pallor
- Diaphoresis
- Significant chest pain of suspected cardiac origin
- Severe dyspnea

## VENTRICULAR FIBRILLATION / PULSELESS VT<sup>1</sup>

- CPR
- Defibrillate at manufacturer's recommended energy dose as soon as monitor available/charged
- Defibrillate at manufacturer's recommended energy dose q2 min while VF/VT persists
- Epinephrine 1:10,000 1 mg IV/IO q3-5 min, begin after second defibrillation

### **Persistent VF/VT after 3 defibrillation attempts**

- Amiodarone 300 mg IV/IO, MR 150 mg q3-5 min (max 450 mg)  
**OR**
- Lidocaine 1.5 mg/kg IV/IO, MR at 0.5 mg/kg IV/IO q5 min to max 3 mg/kg

<sup>1</sup> If patient meets ECPR criteria, make base hospital contact and transport **IMMEDIATELY** to an ECPR Receiving Center (per S-127A).

## PULSELESS ELECTRICAL ACTIVITY

- CPR
- Epinephrine 1:10,000 1 mg IV/IO q3-5 min

### **Suspected hyperkalemia**

- $\text{CaCl}_2$  1 gm IV/IO
- $\text{NaHCO}_3$  1 mEq/kg IV/IO
- Continuous albuterol/levalbuterol 6 mL via nebulizer <sup>(A)</sup>

### **Suspected hypovolemia**

- 1,000 mL fluid bolus IV/IO, MR x2 <sup>(A)</sup>

### **Suspected poisoning / OD**

- For suspected tricyclic antidepressant, beta blocker, or calcium channel blocker overdoses, consider treatment per Poisoning / Overdose Protocol (S-134)<sup>2</sup>

**For consideration of non-transport, see Asystole/Termination of Resuscitation protocol**

---

<sup>2</sup> Naloxone is not authorized in cardiac arrest.

## ASYSTOLE / TERMINATION OF RESUSCITATION

### ASYSTOLE

- CPR
- Epinephrine 1:10,000 1 mg IV/IO q3-5 min

### TERMINATION OF RESUSCITATION (TOR)

**Resuscitation may be terminated on SO<sup>§</sup> if all the following conditions are met:**

- Persistent asystole (NO other rhythms detected)
- Unwitnessed arrest (by bystanders or EMS)
- No bystander CPR
- No AED or other defibrillation
- No return of pulses
- ≥20 min on-scene resuscitation time

**Base Hospital contact is not required if all criteria are met, even if ALS interventions are performed**

- Document time of death recognition, full name of paramedic making determination of apparent death, and circumstances under TOR determination

**BHPO is required for TOR for all other presentations, rhythms, and situations**

- Document time of death pronouncement, full name of physician, and circumstances under which TOR was ordered

<sup>§</sup>Applies to cardiac arrests of presumed cardiac origin. Excludes drowning, hypothermia, trauma, and electrocution.

## RETURN OF SPONTANEOUS CIRCULATION

- Ventilate PRN (goal of EtCO<sub>2</sub> = 40 mmHg)
- Obtain BP
- Obtain 12-lead ECG
- Transport to closest STEMI Center<sup>3</sup> regardless of 12-lead ECG reading
- Provide cardiac monitor data to agency QA/QI department
- Monitor blood glucose PRN

### SBP <90 mmHg

- If rales not present, 250 mL fluid bolus IV/IO, MR <sup>Ⓐ</sup>
- Push-dose epinephrine 1:100,000 (0.01 mg/mL) 1 mL IV/IO. MR q3 min, titrate to SBP ≥90 mmHg

#### Push-dose epinephrine mixing instructions

1. Remove 1 mL normal saline (NS) from the 10 mL NS syringe
2. Add 1 mL of epinephrine 1:10,000 (0.1 mg/mL) to 9 mL NS syringe

The mixture now has 10 mL of epinephrine at 0.01 mg/mL (10 mcg/mL) concentration.

<sup>3</sup> Do not change destination if already enroute to an ECPR Receiving Center.

## ADJUNCT CARDIAC DEVICES

Transport equipment and any knowledgeable family/support persons to ED with patient

### VAD

- Contact BH and VAD coordinator
- Follow protocols for CPR and treatment of arrhythmias, including use of cardioversion, pacing, and defibrillation PRN

### TAH

- Contact TAH coordinator
- Consult BH Physician for orders for TAH recommended treatments

### Wearable defibrillators (vest)

- If vest device is broadcasting specific verbal directions, follow device's prompts
- If device not broadcasting directions and patient requires CPR or cardiac treatment, remove vest and treat

### Malfunctioning pacemakers

- Treat per applicable arrhythmia protocol
- Treat pain per Pain Management Protocol (S-141) PRN

### Reported/witnessed AICD firing $\geq 2$

Pulse  $\geq 60$

- Lidocaine 1.5 mg/kg IV/IO, MR at 0.5 mg/kg IV/IO q5 min to max 3 mg/kg

**OR**

- Amiodarone 150 mg in 100 mL of NS over 10 min IV/IO, MR x1 in 10 min




## EXTRACORPOREAL CARDIOPULMONARY RESUSCITATION (ECPR) CRITERIA<sup>4</sup>

<p><b>Age 18-70</b></p> <p><b>Witnessed cardiac arrest</b></p> <p><b>CPR</b></p> <ul style="list-style-type: none"><li>• Must be established within 5 minutes of cardiac arrest</li><li>• High-quality compressions throughout resuscitation, including during transport</li></ul> <p><b>Use of automated mechanical chest compression device</b></p> <p><b>Refractory Ventricular Fibrillation/Pulseless VT</b></p> <ul style="list-style-type: none"><li>• Defined as persistent pulseless shockable rhythm after 2 defibrillation attempts (including AED-delivered shocks, but not AICD firings)</li></ul> <p><b>Time interval from cardiac arrest to arrival at ECPR receiving center ≤45 minutes</b></p>
--

<sup>4</sup> If patient meets ECPR criteria, make base hospital contact and transport **IMMEDIATELY** to an ECPR Receiving Center (per S-127A).

## EXTRACORPOREAL CARDIOPULMONARY RESUSCITATION (ECPR) DECISION ALGORITHM



\*Bypass non-ECPR STEMI Receiving Centers



**COUNTY OF SAN DIEGO**  
EMERGENCY MEDICAL SERVICES

TREATMENT PROTOCOL

**S-129**

**ENVENOMATION INJURIES**

Date: 7/1/2024

Page 1 of 1

**BLS**

**ALS**

- O<sub>2</sub> and/or ventilate PRN
- If antivenin available on site, transport with patient to hospital

**Jellyfish sting**

- Liberally rinse with seawater
- Scrape to remove stinger(s)
- Heat as tolerated (not to exceed 110 °F / 43 °C)

**Stingray or sculpin injury**

- Immersion in hot water (as hot as tolerated, not to exceed 110 °F / 43 °C)

**Snakebite**

- Mark proximal extent of swelling and/or tenderness
- Keep involved extremity at heart level and immobile
- Remove constrictive device(s)
- Remove jewelry distal to bite

- IV <sup>Ⓐ</sup>
- Treat per Pain Management Protocol (S-141)



**BLS**

**ALS**

- Ensure patent airway
- O<sub>2</sub> saturation PRN
- O<sub>2</sub> and/or ventilate PRN
- Remove excess/wet clothing
- Obtain temperature

**Heat exhaustion**

- Cool gradually
- Fan and sponge with tepid water
- Avoid shivering
- If conscious, give small amounts of fluids

**Heat stroke**

- Rapid cooling
- Spray with cool water and fan
- Avoid shivering
- Apply ice packs to carotid, inguinal, and axillary regions

**Cold exposure**

- Gentle warming
- Apply blankets, warm packs, and dry dressings
- Avoid unnecessary movement or rubbing
- If alert, give warm liquids. If altered LOC, NPO
- Prolonged CPR may be indicated

**Drowning**

- CPR, if cardiac arrest. Emphasize ventilations.
- High-flow O<sub>2</sub> if spontaneous respirations
- Remove wet clothing
- Spinal motion restriction PRN

- Monitor/EGC
- IV/IO <sup>Ⓐ</sup>
- Capnography

**Cardiac arrest with hypothermia**

- CPR
- Persistent VF/VT, defibrillate per CPR / Arrhythmias Protocol (S-127)\*
- Epinephrine 1:10,000 1 mg IV/IO x1<sup>†</sup>
- Rewarm

**Heat exhaustion/heat stroke**

- 500 mL fluid bolus IV/IO, if no rales MR x1 <sup>Ⓐ</sup>

**Drowning with respiratory distress**

- CPAP at 5-10 cmH<sub>2</sub>O for respiratory distress

\*Defibrillation attempts may be unsuccessful during rewarming until temperature ≥86 °F / ≥30 °C

<sup>†</sup>Limit epinephrine to 1 dose and withhold antiarrhythmic medications until temperature ≥86 °F / ≥30 °C



**COUNTY OF SAN DIEGO**  
EMERGENCY MEDICAL SERVICES

TREATMENT PROTOCOL

**S-131**

**HEMODIALYSIS PATIENT**

Date: 7/1/2025

Page 1 of 1


**BLS**

**ALS**

- Ensure patent airway
- O<sub>2</sub> saturation
- Give O<sub>2</sub> to maintain SpO<sub>2</sub> at 94% to 98%
- Ventilate PRN

- Monitor/ECG
  - Determine time of last dialysis
  - IV in upper extremity without working graft/AV fistula <sup>Ⓐ</sup>
- For immediate life threat only**
- EJ/IO access preferred over accessing percutaneous dialysis catheter (e.g., Vascath) or shunt/graft
  - Monitor and administer via existing dialysis catheter (aspirate 5 mL **prior** to infusion\*)
- OR**
- Access graft/AV fistula
- Fluid overload with rales**
- Treat CHF per Respiratory Distress Protocol (S-136)
- Suspected hyperkalemia (e.g., peaked T-waves or widened QRS complex)**
- Obtain 12-lead ECG
  - If widened QRS complex, immediately administer CaCl<sub>2</sub> 1 gm IV/IO
  - NaHCO<sub>3</sub> 1 mEq/kg IV/IO
  - Continuous albuterol/levalbuterol 6 mL via nebulizer <sup>Ⓐ</sup>
- For patients not on hemodialysis with suspected hyperkalemia**
- Obtain 12-lead ECG
  - If findings consistent with hyperkalemia (e.g., peaked T-waves or widened QRS complex), contact base hospital

\*Dialysis catheter contains concentrated dose of heparin, which must be aspirated **prior** to infusion

 <b>COUNTY OF SAN DIEGO</b> EMERGENCY MEDICAL SERVICES	TREATMENT PROTOCOL		<b>S-132</b>
	<b>DECOMPRESSION ILLNESS / DIVING /          ALTITUDE-RELATED INCIDENTS</b>		
	Date: 7/1/2024		Page 1 of 1

### BLS

### ALS

<ul style="list-style-type: none"> <li>• 100% O<sub>2</sub> via mask</li> <li>• Ventilate PRN</li> <li>• O<sub>2</sub> saturation</li> <li>• Spinal stabilization PRN</li> <li>• Warming PRN, remove wetsuit, if able</li> </ul>	<ul style="list-style-type: none"> <li>• Monitor/ECG</li> <li>• IV/IO <sup>®</sup></li> </ul>
--	---

**Diving victim:** A person with any symptoms after diving, regardless of whether compressed gasses such as air were used.

**Minor symptoms (non-progressive):** Minimal localized joint pain, mottling of skin surface, or localized swelling with pain.

**Major symptoms:** Symptoms listed above that are severe and/or rapidly progressing, vertigo, altered LOC, progressive paresthesia, seizure, paralysis, severe SOB, blurred vision, crepitus, hematemesis, hemoptysis, pneumothorax, urinary retention, trunk pain, or girdle or band-like burning discomfort.

#### Diving victim disposition

- All patients (including active-duty military) should be transported to UCSD Hillcrest Emergency Department
- Follow policy T-460 if trauma criteria are met
- Bring dive computer and gear if available



OBSTETRICAL EMERGENCIES / NEWBORN  
DELIVERIES

Date: 7/1/2025

Page 1 of 3

PREDELIVERY	
BLS	ALS
<ul style="list-style-type: none"><li>• Ensure patent airway</li><li>• O2 saturation PRN</li><li>• O2 and/or ventilate PRN</li><li>• If no time for transport and delivery is imminent (crowning and pushing), proceed with delivery</li><li>• If no delivery, transport on left side</li><li>• Keep mother warm</li></ul> <p><b>Third-trimester bleeding</b></p> <ul style="list-style-type: none"><li>• Transport immediately to facility with obstetrical services per BH direction</li></ul> <p><b>Eclampsia (seizures)</b></p> <ul style="list-style-type: none"><li>• Protect airway</li><li>• Protect from injury</li></ul>	<ul style="list-style-type: none"><li>• Monitor/ECG</li><li>• IV <sup>Ⓐ</sup></li><li>• Capnography</li></ul> <p><b>Direct to labor/delivery area BHO if ≥20 weeks gestation</b></p> <p><b>Eclampsia (seizures)</b></p> <ul style="list-style-type: none"><li>• Midazolam IN/IM/IV/IO to a max dose of 5 mg (d/c if seizure stops), MR x1 in 10 min. Max 10 mg total.</li></ul>
DELIVERY	
BLS and ALS	
<p><b>Routine delivery</b></p> <ul style="list-style-type: none"><li>• If placenta delivered, massage fundus. Do not wait on scene.</li><li>• Wait 60 sec after delivery, then clamp and cut cord between clamps</li><li>• Document name of person cutting cord, time cut, and delivery location (address)</li><li>• Place identification bands on mother and newborn(s)</li><li>• Complete Out of Hospital Birth Report Form (S-166A) and provide to parent</li></ul> <p><b>Difficult deliveries</b></p> <ul style="list-style-type: none"><li>• High-flow O2</li><li>• Keep mother warm</li></ul> <p><b>Nuchal cord (cord wrapped around neck)</b></p> <ul style="list-style-type: none"><li>• Slip cord over the head and off neck</li><li>• Clamp and cut cord, if wrapped too tightly</li></ul> <p><b>Prolapsed cord</b></p> <ul style="list-style-type: none"><li>• Place mother with her hips elevated on pillows</li><li>• Insert a gloved hand into vagina and gently push presenting part off cord</li><li>• Transport immediately while retaining this position. Do not remove hand until relieved by hospital personnel.</li><li>• Cover exposed cord with saline-soaked gauze</li></ul> <p><b>Shoulder dystocia</b></p> <ul style="list-style-type: none"><li>• Hyperflex mother's knees to her chest</li></ul> <p><b>Breech birth (arm or single foot visible)</b></p> <ul style="list-style-type: none"><li>• Rapid transport</li></ul>	

**San Diego County Emergency Medical Services Office**  
**Policy / Procedure / Protocol**

<b>Frank breech or double footling and imminent delivery with long transport</b> <ul style="list-style-type: none"> <li>• Allow newborn to deliver to the waist without active assistance (support only)</li> <li>• When legs and buttocks are delivered, assist head out keeping body parallel to the ground. If head does not deliver within 1-2 min, insert gloved hand into the vagina to create airway for newborn.</li> <li>• Transport immediately if head undelivered</li> </ul>	
<b>Eclampsia (seizures)</b> <ul style="list-style-type: none"> <li>• Protect airway, and protect from injury</li> <li>• <b>ALS:</b> Midazolam IN/IM/IV/IO to a max dose of 5 mg (d/c if seizure stops), MR x1 in 10 min. Max 10 mg total.</li> </ul>	
<b>MOTHER POST-DELIVERY</b>	
<b>BLS</b>	<b>ALS</b>
<b>Postpartum hemorrhage</b> <ul style="list-style-type: none"> <li>• Massage fundus vigorously</li> <li>• Baby to breast</li> <li>• High-flow O<sub>2</sub></li> <li>• Keep mother warm</li> </ul> <b>Eclampsia (seizures)</b> <ul style="list-style-type: none"> <li>• Protect airway</li> <li>• Protect from injury</li> </ul>	<b>Postpartum hemorrhage</b> <ul style="list-style-type: none"> <li>• Monitor/ECG</li> <li>• Capnography</li> <li>• 500 mL fluid bolus IV/IO, MR x2 q10 min to maintain SBP ≥90 mmHg <sup>A</sup></li> <li>• If estimated blood loss ≥500 mL and within 3 hours of delivery, tranexamic acid 1 gm/10 mL IV/IO, in 50-100 mL NS, over 10 min</li> </ul> <b>Eclampsia (seizures)</b> <ul style="list-style-type: none"> <li>• Midazolam IN/IM/IV/IO to a max dose of 5 mg (d/c if seizure stops), MR x1 in 10 min. Max 10 mg total.</li> </ul>
<b>NEONATAL POST-DELIVERY</b>	
<b>BLS and ALS</b>	
<b>Warm, dry, and stimulate newborn</b> <ul style="list-style-type: none"> <li>• Wrap newborn in warm, dry blanket. Keep head warm.</li> <li>• Assess breathing, tone, and HR. Palpate HR via umbilical cord.</li> <li>• If placing pulse oximeter, use newborn's right hand</li> <li>• APGAR at 1 and 5 min (do not delay resuscitation to obtain score)</li> <li>• Confirm identification bands placed on mother and newborn(s)</li> <li>• Bring mother and newborn(s) to same hospital</li> <li>• Complete Out of Hospital Birth Report Form (S-166A) and provide to parent</li> </ul>	
<b>Full-term newborn with good tone and breathing</b> <ul style="list-style-type: none"> <li>• Keep newborn warm</li> <li>• Ensure patent airway</li> <li>• If excessive secretions, suction mouth then nose with bulb syringe</li> <li>• O<sub>2</sub> saturation on newborn's right hand PRN</li> <li>• Baby to breast</li> <li>• Ongoing assessment q30 sec</li> </ul>	
<b>Newborn HR ≥100 with respiratory distress or central cyanosis</b> <ul style="list-style-type: none"> <li>• Blow-by O<sub>2</sub></li> </ul>	
<b>Newborn HR &lt;100, poor respiratory effort or persistent central cyanosis</b> <ul style="list-style-type: none"> <li>• Ventilate with BVM on room air</li> <li>• Monitor/ECG</li> <li>• Recheck pulse q30 sec</li> </ul>	



**San Diego County Emergency Medical Services Office**  
**Policy / Procedure / Protocol**

- For persistently poor respiratory rate/effort, or cyanosis despite correct BVM technique, add high-flow O<sub>2</sub> 15 L/min to BVM
- **Stop BVM when patient breathing well and HR ≥100**
- **ALS:** IV/IO <sup>(A)</sup> (do not delay transport)
- **ALS:** NG tube PRN

**Newborn HR <60**

- Continue BVM with high-flow O<sub>2</sub>
- Chest compressions at rate of 120/min
- 3:1 compression to ventilation ratio
- Check pulse q1 min
- Stop compressions when HR ≥60
- **ALS:** Epinephrine 1:10,000 per drug chart IV/IO, MR q3-5 min
- **ALS:** Fluid bolus per drug chart IV/IO, MR x1 in 10 min <sup>(A)</sup>

**Premature and/or low birth weight newborn**

- If amniotic sac intact, remove neonate from sac after delivery
- Place neonate in plastic bag up to axilla to minimize heat loss
- Transport immediately
- CPR need **not** be initiated if there are no signs of life **and** gestational age <24 weeks



POISONING / OVERDOSE

Date: 7/1/2025

Page 1 of 2

BLS

ALS

- Ensure patent airway
- O2 saturation PRN
- O2 and/or ventilate PRN
- Monitor blood glucose PRN
- Carboxyhemoglobin monitor PRN, if available

**Ingestions**

- Identify substance
- Transport pill bottles and containers with patient, PRN

**Skin contamination\***

- Remove clothes
- Brush off dry chemicals
- Flush with copious water

**Toxic inhalation (e.g., CO exposure, smoke, gas)**

- Move patient to safe environment
- 100% O2 via mask
- Consider transport to facility with hyperbaric chamber for suspected CO poisoning, particularly in unconscious or pregnant patients

**Symptomatic suspected opioid OD with RR <12. Use with caution in opioid-dependent, pain-management patients<sup>Ⓐ</sup>**

- Naloxone 4 mg via nasal spray preloaded single-dose device. Administer full dose in one nostril
- OR**
- Naloxone 2 mg via atomizer and syringe. Administer 1 mg into each nostril

EMTs may assist family or friend to medicate with patient's prescribed naloxone in **symptomatic suspected opioid OD**

**Hyperthermia from suspected stimulant intoxication**

- Initiate cooling measures
- Obtain temperature, if possible

- Monitor/ECG
- IV/IO <sup>Ⓐ</sup>
- Capnography

**Ingestions**

- Assure patient has gag reflex and is cooperative
- If not vomiting and within 60 min, activated charcoal 50 gm PO ingestion with any of the following <sup>Ⓐ</sup>:
  1. Acetaminophen
  2. Colchicine
  3. Beta blockers
  4. Calcium channel blockers
  5. Salicylates
  6. Sodium valproate
  7. Oral anticoagulants (including rodenticides)
  8. Paraquat
  9. Amanita mushrooms
  10. Recommendation by Poison Control Center

**Symptomatic suspected opioid OD with respiratory depression (RR<12, SpO<sub>2</sub><96%, or EtCO<sub>2</sub> ≥40 mmHg).**

**Titrate slowly in opioid-dependent patients**

- Naloxone 2 mg IN/IM/IV, MR <sup>Ⓐ</sup>. Titrate IV dose to effect, **to drive the respiratory effort**
- OR**
- Naloxone 4 mg via nasal spray preloaded single-dose device. Administer full dose in one nostril, MR <sup>Ⓐ</sup>
- If patient refuses transport, give additional naloxone 2 mg IM <sup>Ⓐ</sup>
- OR**
- Naloxone 4 mg via nasal spray preloaded single-dose device. Administer full dose in one nostril, MR <sup>Ⓐ</sup>

**Symptomatic organophosphate poisoning**

- Atropine 2 mg IV/IO
- For continued signs/symptoms of SLUDGE/BBB, double prior atropine dose IV/IO q3-5 min

**Extrapyramidal reactions**

- Diphenhydramine 50 mg slow IV/IM

**Suspected tricyclic antidepressant OD with cardiac effects (e.g., hypotension, heart block, or widened QRS)**

- NaHCO<sub>3</sub> 1 mEq/kg IV/IO

**San Diego County Emergency Medical Services Office**  
**Policy / Procedure / Protocol**

	<p><b>Suspected beta blocker OD with cardiac effects (e.g., bradycardia with hypotension)</b></p> <ul style="list-style-type: none"><li>• Glucagon 1-5 mg IV, MR 5-10 min, for a total of 10 mg</li></ul> <p><b>Suspected calcium channel blocker OD (SBP &lt;90 mmHg)</b></p> <ul style="list-style-type: none"><li>• CaCl<sub>2</sub> 1 gm IV/IO</li></ul> <p><b>Suspected cyanide poisoning</b> If cyanide kit available on site (e.g., industrial site), may administer if patient is exhibiting significant symptoms</p> <ul style="list-style-type: none"><li>• Amyl nitrite inhalation (over 30 seconds)</li><li>• Sodium thiosulfate 25%, 12.5 gm IV <b>or</b> hydroxocobalamin (CYANOKIT®) 5 gm IV</li></ul>
--	---

\* Per Title 22, Division 9, Chapter 2.3, § 100027.03 public safety personnel may administer nasal naloxone when authorized by the County of San Diego EMS Medical Director.

\* For radioactive material, treatment of traumatic injuries takes precedence over decontamination.



EXISTING DEVICES AND MEDICATIONS

Date: 7/1/2025

Page 1 of 1

BLS

- If patient or accompanying person able to manage existing device, proceed with transport
- Bring back-up equipment/batteries as appropriate

**Established electrolyte and/or glucose-containing peripheral IV lines**

- Maintain at preset rates

**Established IV pumps or other existing devices**

- Contact BH for direction, if person responsible for operating IV pump or device is unable to accompany patient and manage IV during transport

**BH may only direct BLS personnel to leave device as found or turn the device off, then transport patient or wait for ALS arrival**

**Transdermal medication**

- Remove patches PRN (e.g., unstable, CPR status)

**Transports to another facility or home**

- No waiting period is required after medication administration
- IV solutions with added medications or other ALS treatment/monitoring modalities require ALS personnel (or RN/MD) in attendance during transport
- Cap end of catheter with device that occludes end if there is a central line

ALS

**Criteria for use of existing peripheral vascular access with external port**

- For immediate life threat **only**
  - EJ/IO access preferred over accessing percutaneous dialysis catheter (e.g., Vascath) or shunt/graft
  - Monitor and administer via existing dialysis catheter (aspirate 5 mL **prior** to infusion\*)
- OR**
- Access graft/AV fistula

**Assist with administration of physician-prescribed self-administered emergency medication<sup>Ⓢ</sup> [e.g., hydrocortisone (Solu-Cortef®) for Congenital Adrenal Hyperplasia]**

- Paramedics may assist patient/surrogate with the administration of emergency medications prescribed for self-administration BHO

**Intubated patients with agitation and potential for airway compromise**

- Midazolam 2-5 mg IM/IN/IV/IO, MR x1 in 5-10 min

**Note:** Existing devices and medications include physician-prescribed medications

\* Dialysis catheter contains concentrated dose of heparin, which must be aspirated **prior** to infusion

<sup>Ⓢ</sup> Per Title 22, Division 9, Chapter 3.1, § 100066.02, EMS clinicians may “assist patients with the administration of physician-prescribed ... self-administered emergency medications...”



RESPIRATORY DISTRESS

Date: 7/1/2025

Page 1 of 1

BLS

ALS

- Ensure patent airway
- Reassurance
- Dislodge any airway obstruction. Treat per Airway Obstruction Protocol (S-121)
- O<sub>2</sub> saturation
- O<sub>2</sub> and/or ventilate PRN
- Transport in position of comfort
- Carboxyhemoglobin monitor PRN, if available
- May assist patient to self-medicate own prescribed MDI **once only**. BH contact required for additional dose(s)

**Toxic inhalation (e.g., CO exposure, smoke, gas)**

- Move patient to safe environment
- 100% O<sub>2</sub> via mask
- Consider transport to facility with hyperbaric chamber for suspected CO poisoning for unconscious or pregnant patients

**Croup-like cough**

- Aerosolized saline or water 5 mL via O<sub>2</sub>-powered nebulizer/mask, MR PRN

- Monitor/ECG
- Capnography
- IV/IO <sup>(A)</sup>
- Intubate PRN
- NG/OG PRN

**Suspected CHF/cardiac origin**

- NTG<sup>1</sup> SL
  - If systolic BP  $\geq 100$  but  $< 150$ : NTG 0.4 mg SL, MR q3-5 min <sup>(A)</sup>
  - If systolic BP  $\geq 150$ : NTG 0.8 mg SL, MR q3-5 min <sup>(A)</sup>
- CPAP 5-10 cmH<sub>2</sub>O

**Suspected non-cardiac origin<sup>2</sup>**

- Albuterol/Levalbuterol 6 mL via nebulizer, MR <sup>(A)</sup>
- Ipratropium bromide 2.5 mL 0.02% via nebulizer added to first dose of albuterol/levalbuterol
- CPAP 5-10 cmH<sub>2</sub>O

**Unable to tolerate CPAP**

- Midazolam 0.5-1 mg IM/IN/IV

**Severe respiratory distress/failure or inadequate response to nebulized treatments consider**

History of asthma or suspected allergic reaction

- Epinephrine 1:1,000 (1 mg/mL) 0.5 mg IM, MR x2 q5 min <sup>(A)</sup>

**Intubated patients with agitation and potential for airway compromise**

- Midazolam 2-5 mg IM/IN/IV/IO, MR x1 in 5-10 min

**Notes:**

- For respiratory arrest, immediately start BVM ventilation
- Use caution with CPAP in patients with COPD; start low and titrate pressure
- Epinephrine IM: Use caution if known cardiac history, history of hypertension, SBP  $> 150$  mmHg, or age  $> 40$
- Fireline paramedics without access to O<sub>2</sub> may use MDI

<sup>1</sup> NTG is contraindicated in patients who have taken erectile dysfunction medications such as sildenafil (Viagra®), tadalafil (Cialis®), and vardenafil (Levitra®) within 48 hours; and pulmonary hypertension medications such as sildenafil (Revatio®), and epoprostenol sodium (Flolan®) and (Veletri®)

<sup>2</sup> Infection control: If concerned about aerosolized infectious exposure, substitute with MDI, if available



SHOCK

Date: 7/1/2025

Page 1 of 1

BLS

- O<sub>2</sub> saturation
- O<sub>2</sub> and/or ventilate PRN
- Control obvious external bleeding
- Treat associated injuries
- NPO, anticipate vomiting
- Remove transdermal patch
- Keep patient warm

ALS

- Monitor/ECG
- IV/IO <sup>Ⓐ</sup>
- Capnography

**Non-traumatic, hypovolemic shock\***

- 500 mL fluid bolus IV/IO, MR to maintain SBP  $\geq$ 90 mmHg <sup>Ⓐ</sup>

SBP <90 mmHg after second fluid bolus

- Push-dose epinephrine 1:100,000 (0.01 mg/mL)  
1 mL IV/IO, MR q3 min, titrate to SBP  $\geq$ 90 mmHg

**Distributive shock<sup>†</sup>**

- 500 mL fluid bolus IV/IO, MR to maintain SBP  $\geq$ 90 mmHg <sup>Ⓐ</sup>

SBP <90 mmHg after second fluid bolus

- Push-dose epinephrine 1:100,000 (0.01 mg/mL)  
1 mL IV/IO, MR q3 min, titrate to SBP  $\geq$ 90 mmHg

**Push-dose epinephrine mixing instructions**

1. Remove 1 mL normal saline (NS) from the 10 mL NS syringe
2. Add 1 mL of epinephrine 1:10,000 (0.1 mg/mL) to 9 mL NS syringe

The mixture now has 10 mL of epinephrine at 0.01 mg/mL (10 mcg/mL) concentration.

\* If suspected AAA, fluid boluses to maintain SBP  $\geq$ 80 mmHg. Treat per Abdominal Discomfort / GI / GU (Non-Traumatic) Protocol (S-120).

<sup>†</sup> Distributive shock includes neurogenic; drug and toxin-induced; and endocrine shock.



TRAUMA

Date: 7/1/2025

Page 1 of 3

BLS

ALS

- Ensure patent airway
- Protect C-spine
- Control obvious bleeding
- Spinal motion restriction per Skills List (S-104) except in penetrating trauma without neurological deficits
- O<sub>2</sub> saturation. Maintain SpO<sub>2</sub> at 94% to 98%
- O<sub>2</sub> and/or ventilate at a rate of 10/min PRN
- Keep warm
- Hemostatic gauze

**Abdominal trauma**

- Cover eviscerated bowel with saline pads

**Chest trauma**

- Cover open chest wound with three-sided occlusive dressing. Release dressing if tension pneumothorax develops.
- Chest seal PRN

**Extremity trauma**

- Splint neurologically stable fractures in position as presented. Traction splint PRN.
- Reduce grossly angulated long bone fractures with no pulse or sensation PRN
- Direct pressure to control external hemorrhage
- Apply gauze or hemostatic dressing PRN
- Tourniquet PRN
- In MCI, direct pressure not required prior to tourniquet application

**Impaled objects**

- Immobilize and leave impaled objects in place
- Remove object impaled in face, cheek, or neck if there is total airway obstruction

**Any suspicion of neurological injury (mechanism, GCS, examination)**

- High-flow O<sub>2</sub> PRN
- Monitor SpO<sub>2</sub>, BP, and HR q3-5 min
- If SpO<sub>2</sub> <90% or hypoventilation (despite high-flow O<sub>2</sub>), assist ventilations with BVM

- Monitor/ECG
- IV/IO <sup>Ⓐ</sup>
- Capnography. Maintain EtCO<sub>2</sub> 35-45 mmHg PRN
- Treat pain per Pain Management Protocol (S-141)

**SBP <90 mmHg or signs of shock**

- 500 mL fluid bolus IV/IO, MR x3 q15 min to maintain SBP ≥90 mmHg <sup>Ⓐ</sup>

**Trauma-associated hemorrhage <3 hours prior and at least one of the following:**

1. SBP <90 mmHg
2. Shock index ≥1.0 (HR ≥ SBP)
3. Uncontrolled external bleeding

- Tranexamic acid 1 gm/10 mL IV/IO, in 50-100 mL NS, over 10 min

**Crush injury requiring extrication with compression of extremity or torso ≥2 hours**

Immediately prior to anticipated release

- 1,000 mL fluid bolus IV/IO <sup>Ⓐ</sup>
- NaHCO<sub>3</sub> 1 mEq/kg IV/IO
- CaCl<sub>2</sub> 1 gm IV/IO over 30 sec
- Continuous albuterol/levalbuterol 6 mL via nebulizer <sup>Ⓐ</sup>

**Grossly angulated long bone fractures**

- Reduce with gentle unidirectional traction for splinting <sup>Ⓐ</sup>

**Severe respiratory distress with diminished or absent breath sounds (unilaterally or bilaterally), and SBP <90 mmHg, and suspected pneumothorax**

- Needle thoracostomy

**For nausea or vomiting**

- Ondansetron 4 mg IV/IM/ODT, MR x1 in 10 min

**For traumatic cardiac arrest**

- 1,000 mL fluid bolus IV/IO <sup>Ⓐ</sup>
- Do not administer epinephrine

**San Diego County Emergency Medical Services Office**  
**Policy / Procedure / Protocol**

<b>Pregnancy ≥6 months</b> <ul style="list-style-type: none"><li>• Where spinal motion restriction indicated, tilt patient to the left 30°</li></ul>	
--	--

**Transportation and Destination Guidelines**

Pediatric patients who meet criteria outlined in T-460 (Identification of the Pediatric Trauma Center Patient) should be transported to the Designated Pediatric Trauma Center, **except** in the following situations.

**1. Adult with child**

- a. If there is a single ambulance (air/ground) with both a pediatric trauma center patient **and** an adult trauma center patient, the ambulance should first transport the more critical patient to the appropriate facility. If both patients are critical, or if there are other questions, both may be transported to the designated adult trauma center.
- b. Field personnel should consider splitting the team using additional ALS transport vehicles, or aeromedical resources to transport the pediatric patient to the pediatric trauma facility and the adult patient to the catchment area trauma facility.


**2. Trauma center diversion**

The pediatric patient who is identified as a trauma patient shall be transported to the designated pediatric trauma center. When the pediatric trauma center is on diversion, including age-specific diversion, the pediatric patient shall be transported to the county-designated backup pediatric trauma center, the University of California, San Diego (UCSD).

**3. Pregnant pediatric patient**

A pediatric pregnant trauma patient shall be transported to UCSD.







PAIN MANAGEMENT

Date: 7/1/2025

Page 1 of 2

BLS

- Assess level of pain
- Ice, immobilize, and splint PRN
- Elevation of extremity PRN

ALS

- Continue to monitor and reassess pain using standardized pain scores
- Document vital signs before and after each medication administration

**Pain medication considerations**

1. When changing route of administration, consider the potential time difference in onset of action
2. If SBP <100 mmHg, ketamine may be preferred over opioids, which can cause hypotension

**For mild pain (score 1-3)<sup>1</sup>, moderate pain (score 4-6), or severe pain (score 7-10)**

- Acetaminophen 1,000 mg IV over 15 min

**For moderate pain (score 4-6) or severe pain (score 7-10)**

Fentanyl (IV dosing)

- Up to 100 mcg IV
- MR up to 50 mcg IV q5 min x2
- Maximum total dose 200 mcg IV

Fentanyl (IN dosing)

- Up to 50 mcg IN q15 min x2
- 3<sup>rd</sup> dose fentanyl up to 50 mcg IN

**If fentanyl unavailable**

Morphine (IV dosing)

- Up to 0.1 mg/kg IV
- MR in 5 min at half initial IV dose
- MR in additional 5 min at half initial IV dose

Morphine (IM dosing)

- Up to 0.1 mg/kg IM
- MR in 15 min at half initial IM dose
- MR in additional 15 min at half initial IM dose

**For moderate to severe pain (score ≥5)**

Requirements for use of ketamine on SO (must meet all)

- ≥15 years old
- GCS of 15
- Not pregnant
- No known or suspected alcohol or drug intoxication

<sup>1</sup> If patient refuses or has contraindications to acetaminophen, may treat as moderate pain

**Diego County Emergency Medical Services Office**  
**Policy / Procedure / Protocol**

	<p><u>Ketamine (IV dosing)</u></p> <ul style="list-style-type: none"><li>• 0.3 mg/kg in 100 mL of NS over 10 min IV. Maximum for any IV dose is 30 mg.</li><li>• MR x1 in 15 min if pain remains <b>moderate</b> or <b>severe</b></li></ul> <p><u>Ketamine (IN dosing)</u></p> <ul style="list-style-type: none"><li>• 0.5 mg/kg IN (50 mg/mL concentration). Maximum for any IN dose is 50 mg.</li><li>• MR x1 in 15 min if pain remains <b>moderate</b> or <b>severe</b></li></ul>
--	--



**BLS**

**ALS**

- Ensure patent airway, O<sub>2</sub> and/or ventilate PRN
- O<sub>2</sub> saturation PRN
- Treat life-threatening injuries
- Ask patient: "Do you have any weapons?"
- Attempt to determine if behavior is related to injury, illness, or drug use
- Employ de-escalation techniques
- Restrain only if necessary to prevent injury
- Document distal neurovascular status q15 min, if restrained
- Avoid unnecessary sirens
- Consider law enforcement support and/or evaluation of patient
- Law enforcement or EMS may remove Taser\* barbs

- Capnography
- Monitor/ECG
- IV <sup>Ⓐ</sup>

**Severely agitated and/or combative patient requiring restraint for patient or provider safety**

- Midazolam<sup>†</sup> 5 mg IM/IN/IV, MR x1 in 5-10 min
- 500 mL fluid bolus IV/IO PRN, MR x1, MR BHO <sup>Ⓐ</sup>

**\*Taser barb considerations**

- Taser discharge for simple behavioral control is usually benign and does not require transport to BEF for evaluation.
- Patients who are injured; appear to be under the influence of drugs; or present with altered mental status or symptoms of illness should have medical evaluation performed by EMS personnel before being transported to BEF.
- If barbs are impaled in anatomically sensitive location such as eye, face, neck, finger/hand, or genitalia, do not remove the barb. Transport patient to BEF.

<sup>†</sup>For severely agitated or combative patients, IN or IM midazolam is the preferred route to decrease risk of injury to the patient and personnel.

**Alert:** Co-administration of midazolam in patients with alcohol intoxication can cause respiratory depression. Consider avoiding or reducing midazolam dose.



SEPSIS

Date: 7/1/2024

Page 1 of 1

BLS

- O<sub>2</sub> saturation PRN
- O<sub>2</sub> and/or ventilate PRN
- NPO, anticipate vomiting
- Remove transdermal patch, if present
- Obtain temperature
- Monitor blood glucose PRN

ALS

- Monitor/ECG
- IV/IO <sup>(A)</sup>
- Capnography

**Suspected sepsis**

If history **suggestive of infection** with  $\geq 2$  of the following<sup>1</sup>:

1. Temperature  $\geq 100.4$  °F (38.0 °C) or  $< 96.8$  °F (36.0 °C)
2. HR  $\geq 90$
3. RR  $\geq 20$  or EtCO<sub>2</sub>  $< 25$  mmHg
4. Altered LOC
5. SBP  $< 90$  mmHg

- 500 mL fluid bolus IV/IO regardless of initial BP or lung sounds <sup>(A)</sup>
  - If no rales or SBP  $< 90$  mmHg, give additional 500 mL fluid bolus IV/IO, MR x2 <sup>(A)</sup>

**SBP  $< 90$  mmHg after fluid boluses**

- Push-dose epinephrine 1:100,000 (0.01 mg/mL)  
1 mL IV/IO, MR q3 min, titrate to SBP  $\geq 90$  mmHg

**Push-dose epinephrine mixing instructions**

1. Remove 1 mL normal saline (NS) from the 10 mL NS syringe
2. Add 1 mL of epinephrine 1:10,000 (0.1 mg/mL) to 9 mL NS syringe

The mixture now has 10 mL of epinephrine at 0.01 mg/mL (10 mcg/mL) concentration.

<sup>1</sup> Suspected sepsis should be reported to the Base Hospital and upon transfer of care at the receiving hospital.



**COUNTY OF SAN DIEGO**  
EMERGENCY MEDICAL SERVICES

TREATMENT PROTOCOL

**S-144**

**STROKE AND TRANSIENT ISCHEMIC ATTACK**

Date: 7/1/2024

Page 1 of 2

**BLS**

**ALS**

**For patients with symptoms suggestive of TIA or stroke with onset of symptoms known to be <24 hours in duration**

- Maintain O<sub>2</sub> saturation at 94% to 98%
- Keep head of bed (HOB) at 15° elevation. If SBP <120 mmHg and patient tolerates, place HOB flat.
- Expedite transport
- Make BH initial notification early to confirm destination
- Notify accepting Stroke Receiving Center of potential stroke code patient enroute
- Provide list of all current medications, especially anticoagulants, upon arrival to Emergency Department

**Important signs/symptoms to recognize, report, and document**

Use *BE-FAST* Prehospital Stroke Screening Scale in assessment of possible TIA or stroke patients

**B** = Balance: Unsteadiness, ataxia

**E** = Eyes: Blurred/double or loss of vision

**F** = Face: Unilateral face droop

**A** = Arms and/or legs: Unilateral weakness exhibited by a drift or drop

**S** = Speech: Slurred, inability to find words, absent

**T** = Time: Accurate last known well time

If *BE-FAST* is positive, calculate and report the *FAST-ED* Prehospital Stroke Severity Scale value

**F** = Facial palsy

**A** = Arm weakness

**S** = Speech changes

**T** = Time

**E** = Eye deviation

**D** = Denial/Neglect

- Sudden severe headache with no known cause
- Get specific **last known well** time in military time (hours: minutes)

**Bring witness to ED to verify time of symptom onset and provide consent for interventions. If witness unable to ride in ambulance, obtain accurate contact phone number.**

**Obtain blood glucose. If blood glucose <60 mg/dL, treat for hypoglycemia.**

- If patient is awake and able to swallow, give 3 oral glucose tabs or paste (15 gm total)
- Patient may eat or drink, if able
- If patient is unconscious, NPO

- IV <sup>Ⓐ</sup> (large-bore antecubital site preferred)
- 250 mL fluid bolus IV/IO to maintain BP ≥120 mmHg if no rales, MR <sup>Ⓐ</sup>

**San Diego County Emergency Medical Services Office**  
**Policy / Procedure / Protocol**

**FAST-ED Severity Scale**

<b>Assessment Item</b>	<b>FAST-ED Score</b>
<b>Facial palsy:</b>	
Normal or minor paralysis	0
Partial or complete paralysis	1
<b>Arm weakness:</b>	
No drift	0
Drift or some effort against gravity	1
No effort against gravity or no movement	2
<b>Speech changes:</b>	
Absent	0
Mild to moderate	1
Severe, global aphasia, or mute	2
<b>Time:</b>	
What time did the symptoms start?	
What time was the patient last known well?	
<b>Eye deviation:</b>	
Absent	0
Partial	1
Forced deviation	2
<b>Denial/Neglect:</b>	
Absent	0
Extinction to bilateral simultaneous stimulation in only 1 sensory modality	1
Does not recognize own hand or orients only to one side of the body	2
<b>Total</b>	



**OPIOID WITHDRAWAL / OPIOID USE DISORDER**

Date: 7/1/2025

Page 1 of 1

**BLS**

**ALS**

- Ensure patent airway
- O<sub>2</sub> saturation PRN
- O<sub>2</sub> and/or ventilate PRN

**Symptomatic suspected opioid OD with RR <12**

- Treat per Poisoning / Overdose Protocol (S-134)

**For suspected opioid withdrawal or opioid use disorder, request for ALS to provide treatment and transport<sup>1</sup>**

**For patients and/or other individuals suspected of opioid use disorder, provide Leave Behind Naloxone Kit with education per the Leave Behind Naloxone Program<sup>2</sup>**

- Monitor/ECG
- IV/IO <sup>(A)</sup>
- Capnography

**Symptomatic suspected opioid OD with respiratory depression (RR<12, SpO<sub>2</sub><96%, or EtCO<sub>2</sub> ≥40 mmHg)**

- Treat per Poisoning / Overdose Protocol (S-134)

**Complete COWS score using S-145A<sup>1</sup>**

**For suspected opioid withdrawal in patients ≥16 years with COWS score ≥8<sup>1</sup>**

- Contact opioid withdrawal base
- Buprenorphine-naloxone (Suboxone®) 16 mg/4 mg SL BHO (opioid withdrawal base)
- Reassess after 15 min
- Repeat with buprenorphine-naloxone (Suboxone®) 8 mg/2 mg SL to a max of 24 mg/6 mg
- Recommend transport to emergency department
- Ensure warm handoff

**If patient declines transport:**

- Verify patient contact information
- Ensure warm handoff
- Attempt to arrange non-EMS transport to appropriate facility
- Provide Leave Behind Naloxone kit and education
- Provide MAT information, coaching, and brochure

**Buprenorphine Pilot Program exclusion criteria:**

- Any methadone use within the last 10 days
- Lack of opioid withdrawal signs or symptoms
- Under 16 years of age
- Severe medical illness (e.g., sepsis, respiratory distress)
- Unable to give consent or comprehend potential risks and benefits for any reason, including altered mental status

<sup>1</sup> For agencies participating in the Buprenorphine Pilot Program

<sup>2</sup> For agencies participating in the Leave Behind Naloxone Program



SUBJECT: TREATMENT PROTOCOL -  
OPIOID WITHDRAWAL / OPIOID USE DISORDER COWS SCORE

Date: 07/1/2023

## Instructions

For each item, select the number that best describes the patient's sign or symptom. Rate it on just the apparent relationship to opiate withdrawal. For example, if heart rate is increased because the patient was jogging prior to assessment, the increased pulse rate would not be added to the score. The scores will be added together on the final page for a total COWS score.

<p><b>Resting Pulse Rate</b> <i>Measured after the patient is sitting or lying down for 1 minute</i></p> <p>0 = pulse rate &lt;80 BPM 1 = pulse rate 81-100 BPM 2 = pulse rate 101-120 BPM 4 = pulse rate &gt;120 BPM</p> <p>Score =</p>	<p><b>Gastrointestinal Upset</b> <i>Over the past 30 minutes</i></p> <p>0 = no GI symptoms 1 = stomach cramps 2 = nausea or loose stool 3 = vomiting or diarrhea 5 = multiple episodes of diarrhea or vomiting</p> <p>Score =</p>
<p><b>Sweating</b> <i>Over the past 30 minutes not accounted for by room temperature or patient activity</i></p> <p>0 = no report of chills or flushing 1 = subjective report of chills or flushing 2 = flushed or observable moistness on face 3 = beads of sweat on brow or face 4 = sweat streaming off of face</p> <p>Score =</p>	<p><b>Tremor</b> <i>Observation of outstretched hands</i></p> <p>0 = no tremor 1 = tremor can be felt, but not observed 2 = slight tremor observable 4 = gross tremor or muscle twitching</p> <p>Score =</p>
<p><b>Restlessness</b> <i>Observation during assessment</i></p> <p>0 = able to sit still 1 = reports difficulty sitting still, but is able to 3 = frequent shifting or extraneous movements of arms or legs 5 = unable to sit still for more than a few seconds</p> <p>Score =</p>	<p><b>Yawning</b> <i>Observation during assessment</i></p> <p>0 = no yawning 1 = yawning 1-2 times during assessment 2 = yawning 3+ times during assessment 4 = yawning several times per minute</p> <p>Score =</p>

*Continued on the next page*

SUBJECT: TREATMENT PROTOCOL -  
OPIOID WITHDRAWAL / OPIOID USE DISORDER COWS SCORE

Date: 07/1/2023

<p><b>Pupil Size</b></p> <p>0 = pupils pinned or normal size for room light 1 = pupils possibly larger than normal for room light 2 = pupils moderately dilated 5 = pupils so dilated that only the rim of the iris is visible</p> <p>Score =</p>	<p><b>Anxiety or Irritability</b></p> <p>0 = none 1 = patient reports increasing irritability or anxiousness 2 = patient obviously irritable or anxious 4 = patient so irritable or anxious that participation in the assessment is difficult</p> <p>Score =</p>
<p><b>Bone or Joint Aches</b></p> <p><i>If the patient was having pain previously, only the additional component attributed to opioid withdrawal is scored</i></p> <p>0 = not present 1 = mild, diffuse discomfort 2 = patient reports severe diffuse aching of joints or muscles 4 = patient is rubbing joints or muscles and is unable to sit still because of discomfort</p> <p>Score =</p>	<p><b>Gooseflesh Skin (Goosebumps)</b></p> <p>0 = skin is smooth 3 = piloerection of skin can be felt or hairs standing up on arms 5 = prominent piloerection</p> <p>Score =</p>
<p><b>Runny Nose or Tearing</b></p> <p><i>Not accounted for by cold symptoms or allergies</i></p> <p>0 = not present 1 = nasal stuffiness or unusually moist eyes 2 = nose running or tearing 4 = nose constantly running or tears streaming down cheeks</p> <p>Score =</p>	<p><b>Total Score</b></p> <p><i>Sum of all 11 criteria</i></p> <p>Score =</p> <p><b>Interpretation</b></p> <p>Score &gt;5 = no active withdrawal Score 5-12 = mild withdrawal Score 13-24 = moderate withdrawal Score 25-36 = moderately severe withdrawal Score &gt;36 = severe withdrawal</p> <p>Interpretation =</p>

SUBJECT: TREATMENT PROTOCOL -  
OPIOID WITHDRAWAL / OPIOID USE DISORDER COWS SCORE

---

Date: 07/01/2023

Patient's Name	Date & Time of Assessment
Assessing Paramedic's Name	Interpretation of Assessment

A digital version of this tool can be found at: <https://tinyurl.com/yc7v95jn>

OR by scanning the QR code



COWS Criteria from Wesson DR, Ling W. The Clinical Opiate Withdrawal Scale (COWS). *J Psychoactive Drugs*. 2003;35(2):253-259. DOI:10.1080/02791072.2003.10400007. Reproduced and modified for clinical use with permission.



**COUNTY OF SAN DIEGO**  
EMERGENCY MEDICAL SERVICES

TREATMENT PROTOCOL

**S-150**

**CHEMPACK DEPLOYMENT AND  
AUTOINJECTOR USE**

Date: 7/1/2025

Page 1 of 2

**BLS**

**ALS**

**Upon identification of a scene involving suspected or known exposure of nerve agent**

- Isolate area
- Notify dispatch of possible Mass Casualty Incident with possible nerve agent involvement
- **DO NOT ENTER AREA**

**If exposed**

- Blot off agent
- Strip off all clothing, avoiding contact with outer clothing surfaces
- Flush affected area(s) with copious amounts of water
- Cover affected area(s)

**If you begin to experience any signs/symptoms of nerve agent exposure, for example**

(Use SLUDGE/BBB mnemonic: Salivation, Lacrimation, Urination, Defecation, Gastrointestinal distress, Emesis, Bronchorrhea, Bronchospasm, Bradycardia)

- Increased secretions (tears, saliva, runny nose, sweating)
- Diminished vision, small pupils
- SOB
- Nausea, vomiting, diarrhea
- Muscle twitching/weakness
- **NOTIFY THE INCIDENT COMMANDER** (or dispatch if no IC) immediately of your exposure and declare yourself a patient

**Self-treat immediately** per the acuity guidelines listed under ALS

**Triage, decontaminate, and treat patient based on severity of symptoms**

**Mild**

Miosis, rhinorrhea, increasing salivation

- DuoDote (or equivalent) autoinjector<sup>1,2</sup> IM

**Moderate**

Miosis, rhinorrhea, shortness of breath, vomiting, diarrhea

- DuoDote (or equivalent) autoinjector<sup>1,2</sup> IM x2 in rapid succession

**Ongoing DuoDote treatment**

- If symptoms of mild or moderate exposure progress after initial evaluation, administer additional DuoDote (or equivalent) autoinjector<sup>1,2</sup> IM up to a cumulative maximum of 3 doses

**Severe**

Severe respiratory distress, respiratory arrest, cyanosis, extreme SLUDGE/BBB, seizures, unconsciousness

- DuoDote (or equivalent) autoinjector<sup>1,2</sup> IM x3 in rapid succession

**For seizures**

- Diazepam autoinjector 10mg IM
- If no diazepam autoinjector available, treat per Altered Neurologic Function (Non-Traumatic) Protocol (S-123)

**Ongoing organophosphate SLUDGE/BBB signs and symptoms after completion of initial 3 doses of DuoDote**

- Atropine autoinjector or atropine per Poisoning/Overdose Protocol (S-134)

**PEDIATRIC DOSING**

**Mild**

Miosis, rhinorrhea, increased salivation

- Pediatric atropine autoinjector or atropine per Poisoning/Overdose Protocol (S-165)

**Moderate**

Miosis, rhinorrhea, shortness of breath, vomiting, diarrhea

- DuoDote (or equivalent) autoinjector<sup>1,2</sup> IM (dose per weight):

<sup>1</sup> DuoDote (or equivalent) autoinjectors are authorized for use by Paramedics, and by EMT/AEMTs as an optional skill, subject to completion of County of San Diego approved training or on scene just-in-time (JIT) training.

<sup>2</sup> DuoDote autoinjectors contain atropine 2.1 mg and pralidoxime (2-PAM) 600 mg. If no DuoDote (or equivalent) autoinjectors are available, coadministration of an atropine autoinjector 2mg IM plus a pralidoxime (2-PAM) autoinjector 600 mg IM is an authorized substitution.

Weight	LBRT Color		DuoDote
5 kg	GREY	PINK	1 DuoDote
10 kg	RED	PURPLE YELLOW	1 DuoDote
15 kg	WHITE		1 DuoDote
20 kg	BLUE		1 DuoDote
25 kg	ORANGE		1 DuoDote
35 kg	GREEN		1 DuoDote
>36 kg	TURQUOISE		2 DuoDotes (adult dose)

#### Severe

Severe respiratory distress, respiratory arrest, cyanosis, extreme SLUDGE/BBB, seizures, unconsciousness

- For seizures, treat per Altered Neurologic Function (Non-Traumatic) Protocol (S-161)
- DuoDote(s) (or equivalent) autoinjector<sup>1,2</sup> IM (dose per weight):

Weight	LBRT Color		DuoDote
5 kg	GREY	PINK	1 DuoDote
10 kg	RED	PURPLE YELLOW	1 DuoDote
15 kg	WHITE		1 DuoDote
20 kg	BLUE		1 DuoDote
25 kg	ORANGE		2 DuoDotes
35 kg	GREEN		2 DuoDotes
>36 kg	TURQUOISE		3 DuoDotes (adult dose)

#### Ongoing organophosphate SLUDGE/BBB signs and symptoms after completion of initial DuoDote doses

- Pediatric atropine autoinjector or atropine per Poisoning/Overdose Protocol (S-165)

Weight	LBRT Color		Atropine Autoinjector
5 kg	GREY	PINK	0.5 mg
10 kg	RED	PURPLE YELLOW	0.5 mg
15 kg	WHITE		0.5 mg
20 kg	BLUE		1 mg
25 kg	ORANGE		1 mg
35 kg	GREEN		1 mg
>36 kg	TURQUOISE		2 mg

**Note:** If there are no autoinjectors in the CHEMPACK, paramedics may administer medications from multi-dose vials.



**AIRWAY OBSTRUCTION**

Date: 7/1/2025

Page 1 of 1

**BLS**

**ALS**

**For conscious patient**

- Reassure, encourage coughing
- O<sub>2</sub> PRN

**For inadequate air exchange**

Airway maneuvers (AHA)

- Abdominal thrusts
- For obese or pregnant patients, perform chest thrusts
- For infants <1 year, perform 5 back blows and 5 chest thrusts, MR PRN

**If patient found or becomes unconscious**

- Begin CPR

**Once obstruction is removed**

- Ventilate with high-flow O<sub>2</sub> PRN
- O<sub>2</sub> saturation

**If suspected epiglottitis**

- Place patient in sitting position
- Do not visualize the oropharynx

**Treat per Respiratory Distress Protocol (S-167)**

**If patient becomes unconscious or has a decreasing LOC**

- Direct or video laryngoscopy and Magill forceps, MR PRN
- Capnography

**Once obstruction is removed**

- Monitor/ECG
- IV/IO <sup>®</sup>

**Note:** If unable to ventilate effectively, transport immediately while continuing CPR (unconscious patient)



ALTERED NEUROLOGIC FUNCTION  
(NON-TRAUMATIC)

Date: 7/1/2025

Page 1 of 1

BLS

- Ensure patent airway
- O<sub>2</sub> saturation, O<sub>2</sub> and/or ventilate PRN
- Spinal motion restriction PRN
- Position on affected side if difficulty managing secretions
- Do not allow patient to walk
- Restrain PRN
- Monitor blood glucose

**Symptomatic suspected opioid OD with RR low for age. Use with caution in opioid-dependent, pain-management patients<sup>Ⓐ</sup>**

Patients <35 kg (77 lbs)

- Ventilate PRN
- Call for ALS

Patients ≥35 kg

- Naloxone 4 mg via nasal spray preloaded single-dose device. Administer full dose in one nostril
- OR**
- Naloxone 2 mg via atomizer and syringe. Administer 1 mg into each nostril

EMTs may assist family or friend to medicate with patient's prescribed naloxone in **symptomatic suspected opioid OD**

**Suspected hypoglycemia or patient's blood sugar is <60 mg/dL (<45 mg/dL for neonates)**

- If patient is awake and able to manage oral secretions, give 3 oral glucose tabs or paste (15 gm total)
- Patient may eat or drink, if able
- If patient is unconscious, NPO

**Stroke/TIA**

- Treat per Adult Stroke and Transient Ischemic Attack (S-144)
- Pediatric patients presenting with stroke symptoms should be transported to Rady Children's Hospital

**Seizures**

- Protect airway and protect from injury
- Treat associated injuries
- If febrile, remove excess clothing/covering

ALS

- Monitor/ECG
- Capnography
- IV <sup>Ⓐ</sup>

**Symptomatic suspected opioid OD with respiratory depression (RR low for age, SpO<sub>2</sub><96%, or EtCO<sub>2</sub> ≥40 mmHg)**

- Naloxone per drug chart IN/IV/IM, MR <sup>Ⓐ</sup>
- For opioid-dependent patients, dilute and titrate slowly per drug chart.

**Symptomatic hypoglycemia with altered LOC or unresponsive to oral glucose agents**

- D<sub>10</sub> per drug chart IV if BS <60 mg/dL (<45 mg/dL for neonate)
- If patient remains symptomatic and BS remains <60 mg/dL (<45 mg/dL for neonate), MR
- If no IV, glucagon per drug chart IM if BS <60 mg/dL (<45 mg/dL for neonate) <sup>Ⓐ</sup>

**Status epilepticus (generalized, ongoing, and recurrent seizures without lucid interval)**

- Midazolam IM per drug chart

**If vascular access present**

- Midazolam IV/IO per drug chart, MR x1 in 10 min

**Partial seizure lasting ≥5 min (includes seizure time prior to arrival of prehospital provider)**

- Midazolam IN/IM/IV/IO per drug chart, MR x1 in 10 min

**Eclamptic seizure of any duration**

- Treat per Adult Obstetrical Emergencies / Newborn Deliveries (S-133)

<sup>Ⓐ</sup>Authorized by County of San Diego EMS Medical Director for public safety personnel per Title 22, Division 9, Chapter 2.3, §100027.03



ALLERGIC REACTION / ANAPHYLAXIS

Date: 7/1/2025

Page 1 of 2

BLS

ALS

- Ensure patent airway
- O<sub>2</sub> saturation PRN
- O<sub>2</sub> and/or ventilate PRN
- Attempt to identify allergen and route (injected, ingested, absorbed, or inhaled)
- Remove allergen (e.g., stinger, injection mechanism), if possible
- Epinephrine auto-injector
  - Patient 15 to 33 kg (33 to 73 lbs), 0.15 mg IM x1
  - Patient ≥33 kg (≥73 lbs), 0.3 mg IM x1

OR

Assist patient to self-medicate own prescribed epinephrine auto-injector or albuterol MDI **once only**. BH contact required for additional dose(s)

Assess for hypotension

- <1 month: SBP <60 mmHg
- 1 month – 1 year: SBP <70 mmHg
- 1 year – 10 years: SBP <70 mmHg + (2x age in years)
- ≥10 years: SBP <90 mmHg

- Monitor/ECG
- IV/IO <sup>Ⓐ</sup>
- Capnography

Allergic reaction (skin signs only)

- Urticaria (hives, rash)
- Erythema (flushing)
- Pruritus (itching)

Allergic reaction treatment

- Diphenhydramine per drug chart IV/IM

Suspected anaphylaxis reaction

- Respiratory: throat tightness, hoarse voice, wheezing/stridor, cough, SOB
- Cardiovascular: fainting, dizziness, tachycardia, low BP
- GI: nausea, vomiting, abdominal cramping
- Tissues: angioedema of eyelids, lips, tongue, face

Anaphylaxis treatment

- Epinephrine 1:1,000 (1 mg/mL) per drug chart IM (lateral thigh), MR x2 q5 min <sup>Ⓐ</sup> **then**
- Diphenhydramine per drug chart IV/IM

If respiratory involvement<sup>1</sup>

- Albuterol/Levalbuterol per drug chart via nebulizer, MR <sup>Ⓐ</sup>
- Ipratropium bromide per drug chart via nebulizer added to first dose of albuterol/levalbuterol

Respiratory distress with stridor at rest

- Epinephrine 1:1,000 per drug chart (combined with 3 mL normal saline) via nebulizer, MR x1

Severe anaphylaxis or inadequate response to treatment

- Fluid bolus IV/IO per drug chart MR to maintain adequate perfusion <sup>Ⓐ</sup>
- Push-dose epinephrine 1:100,000 (0.01 mg/mL) per drug chart IV/IO, MR q3 min, titrate to adequate perfusion or improvement in status

Push-dose epinephrine mixing instructions

1. Remove 1 mL normal saline (NS) from the 10 mL NS syringe

<sup>1</sup> **Infection control:** If concerned about aerosolized infectious exposure, substitute with MDI, if available



	<p>2. Add 1 mL of epinephrine 1:10,000 (0.1 mg/mL) to 9 mL NS syringe The mixture now has 10 mL of epinephrine at 0.01 mg/mL (10 mcg/mL) concentration.</p>	
--	---	--



**BLS**

**ALS**

- Compression rate 100-120/min
- Ventilation rate (compression-to-ventilation ratio)
  - Neonate: 20-30/min (3:1)
  - Pediatric: 10-12/min (15:2)\*
- Use metronome or other real-time audiovisual feedback device
- Rotate compressor at least every 2 min
- Use mechanical compression device, if size-appropriate available
- O2 and/or ventilate with BVM
- Monitor O2 saturation
- Apply AED during CPR and analyze as soon as ready

**VAD**

- Perform CPR
- Contact BH for additional instructions

**TAH**

- Contact BH for instructions

- Apply defibrillator pads during CPR. Defibrillate immediately for VF/pulseless VT.
- IV/IO <sup>(A)</sup>
- Capnography with waveform and value
- NG/OG tube PRN

**Team leader priorities**

- Monitor CPR quality, rate, depth, full chest recoil, and capnography value and waveform
- Minimize interruption of compressions (<5 sec) during ECG rhythm checks
- Charge monitor prior to rhythm checks. Do not interrupt CPR while charging.

**VAD/TAH**

- See Adjunct Cardiac Devices section

**Capnography**

- If EtCO<sub>2</sub> rises rapidly during CPR, pause CPR and check for pulse

**Specific protocols (see below)**

- Arrhythmias
  - Unstable bradycardia
  - Supraventricular tachycardia
  - Ventricular tachycardia
  - Ventricular fibrillation / pulseless VT
  - Pulseless electrical activity / asystole
- Return of Spontaneous Circulation
- Adjunct Cardiac Devices

\*Continuous compressions are an acceptable alternative for pediatric CPR

## **UNSTABLE‡ BRADYCARDIA**

- Obtain 12-lead ECG, when able

**Infant/child (<9 years) with HR <60 BPM**

**OR**

**Child (9-14 years) with HR <40 BPM**

- Ventilate with BVM

**If no increase in HR after 30 sec of BVM ventilations**

- If unconscious, begin CPR
- Epinephrine 1:10,000 per drug chart IV/IO, MR x2 q3-5 minutes. MR q3-5 minutes BHO
- After 3 doses of epinephrine
  - Atropine per drug chart IV/IO, MR x1 in 5 min
- Consider midazolam per drug chart IV/IO PRN pre-pacing BHO
- Consider cardiac pacing BHO

‡Exhibiting any of the following signs/symptoms of inadequate perfusion, e.g.,

- Altered mental status (decreased LOC, confusion, agitation)
- Pallor, mottling, or cyanosis
- Diaphoresis
- Difference in peripheral vs. central pulses
- Delayed capillary refill
- Hypotension by age
  - <1 month: SBP <60 mmHg
  - 1 month – 1 year: SBP <70 mmHg
  - 1 year – 10 years: SBP <70 mmHg + (2x age in years)
  - ≥10 years: SBP <90 mmHg

## SUPRAVENTRICULAR TACHYCARDIA

- Obtain 12-lead ECG

**Infant/child (<4 years) with HR  $\geq$ 220 BPM**

**OR**

**Child ( $\geq$ 4 years) with HR  $\geq$ 180 BPM**

**Stable (symptomatic)**

- Consider VSM
- Fluid bolus per drug chart IV/IO <sup>(A)</sup>
- Adenosine per drug chart rapid IV/IO, followed with 20 mL NS rapid IV/IO, MR x2

**Unstable<sup>‡</sup>**

- Consider midazolam per drug chart IV/IO pre-cardioversion
- Synchronized cardioversion per drug chart, MR BHPO

<sup>‡</sup>Exhibiting any of the following signs/symptoms of inadequate perfusion, e.g.,

- Altered mental status (decreased LOC, confusion, agitation)
- Pallor, mottling, or cyanosis
- Diaphoresis
- Difference in peripheral vs. central pulses
- Delayed capillary refill
- Hypotension by age
  - <1 month: SBP <60 mmHg
  - 1 month – 1 year: SBP <70 mmHg
  - 1 year – 10 years: SBP <70 mmHg + (2x age in years)
  - $\geq$ 10 years: SBP <90 mmHg

## VENTRICULAR TACHYCARDIA

- Obtain 12-lead ECG

### Stable

- Fluid boluses per drug chart IV/IO to maintain SBP appropriate for age <sup>®</sup>
- Amiodarone per drug chart BHPO

### OR

- Lidocaine per drug chart BHPO

### Unstable<sup>‡</sup>

- Consider midazolam per drug chart IV/IO pre-cardioversion
- Synchronized cardioversion per drug chart, MR BHPO
- After successful cardioversion
  - Check BP. If hypotensive for age<sup>§</sup> and rales not present, fluid bolus per drug chart IV/IO, MR
  - Obtain 12-lead ECG

<sup>‡</sup>Exhibiting any of the following signs/symptoms of inadequate perfusion, e.g.,

- Altered mental status (decreased LOC, confusion, agitation)
- Pallor, mottling, or cyanosis
- Diaphoresis
- Difference in peripheral vs. central pulses
- Delayed capillary refill
- <sup>§</sup>Hypotension by age
  - <1 month: SBP <60 mmHg
  - 1 month – 1 year: SBP <70 mmHg
  - 1 year – 10 years: SBP <70 mmHg + (2x age in years)
  - ≥10 years: SBP <90 mmHg

## VENTRICULAR FIBRILLATION / PULSELESS VT

- CPR
- Defibrillate per drug chart as soon as monitor available/charged
- Defibrillate per drug chart q2 min while VF/VT persists
- Epinephrine 1:10,000 per drug chart IV/IO q3-5 min, begin after second defibrillation

### **Persistent VF/VT after 3 defibrillation attempts**

- Amiodarone per drug chart IV/IO, MR per drug chart x2
- OR**
- Lidocaine per drug chart IV/IO, MR per drug chart x1 q5 min

## PULSELESS ELECTRICAL ACTIVITY / ASYSTOLE

- CPR
- Epinephrine 1:10,000 per drug chart IV/IO q3-5 min

### **Suspected hyperkalemia**

- $\text{CaCl}_2$  per drug chart IV/IO, MR x1 in 5 min for continued ECG findings consistent with hyperkalemia
- $\text{NaHCO}_3$  per drug chart IV/IO
- Continuous albuterol/levalbuterol per drug chart via nebulizer <sup>(A)</sup>

### **Suspected hypovolemia**

- Fluid bolus per drug chart IV/IO, MR x2 <sup>(A)</sup>

### **Suspected poisoning / OD**

- For suspected tricyclic antidepressant, beta blocker, or calcium channel blocker overdoses, consider treatment per Poisoning / Overdose Protocol (S-165)<sup>1</sup>

### **Prolonged asystole / PEA**

- After  $\geq 20$  min, contact BH physician for direction

---

<sup>1</sup> Naloxone is not authorized in cardiac arrest.

## RETURN OF SPONTANEOUS CIRCULATION

- Ventilate PRN (goal of EtCO<sub>2</sub> = 40 mmHg)
- Obtain BP
  - If hypotensive<sup>§</sup> and rales not present, fluid bolus per drug chart IV/IO, MR <sup>®</sup>
    - If unresponsive to fluid boluses, push-dose epinephrine 1:100,000 (0.01 mg/mL) per drug chart IV/IO, MR q3 min, titrate to adequate perfusion
- Obtain 12-lead ECG
- Provide cardiac monitor data to agency QA/QI department
- Monitor blood glucose PRN

### Push-dose epinephrine mixing instructions

1. Remove 1 mL normal saline (NS) from the 10 mL NS syringe
2. Add 1 mL of epinephrine 1:10,000 (0.1 mg/mL) to 9 mL NS syringe

The mixture now has 10 mL of epinephrine at 0.01 mg/mL (10 mcg/mL) concentration.

### <sup>§</sup>Hypotension by age

- <1 month: SBP <60 mmHg
- 1 month – 1 year: SBP <70 mmHg
- 1 year – 10 years: SBP <70 mmHg + (2x age in years)
- ≥10 years: SBP <90 mmHg



## ADJUNCT CARDIAC DEVICES

Transport equipment and any knowledgeable family/support persons to ED with patient

### **VAD**

- Contact BH and VAD coordinator
- Follow protocols for CPR and treatment of arrhythmias, including use of cardioversion, pacing, and defibrillation PRN

### **TAH**

- Contact TAH coordinator
- Consult BH Physician for orders for TAH recommended treatments

### **Wearable defibrillators (vest)**

- If vest device is broadcasting specific verbal directions, follow device's prompts
- If device not broadcasting directions and patient requires CPR or cardiac treatment, remove vest and treat

### **Malfunctioning pacemakers**

- Treat per applicable arrhythmia protocol
- Treat pain per Pain Management Protocol (S-173) PRN

### **Reported/witnessed AICD firing $\geq 2$**

- Amiodarone per drug chart, MR BHPO

### **OR**

- Lidocaine per drug chart, MR BHPO



**COUNTY OF SAN DIEGO**  
EMERGENCY MEDICAL SERVICES

PEDIATRIC TREATMENT PROTOCOL

**S-164**

**ENVENOMATION INJURIES**

**Date: 7/1/2024**

**Page 1 of 1**

**BLS**

**ALS**

- O<sub>2</sub> and/or ventilate PRN
  - If antivenin available on site, transport with patient to hospital
- Jellyfish sting**
- Liberally rinse with seawater
  - Scrape to remove stinger(s)
  - Heat as tolerated (not to exceed 110 °F / 43 °C)
- Stingray or sculpin injury**
- Immersion in hot water (as hot as tolerated, not to exceed 110 °F / 43 °C)
- Snakebite**
- Mark proximal extent of swelling and/or tenderness
  - Keep involved extremity at heart level and immobile
  - Remove constrictive device(s)
  - Remove jewelry distal to bite

- IV <sup>A</sup>
- Treat per Pain Management Protocol (S-173)



POISONING / OVERDOSE

Date: 7/1/2025

Page 1 of 1

BLS

ALS

- Ensure patent airway
- O<sub>2</sub> saturation PRN
- O<sub>2</sub> and/or ventilate PRN
- Monitor blood glucose PRN
- Carboxyhemoglobin monitor PRN, if available

**Ingestions**

- Identify substance
- Transport pill bottles and containers with patient PRN

**Skin contamination\***

- Remove clothes
- Brush off dry chemicals
- Flush with copious water

**Toxic inhalation (e.g., CO exposure, smoke, gas)**

- Move patient to safe environment
- 100% O<sub>2</sub> via mask
- Consider transport to facility with hyperbaric chamber for suspected CO poisoning, particularly in unconscious or pregnant patients

**Symptomatic suspected opioid OD with RR low for age. Use with caution in opioid-dependent, pain-management patients<sup>⊗</sup>**

Patients <35 kg (77 lbs)

- Ventilate PRN
- Call for ALS

Patients ≥35 kg

- Naloxone 4 mg via nasal spray preloaded single-dose device. Administer full dose in one nostril OR
- Naloxone 2 mg via atomizer and syringe. Administer 1 mg into each nostril.

EMTs may assist family or friend to medicate with patient's prescribed naloxone in **symptomatic suspected opioid OD**

- Monitor/ECG
- IV/IO <sup>Ⓐ</sup>
- Capnography

**Ingestions**

- Assure patient has gag reflex and is cooperative
- Activated charcoal per drug chart PO if ingestion within 60 minutes and recommended by Poison Control Center <sup>Ⓐ</sup>
- In oral hypoglycemic agent ingestion, any change in mentation requires blood glucose check or recheck

**Symptomatic suspected opioid OD with respiratory depression (RR low for age, SpO<sub>2</sub><96%, or EtCO<sub>2</sub> ≥40 mmHg)**

- Naloxone per drug chart IN/IV/IM, MR <sup>Ⓐ</sup>
- In opioid-dependent patients, dilute and titrate slowly per drug chart

**Symptomatic organophosphate poisoning**

- Atropine per drug chart IV/IO
- For continued signs/symptoms of SLUDGE/BBB, double prior atropine dose IV/IO q3-5 min

**Extrapyramidal reactions**

- Diphenhydramine per drug chart slow IV/IM

**Suspected tricyclic antidepressant OD with cardiac effects (e.g., hypotension, heart block, or widened QRS)**

- NaHCO<sub>3</sub> per drug chart IV/IO

**Suspected beta blocker or calcium channel blocker OD, contact Poison Control Center and Base Hospital<sup>‡</sup>**

<sup>⊗</sup> Per Title 22, Division 9, Chapter 2.3, § 100027.03 public safety personnel may administer nasal naloxone when authorized by the County of San Diego EMS Medical Director

\*For radioactive material, treatment of traumatic injuries takes precedence over decontamination

<sup>‡</sup> Base Hospital Physician may order recommendation from Poison Control Center



PREDELIVERY	
BLS	ALS
<ul style="list-style-type: none"><li>• Ensure patent airway</li><li>• O<sub>2</sub> saturation PRN</li><li>• O<sub>2</sub> and/or ventilate PRN</li><li>• If no time for transport and delivery is imminent (crowning and pushing), proceed with delivery</li><li>• If no delivery, transport on left side</li><li>• Keep mother warm</li></ul> <p><b>Third-trimester bleeding</b></p> <ul style="list-style-type: none"><li>• Transport immediately to facility with obstetrical services per BH direction</li></ul> <p><b>Eclampsia (seizures)</b></p> <ul style="list-style-type: none"><li>• Protect airway</li><li>• Protect from injury</li></ul>	<ul style="list-style-type: none"><li>• Monitor/ECG</li><li>• IV <sup>®</sup></li><li>• Capnography</li></ul> <p><b>Direct to labor/delivery area BHO if ≥20 weeks gestation</b></p> <p><b>Eclampsia (seizures)</b></p> <ul style="list-style-type: none"><li>• Midazolam IN/IM/IV/IO to a max dose of 5 mg (d/c if seizure stops), MR x1 in 10 min. Max 10 mg total.</li></ul>
DELIVERY	
BLS and ALS	
<p><b>Routine delivery</b></p> <ul style="list-style-type: none"><li>• If placenta delivered, massage fundus. Do not wait on scene.</li><li>• Wait 60 sec after delivery, then clamp and cut cord between clamps</li><li>• Document name of person cutting cord, time cut, and delivery location (address)</li><li>• Place identification bands on mother and newborn(s)</li><li>• Complete Out of Hospital Birth Report Form (S-166A) and provide to parent</li></ul> <p><b>Difficult deliveries</b></p> <ul style="list-style-type: none"><li>• High-flow O<sub>2</sub></li><li>• Keep mother warm</li></ul> <p><b>Nuchal cord (cord wrapped around neck)</b></p> <ul style="list-style-type: none"><li>• Slip cord over the head and off neck</li><li>• Clamp and cut cord, if wrapped too tightly</li></ul> <p><b>Prolapsed cord</b></p> <ul style="list-style-type: none"><li>• Place mother with her hips elevated on pillows</li><li>• Insert a gloved hand into vagina and gently push presenting part off cord</li><li>• Transport immediately while retaining this position. Do not remove hand until relieved by hospital personnel.</li><li>• Cover exposed cord with saline-soaked gauze</li></ul> <p><b>Shoulder dystocia</b></p> <ul style="list-style-type: none"><li>• Hyperflex mother's knees to her chest</li></ul> <p><b>Breech birth (arm or single foot visible)</b></p> <ul style="list-style-type: none"><li>• Rapid transport</li></ul>	

**San Diego County Emergency Medical Services Office**  
**Policy / Procedure / Protocol**

<b>Frank breech or double footling and imminent delivery with long transport</b> <ul style="list-style-type: none"> <li>• Allow newborn to deliver to the waist without active assistance (support only)</li> <li>• When legs and buttocks are delivered, assist head out keeping body parallel to the ground. If head does not deliver within 1-2 min, insert gloved hand into the vagina to create airway for newborn.</li> <li>• Transport immediately if head undelivered</li> </ul>	
<b>Eclampsia (seizures)</b> <ul style="list-style-type: none"> <li>• Protect airway, and protect from injury</li> <li>• <b>ALS:</b> Midazolam IN/IM/IV/IO to a max dose of 5 mg (d/c if seizure stops), MR x1 in 10 min. Max 10 mg total.</li> </ul>	
<b>MOTHER POST-DELIVERY</b>	
<b>BLS</b>	<b>ALS</b>
<b>Postpartum hemorrhage</b> <ul style="list-style-type: none"> <li>• Massage fundus vigorously</li> <li>• Baby to breast</li> <li>• High-flow O<sub>2</sub></li> <li>• Keep mother warm</li> </ul> <b>Eclampsia (seizures)</b> <ul style="list-style-type: none"> <li>• Protect airway</li> <li>• Protect from injury</li> </ul>	<b>Postpartum hemorrhage</b> <ul style="list-style-type: none"> <li>• Monitor/ECG</li> <li>• Capnography</li> <li>• 500 mL fluid bolus IV/IO, MR x2 q10 min to maintain SBP ≥90 mmHg <sup>A</sup></li> <li>• If estimated blood loss ≥500 mL and within 3 hours of delivery, tranexamic acid 1 gm/ 10mL IV/IO, in 50-100 mL NS, over 10 min</li> </ul> <b>Eclampsia (seizures)</b> <ul style="list-style-type: none"> <li>• Midazolam IN/IM/IV/IO to a max dose of 5 mg (d/c if seizure stops), MR x1 in 10 min. Max 10 mg total.</li> </ul>
<b>NEONATAL POST-DELIVERY</b>	
<b>BLS and ALS</b>	
<b>Warm, dry, and stimulate newborn</b> <ul style="list-style-type: none"> <li>• Wrap newborn in warm, dry blanket. Keep head warm.</li> <li>• Assess breathing, tone, and HR. Palpate HR via umbilical cord.</li> <li>• If placing pulse oximeter, use newborn's right hand</li> <li>• APGAR at 1 and 5 min (do not delay resuscitation to obtain score)</li> <li>• Confirm identification bands placed on mother and newborn(s)</li> <li>• Bring mother and newborn(s) to same hospital</li> <li>• Complete Out of Hospital Birth Report Form (S-166A) and provide to parent</li> </ul>	
<b>Full-term newborn with good tone and breathing</b> <ul style="list-style-type: none"> <li>• Keep newborn warm</li> <li>• Ensure patent airway</li> <li>• If excessive secretions, suction mouth then nose with bulb syringe</li> <li>• O<sub>2</sub> saturation on newborn's right hand PRN</li> <li>• Baby to breast</li> <li>• Ongoing assessment q30 sec</li> </ul>	
<b>Newborn HR ≥100 with respiratory distress or central cyanosis</b> <ul style="list-style-type: none"> <li>• Blow-by O<sub>2</sub></li> </ul>	
<b>Newborn HR &lt;100, poor respiratory effort or persistent central cyanosis</b> <ul style="list-style-type: none"> <li>• Ventilate with BVM on room air</li> <li>• Monitor/ECG</li> <li>• Recheck pulse q30 sec</li> <li>• For persistently poor respiratory rate/effort, or cyanosis despite correct BVM technique, add high-</li> </ul>	

**San Diego County Emergency Medical Services Office**  
**Policy / Procedure / Protocol**

flow O<sub>2</sub> 15 L/min to BVM

- **Stop BVM when patient breathing well and HR  $\geq 100$**
- **ALS:** IV/IO <sup>(A)</sup> (do not delay transport)
- **ALS:** NG tube PRN

**Newborn HR  $< 60$**

- Continue BVM with high-flow O<sub>2</sub>
- Chest compressions at rate of 120/min
- 3:1 compression to ventilation ratio
- Check pulse q1 min
- Stop compressions when HR  $\geq 60$
- **ALS:** Epinephrine 1:10,000 per drug chart IV/IO, MR q3-5 min
- **ALS:** Fluid bolus per drug chart IV/IO, MR x1 in 10 min <sup>(A)</sup>

**Premature and/or low birth weight newborn**

- If amniotic sac intact, remove neonate from sac after delivery
- Place neonate in plastic bag up to axilla to minimize heat loss
- Transport immediately
- CPR need **not** be initiated if there are no signs of life **and** gestational age  $< 24$  weeks



**COUNTY OF SAN DIEGO**  
EMERGENCY MEDICAL SERVICES

PEDIATRIC TREATMENT PROTOCOL

**S-166A**

**OUT OF HOSPITAL BIRTH REPORT**

Date: 7/1/2024

Page 1 of 2

**Out of Hospital Birth Report**

<b>Name of Mother</b>		
<b>Date and Time of Delivery</b>	<b>Address of Delivery</b>	
<u>Date:</u>	<u>Street:</u>	
<u>Time:</u>	<u>City:</u>	
<b>Name</b>	<b>*If person who cut the umbilical cord/delivered placenta is an EMT or Paramedic fill out below info:</b>	
<u>Person who cut umbilical cord*:</u>	<u>Certification/ License #:</u>	
<u>First Name:</u>	<u>Agency:</u>	
<u>Last Name:</u>	<u>Agency Phone #:</u>	
	<u>Signature:</u>	
<u>Person who delivered placenta (if delivered)*:</u>	<u>Certification/ License #:</u>	
<u>First Name:</u>	<u>Agency:</u>	
<u>Last Name:</u>	<u>Agency Phone #:</u>	
	<u>Signature:</u>	
<b>Weight and Apgar Scores (if taken)</b>		<b>CAD Incident #:</b>
<u>Weight:</u>	<u>APGAR Score:</u>	

**KEEP THIS FORM – It will be required when you visit the Office of Vital Records.**

**Failure to register a child's birth in a timely manner could prohibit parents from obtaining a social security card, passport, medical insurance, and cash aid.**

**For more information on required documents and fees, search "out of hospital births" on the County web site: [www.sandiegocounty.gov](http://www.sandiegocounty.gov)**

**Por Favor de mantener esta forma - Esta requerida cuando llegue a su visita con la Oficina de Vital Records.**

**Fracaso de no registrar el nacimiento de su niño a tiempo, se podrá prohibir de obtener el número del seguro social, pasaporté, seguro medica, y ayuda financiera.**

**Para información sobre documentos requeridos y el costo, por favor buscar, solo en inglés, "out of hospital births" en el sitio del Condado:  
[www.sandiegocounty.gov](http://www.sandiegocounty.gov)**



**County of San Diego  
Health and Human Services Agency  
Office of Vital Records  
5530 Overland Avenue, Suite 170  
San Diego, CA 92123  
619-692-5733**





**RESPIRATORY DISTRESS**

Date: 7/1/2025

Page 1 of 1

**BLS**

- Ensure patent airway
- Reassurance
- Dislodge any airway obstruction. Treat per Airway Obstruction Protocol (S-160).
- O2 saturation
- O2 and/or ventilate PRN
- Transport in position of comfort
- Carboxyhemoglobin monitor PRN, if available
- May assist patient to self-medicate own prescribed albuterol MDI **once only**. BH contact required for additional dose(s).

**Toxic inhalation (e.g., CO exposure, smoke, gas)**

- Move patient to safe environment
- 100% O2 via mask
- Consider transport to facility with hyperbaric chamber for suspected CO poisoning for unconscious or pregnant patients

**Croup-like cough**

- Aerosolized saline or water 5 mL via O<sub>2</sub>-powered nebulizer/mask, MR PRN

**Suspected bronchiolitis (<2 years old with no prior albuterol use)**

- Place in position of comfort
- Suction nose with bulb syringe PRN

**ALS**

- Monitor/ECG
- Capnography
- IV <sup>Ⓐ</sup>
- BVM PRN

**Respiratory distress with bronchospasm<sup>1</sup>**

- Albuterol/Levalbuterol per drug chart via nebulizer, MR <sup>Ⓐ</sup>
- Ipratropium bromide per drug chart via nebulizer added to first dose of albuterol/levalbuterol

**Severe respiratory distress/failure or inadequate response to nebulized treatments consider**

- Epinephrine 1:1,000 per drug chart IM, MR x2 q5 min <sup>Ⓐ</sup>

**Respiratory distress with stridor at rest**

- Epinephrine 1:1,000 per drug chart (combined with 3 mL normal saline) via nebulizer, MR x1 <sup>Ⓐ</sup>

**No improvement after epinephrine via nebulizer x2 or impending respiratory/airway compromise**

- Epinephrine 1:1,000 per drug chart IM, MR x2 q5 min <sup>Ⓐ</sup>

**If history suggests epiglottitis, do not visualize airway. Use calming measures**

**Note:** For respiratory arrest, immediately start BVM ventilation

<sup>1</sup> **Infection control:** If concerned about aerosolized infectious exposure, substitute with MDI, if available



**SHOCK**

Date: 7/1/2025

Page 1 of 1

**BLS**

**ALS**

- O<sub>2</sub> saturation
- O<sub>2</sub> and/or ventilate PRN
- Control obvious external bleeding
- Treat associated injuries
- NPO, anticipate vomiting
- Remove transdermal patch
- Keep patient warm

**Assess for hypotension**

- <1 month: SBP <60 mmHg
- 1 month – 1 year: SBP <70 mmHg
- 1 year – 10 years:  
SBP <70 mmHg + (2x age in years)
- ≥10 years: SBP <90 mmHg

- Monitor/ECG
- IV/IO <sup>Ⓐ</sup>
- Capnography

**Hypovolemic shock**

- IV/IO fluid bolus per drug chart, MR if no rales <sup>Ⓐ</sup>

**Distributive<sup>†</sup>/cardiogenic shock**

- IV/IO fluid bolus per drug chart, MR if no rales <sup>Ⓐ</sup>

**Hypotensive for age after second fluid bolus**

- Push-dose epinephrine 1:100,000 (0.01 mg/mL)  
IV/IO per drug chart, MR q3 min, titrate to adequate perfusion

**Push-dose epinephrine mixing instructions**

1. Remove 1 mL normal saline (NS) from the 10 mL NS syringe
2. Add 1 mL of epinephrine 1:10,000 (0.1 mg/mL) to 9 mL NS syringe

The mixture now has 10 mL of epinephrine at 0.01 mg/mL (10 mcg/mL) concentration.

<sup>†</sup> Distributive shock includes neurogenic; drug and toxin-induced; and endocrine shock.



**BLS**

**ALS**

- Ensure patent airway
- Protect C-spine
- Control obvious bleeding
- Spinal motion restriction per Skills List (S-104) except in penetrating trauma without neurological deficits
- O2 saturation. Maintain SpO2 ≥90%.
- O2 and/or ventilate PRN
- Keep warm
- Hemostatic gauze

**Abdominal trauma**

- Cover eviscerated bowel with saline pads

**Chest trauma**

- Cover open chest wound with three-sided occlusive dressing. Release dressing if tension pneumothorax develops.
- Chest seal PRN

**Extremity trauma**

- Splint neurologically stable fractures in position as presented. Traction splint PRN.
- Reduce grossly angulated long bone fractures with no pulse or sensation PRN
- Direct pressure to control external hemorrhage
- Apply gauze or hemostatic dressing PRN
- Tourniquet PRN
- In MCI, direct pressure not required prior to tourniquet application

**Impaled objects**

- Immobilize and leave impaled objects in place
- Remove object impaled in face, cheek, or neck if there is total airway obstruction

**Any suspicion of neurological injury (mechanism, GCS, examination)**

- High-flow O2 PRN
- Monitor SpO2, BP, and HR q3-5 min
- If SpO2 <90% or inadequate respirations (despite high-flow O2), assist ventilations with BVM

- Monitor/ECG
- IV/IO <sup>Ⓐ</sup>
- Capnography. Maintain EtCO2 35-45 mmHg PRN
- Treat pain per Pain Management Protocol (S-173)

**Signs of shock or hypotensive for age**

- Fluid bolus IV/IO per drug chart, MR x3 q15 min to maintain adequate perfusion <sup>Ⓐ</sup>

**Crush injury requiring extrication with compression of extremity or torso ≥2 hours**

Immediately prior to anticipated release

- IV/IO fluid bolus per drug chart, MR BHPO <sup>Ⓐ</sup>
- NaHCO<sub>3</sub> IV/IO per drug chart
- CaCl<sub>2</sub> IV/IO over 30 sec per drug chart, MR x1 in 5 min for continued ECG findings consistent with hyperkalemia
- Continuous albuterol/levalbuterol per drug chart via nebulizer

**Grossly angulated long bone fractures**

- Reduce with gentle unidirectional traction for splinting <sup>Ⓐ</sup>

**Severe respiratory distress with diminished or absent breath sounds (unilaterally or bilaterally), and hypotensive for age, and suspected pneumothorax**

- Needle thoracostomy

**For nausea or vomiting**

- ≥6 months
- Ondansetron IV/IM/ODT per drug chart

**For traumatic cardiac arrest**

- IV/IO fluid bolus per drug chart <sup>Ⓐ</sup>
- Do not administer epinephrine

**San Diego County Emergency Medical Services Office**  
**Policy / Procedure / Protocol**

<b>Pregnancy ≥6 months</b> <ul style="list-style-type: none"><li>• If spinal motion restriction indicated, tilt patient to the left 30°</li></ul>	
---	--



**Hypotension by age**

- <1 month: SBP <60 mmHg
- 1 month – 1 year: SBP <70 mmHg
- 1 year – 10 years: SBP <70 mmHg + (2x age in years)
- ≥10 years: SBP <90 mmHg

**Transportation and Destination Guidelines**

Pediatric patients who meet criteria outlined in T-460 (Identification of the Pediatric Trauma Center Patient) should be transported to the Designated Pediatric Trauma Center, **except** in the following situations.

**1. Adult with child**

- a. If there is a single ambulance (air/ground) with both a pediatric trauma center patient **and** an adult trauma center patient, the ambulance should first transport the more critical patient to the appropriate facility. If both patients are critical, or if there are other questions, both may be transported to the designated adult trauma center.
- b. Field personnel should consider splitting the team using additional ALS transport vehicles, or aeromedical resources to transport the pediatric patient to the pediatric trauma facility and the adult patient to the catchment area trauma facility.


**2. Trauma center diversion**

The pediatric patient who is identified as a trauma patient shall be transported to the designated pediatric trauma center. When the pediatric trauma center is on diversion, including age-specific diversion, the pediatric patient shall be transported to the county-designated backup pediatric trauma center, the University of California, San Diego (UCSD).

**3. Pregnant pediatric patient**

A pediatric pregnant trauma patient shall be transported to UCSD.

## PEDIATRIC TRAUMATIC CARDIAC ARREST





BURNS

Date: 7/1/2025

Page 1 of 1

BLS

ALS

- Move to a safe environment
- Break contact with causative agent
- Ensure patent airway, O<sub>2</sub>, and/or ventilate PRN
- O<sub>2</sub> saturation PRN
- Treat other life-threatening injuries
- Carboxyhemoglobin monitor PRN, if available

**Thermal burns**

- For burns of <10% BSA, stop burning with non-chilled water or saline
- For burns of >10% BSA, cover with dry dressing and keep patient warm
- Do not allow patient to become hypothermic

**Toxic inhalation (e.g., CO exposure, smoke, gas)**

- Move patient to safe environment
- 100% O<sub>2</sub> via mask
- Consider transport to facility with hyperbaric chamber for suspected CO poisoning, particularly in unconscious or pregnant patients

**Chemical burns**

- Brush off dry chemicals
- Flush with copious amounts of water

**Tar burns**

- Do not remove tar
- Cool with water, then transport

- Monitor/ECG
- IV/IO <sup>Ⓐ</sup>
- Capnography
- Treat pain per Pain Management Protocol (S-173)

**Patients with >10% partial-thickness or >5% full-thickness burns**

- Fluid bolus IV/IO per drug chart then TKO <sup>Ⓐ</sup>

**Respiratory distress with bronchospasm<sup>1</sup>**

- Albuterol/Levalbuterol per drug chart via nebulizer, MR <sup>Ⓐ</sup>

**Respiratory distress with stridor**

- Epinephrine 1:1,000 per drug chart (combined with 3 mL normal saline) via nebulizer, MR x1

**No improvement after epinephrine via nebulizer x2 or impending airway compromise**

- Epinephrine 1:1,000 per drug chart IM, MR x2 q5 min <sup>Ⓐ</sup>

Contact UCSD Base Hospital for patients meeting burn center criteria<sup>†</sup>

See Base Hospital Contact/Patient Transportation and Report (S-415)

**<sup>†</sup>Burn center criteria**

Patients with burns involving

- >10% BSA partial thickness or >5% BSA full thickness
- Suspected respiratory involvement or significant smoke inhalation
- Circumferential burn or burn to face, hands, feet, or perineum
- Electrical injury due to high voltage (≥1,000 volts)

<sup>1</sup> **Infection control:** If concerned about aerosolized infectious exposure, substitute with MDI, if available



**COUNTY OF SAN DIEGO**  
EMERGENCY MEDICAL SERVICES

PEDIATRIC TREATMENT PROTOCOL

**S-172**

**BRUE (BRIEF, RESOLVED, UNEXPLAINED EVENT)**

Date: 7/1/2025

Page 1 of 1

**BLS**

- Ensure patent airway
- O<sub>2</sub> saturation
- O<sub>2</sub> and/or ventilate PRN
- Monitor blood glucose

**Suspected hypoglycemia or patient's blood sugar is <60 mg/dL (<45 mg/dL for neonates)**

- If patient is awake and able to manage oral secretions, give oral glucose paste or 3 tablets (15 gm total)
- Patient may eat or drink, if able
- If patient is unconscious, NPO

**ALS**

- Monitor/ECG
- IV <sup>®</sup>



**PAIN MANAGEMENT**

Date: 7/1/2025

Page 1 of 1

**BLS**

- Assess level of pain
- Ice, immobilize, and splint PRN
- Elevate extremity trauma PRN

**ALS**

- Continue to monitor and reassess pain as appropriate
- Document vital signs before and after each medication administration

**Pain medication considerations**

1. When changing route of administration, consider the potential time difference in onset of action
2. Document **adequate perfusion** prior to opioid administration

**For mild pain (score 1-3)<sup>1</sup> or moderate pain (score 4-6)**

- Acetaminophen\* IV per drug chart in 100 ml of NS over 15 min

**For moderate pain (score 4-6) or severe pain (score 7-10)**

Fentanyl (IV dosing)

- <10 kg, fentanyl IV per drug chart
- MR at half initial IV dose BHO

- ≥10 kg, fentanyl IV per drug chart
- MR at half initial IV dose

Fentanyl (IN dosing)

- <10 kg, fentanyl IN per drug chart
- MR at initial IN dose BHO

- ≥10 kg, fentanyl IN per drug chart
- MR at initial IN dose

**If fentanyl unavailable, morphine IV/IM per drug chart**

\*IV acetaminophen contraindicated if patient <2 years of age

<sup>1</sup> If patient refuses or has contraindications to acetaminophen, may treat as moderate pain





**COUNTY OF SAN DIEGO**  
EMERGENCY MEDICAL SERVICES

PEDIATRIC TREATMENT PROTOCOL

**S-174**

**ABDOMINAL DISCOMFORT / GI / GU  
(NON-TRAUMATIC)**

Date: 7/1/2024

Page 1 of 1

**BLS**

- Ensure patent airway
- O<sub>2</sub> saturation PRN
- NPO

**ALS**

- Monitor/ECG
- IV/IO <sup>Ⓐ</sup>
- Fluid bolus IV/IO for suspected volume depletion per drug chart <sup>Ⓐ</sup>
- Treat pain per Pain Management Protocol (S-173)

**For nausea or vomiting**

≥6 months

- Ondansetron IV/IM/ODT per drug chart



**BLS**

- Ensure patent airway, O<sub>2</sub> and/or ventilate PRN
- O<sub>2</sub> saturation PRN
- Treat life-threatening injuries
- Ask patient: "Do you have any weapons?"
- Attempt to determine if behavior is related to injury, illness, or drug use
- Employ de-escalation techniques
- Restrain only if necessary to prevent injury
- Document distal neurovascular status q15 min, if restrained
- Avoid unnecessary sirens
- Consider law enforcement support
- Law enforcement or EMS may remove Taser\* barbs

**ALS**

- Capnography
- Monitor/ECG
- IV <sup>(A)</sup>

**Severely agitated and/or combative patient requiring restraint for patient or provider safety**

- Midazolam<sup>†</sup> per drug chart IM/IN/IV, MR x1 in 10 min
- Fluid bolus IV/IO per drug chart PRN, MR x1, MR BHO <sup>(A)</sup>

**\*Taser barb considerations**

- Taser discharge for simple behavioral control is usually benign and does not require transport to BEF for evaluation.
- Patients who are injured; appear to be under the influence of drugs; or present with altered mental status or symptoms of illness should have medical evaluation performed by EMS personnel before being transported to BEF.
- If barbs are impaled in anatomically sensitive location such as eye, face, neck, finger/hand, or genitalia, do not remove the barb. Transport patient to BEF.

<sup>†</sup>For severely agitated or combative patients, IN or IM midazolam is the preferred route to decrease risk of injury to the patient and personnel.

**Alert:** Co-administration of midazolam in patients with alcohol intoxication can cause respiratory depression. Consider avoiding or reducing midazolam dose.



**ENVIRONMENTAL EXPOSURE**

Date: 7/1/2025

Page 1 of 1

**BLS**

**ALS**

- Ensure patent airway
- O<sub>2</sub> saturation PRN
- O<sub>2</sub> and/or ventilate PRN
- Remove excess/wet clothing
- Obtain temperature

**Heat exhaustion**

- Cool gradually
- Fan and sponge with tepid water
- Avoid shivering
- If conscious, give small amounts of fluids

**Heat stroke**

- Rapid cooling
- Spray with cool water and fan
- Avoid shivering
- Apply ice packs to carotid, inguinal, and axillary regions

**Cold exposure**

- Gentle warming
- Apply blankets, warm packs, and dry dressings
- Avoid unnecessary movement or rubbing
- If alert, give warm liquids. If altered LOC, NPO.
- Prolonged CPR may be indicated

**Drowning**

- CPR, if cardiac arrest. Emphasize ventilations.
- High-flow O<sub>2</sub> if spontaneous respirations
- Remove wet clothing
- Spinal motion restriction PRN

- Monitor/ECG
- IV/IO <sup>Ⓐ</sup>
- Capnography

**Cardiac arrest with hypothermia**

- CPR
- Persistent VF/VT, defibrillate per S-163\*
- Epinephrine 1:10,000 per drug chart IV/IO x1†
- Rewarm

**Heat exhaustion/heat stroke**

- Fluid bolus IV/IO per drug chart, if no rales MR x1

\*Defibrillation attempts may be unsuccessful during rewarming until temperature  $\geq 86^{\circ}\text{F}$  /  $\geq 30^{\circ}\text{C}$

†Limit epinephrine to 1 dose and withhold antiarrhythmic medications until temperature  $\geq 86^{\circ}\text{F}$  /  $\geq 30^{\circ}\text{C}$



SEPSIS

Date: 7/1/2024

Page 1 of 1

BLS

- O<sub>2</sub> saturation PRN
- O<sub>2</sub> and/or ventilate PRN
- NPO, anticipate vomiting
- Obtain temperature
- If febrile, remove excess clothing
- Monitor blood glucose PRN

**Assess for hypotension**

- <1 month: SBP <60 mmHg
- 1 month – 1 year: SBP <70 mmHg
- 1 year – 10 years:  
SBP <70mm Hg + (2x age in years)
- ≥10 years: SBP <90 mmHg

**Assess for altered mental status**

- 1 month – 1 year: lethargic or irritable, limp and flaccid
- 1 year – 10 years: lethargic, change in baseline per guardian

ALS

- Monitor/ECG
- IV/IO <sup>Ⓐ</sup>
- Capnography

**Suspected sepsis**

If history **suggestive of infection** with ≥2 of the following<sup>1</sup>:

1. Temperature ≥100.4 °F (38.0 °C) or <96.8 °F (36.0 °C)
2. Tachycardia
3. Tachypnea or EtCO<sub>2</sub> <25 mmHg
4. Altered LOC
5. Hypotension
6. Weak peripheral pulses
7. Delayed capillary refill

- IV/IO fluid bolus per drug chart regardless of initial BP or lung sounds <sup>Ⓐ</sup>

- If no rales or hypotensive for age, give additional IV/IO fluid bolus per drug chart, MR x2 <sup>Ⓐ</sup>

**Hypotensive for age after fluid boluses**

- Push-dose epinephrine 1:100,000 (0.01 mg/mL) IV/IO per drug chart, MR q3 min, titrate to adequate perfusion

**Push-dose epinephrine mixing instructions**

1. Remove 1 mL normal saline (NS) from the 10 mL NS syringe
2. Add 1 mL of epinephrine 1:10,000 (0.1 mg/mL) to 9 mL NS syringe

The mixture now has 10 mL of epinephrine at 0.01 mg/mL (10 mcg/mL) concentration.

<sup>1</sup> Suspected sepsis should be reported to the Base Hospital and upon transfer of care at the receiving hospital.

LBRT Color:

GREY

PINK

Age Range:

Newborn to 6 months

Weight Range:

<8 kg

Approximate kg:

5 kg

Approximate lbs:

10 lbs

NG tube size:

5-8 Fr

(or clinically equivalent biphasic energy dose)

1<sup>st</sup> 2<sup>nd</sup> 3<sup>rd</sup>

Defib: 10 J 20 J 20 J

Cardiovert: 5 J 10 J 10 J

Normal vital signs	HR: 100-160	RR: 25-60	SBP: >60 mmHg
--------------------	-------------	-----------	---------------

VOL	MEDICATION	DOSE	CONCENTRATION
-	Acetaminophen <b>DO NOT ADMINISTER</b>	-	-
0.2 mL	Adenosine <b>IV 1<sup>st</sup></b>	0.5 mg	6 mg/2 mL
0.4 mL	Adenosine <b>IV 2<sup>nd</sup>/3<sup>rd</sup></b>	1 mg	6 mg/2 mL
6 mL	Albuterol <b>Nebulized</b>	5 mg	2.5 mg/3 mL
0.5 mL <sup>◇</sup>	Amiodarone ( <b>VF/Pulseless VT<sup>◇</sup></b> ) <b>IV/IO</b>	25 mg	150 mg/3 mL
1 mL	Atropine ( <b>Bradycardia</b> ) <b>IV/IO</b>	0.1 mg	1 mg/10 mL
0.3 mL*	Atropine ( <b>Organophosphate</b> ) <b>IV/IO</b>	0.1 mg	8 mg/20 mL
1 mL	Calcium Chloride <b>IV/IO</b>	100 mg	1 gm/10 mL
24 mL	Charcoal <b>PO</b>	5 gm	50 gm/240 mL
25 mL	Dextrose <b>10% IV</b>	2.5 gm	25 gm/250 mL
0.1 mL	Diphenhydramine <b>IV/IM</b>	5 mg	50 mg/1 mL
0.1 mL*	Epinephrine <b>IM</b>	0.05 mg	<b>1:1,000</b> 1 mg/1 mL
0.5 mL	Epinephrine <b>IV/IO</b>	0.05 mg	<b>1:10,000</b> 1 mg/10 mL
0.5 mL	Epinephrine ( <b>Push-Dose</b> ) <b>IV slow/IO</b>	0.005 mg	<b>1:100,000</b> 0.1 mg/10 mL
2.5 mL	Epinephrine <b>Nebulized</b>	2.5 mg	<b>1:1,000</b> 1 mg/1 mL
0.1 mL	Fentanyl <b>IV</b>	5 mcg	100 mcg/2 mL
0.1 mL	Fentanyl <b>IN</b>	5 mcg	100 mcg/2 mL
0.3 mL*	Glucagon <b>IM</b>	0.25 mg	1 unit (mg)/1 mL
1.25 mL	Ipratropium Bromide <b>Nebulized</b>	0.25 mg	0.5 mg/2.5 mL
0.3 mL <sup>*,◇</sup>	Lidocaine <b>2% IV/IO</b>	5 mg	100 mg/5 mL
0.1 mL	Midazolam <b>IV slow</b>	0.5 mg	5 mg/1 mL
0.2 mL	Midazolam <b>IN/IM</b>	1 mg	5 mg/1 mL
NONE	Morphine Sulfate <b>IV/IM</b>	NONE	10 mg/1 mL
0.5 mL	Naloxone <b>IN/IM/IV</b>	0.5 mg	2 mg/2 mL
5 mL	Naloxone <b>IV titrated increments</b>	0.5 mg	Diluted to 1 mg/10 mL
100 mL	Normal Saline Fluid Bolus		Standard
1 mL	Ondansetron <b>IM/IV</b> (6 months - 3 years)	2 mg	4 mg/2 mL
½ tablet	Ondansetron <b>ODT</b> (6 months - 3 years)	2 mg	4 mg tablet
5 mL	Sodium Bicarbonate <b>IV</b>	5 mEq	50 mEq/50 mL

- Neonates involve base physician.
- To assure accuracy, be sure the designated **concentration** of medication is used.
- \* Volume rounded for ease of administration
- ◇ Dosing for stable VT per BHPO

LBRT Color:

RED

PURPLE

YELLOW

**Age Range:** 6 months to 3 years

**Weight Range:** 8-14 kg

**Approximate kg:** 10 kg

**Approximate lbs:** 20 lbs

**NG tube size:**

5-8 Fr

8-10 Fr

10 Fr

(or clinically equivalent biphasic energy dose)

**Defib:** 1<sup>st</sup> 20 J 2<sup>nd</sup> 40 J 3<sup>rd</sup> 40 J

**Cardiovert:** 10 J 20 J 20 J

**Normal vital signs:**

**HR: 90-160**

**RR: 20-40**

**SBP: >70 mmHg**

VOL	MEDICATION	DOSE	CONCENTRATION
21 mL	Acetaminophen IV (≥2 years of age)	210 mg	1 gm/100 mL
0.3 mL *	Adenosine <b>IV fast</b> 1 <sup>st</sup>	1 mg	6 mg/2 mL
0.7 mL *	Adenosine <b>IV fast</b> 2 <sup>nd</sup> /3 <sup>rd</sup>	2 mg	6 mg/2 mL
6 mL	Albuterol <b>Nebulized</b>	5 mg	2.5 mg/3 mL
1 mL <sup>◇</sup>	Amiodarone ( <b>VF/Pulseless VT</b> <sup>◇</sup> ) <b>IV/IO</b>	50 mg	150 mg/3 mL
2 mL	Atropine ( <b>Bradycardia</b> ) <b>IV/IO</b>	0.2 mg	1 mg/10 mL
0.5 mL	Atropine ( <b>Organophosphate</b> ) <b>IV/IO</b>	0.2 mg	8 mg/20 mL
2 mL	Calcium Chloride <b>IV/IO</b>	200 mg	1 gm/10 mL
50 mL *	Charcoal <b>PO</b>	10 gm	50 gm/240 mL
50 mL	Dextrose <b>10% IV</b>	5 gm	25 gm/250 mL
0.2 mL	Diphenhydramine <b>IV/IM</b>	10 mg	50 mg/1 mL
0.1 mL	Epinephrine <b>IM</b>	0.1 mg	<b>1:1,000</b> 1 mg/1 mL
1 mL	Epinephrine <b>IV/IO</b>	0.1 mg	<b>1:10,000</b> 1 mg/10 mL
1 mL	Epinephrine ( <b>Push-Dose</b> ) <b>IV slow/IO</b>	0.01 mg	<b>1:100,000</b> 0.1mg/10 mL
2.5 mL	Epinephrine <b>Nebulized</b>	2.5 mg	<b>1:1,000</b> 1 mg/1 mL
0.3 mL	Fentanyl <b>IN</b>	15 mcg	100 mcg/2 mL
0.2 mL	Fentanyl <b>IV</b>	10 mcg	100 mcg/2 mL
0.5 mL	Glucagon <b>IM</b>	0.5 mg	1 unit (mg)/1 mL
1.25 mL	Ipratropium Bromide <b>Nebulized</b>	0.25 mg	0.5 mg/2.5 mL
0.5 mL <sup>◇</sup>	Lidocaine <b>2% IV/IO</b>	10 mg	100 mg/5 mL
0.2 mL	Midazolam <b>IV slow</b>	1 mg	5 mg/1 mL
0.4 mL	Midazolam <b>IN/IM</b>	2 mg	5 mg/1 mL
0.1 mL	Morphine Sulfate <b>IV/IM</b>	1 mg	10 mg/1 mL
1 mL	Naloxone <b>IN/IM/IV</b>	1 mg	2 mg/2 mL
10 mL	Naloxone <b>IV titrated increments</b>	1 mg	Diluted to 1 mg/10 mL
200 mL	Normal Saline Fluid Bolus		Standard
1 mL	Ondansetron <b>IM/IV</b> (6 months - 3 years)	2 mg	4 mg/2 mL
½ tablet	Ondansetron <b>ODT</b> (6 months - 3 years)	2 mg	4 mg tablet
2 mL	Ondansetron <b>IM/IV</b> (>3 years of age)	4 mg	4 mg/2 mL
1 tablet	Ondansetron <b>ODT</b> (>3 years of age)	4 mg	4 mg tablet
10 mL	Sodium Bicarbonate <b>IV</b>	10 mEq	50 mEq/50 mL

- Neonates involve base physician.
- To assure accuracy, be sure the designated **concentration** of medication is used.
- \* Volume rounded for ease of administration
- ◇ Dosing for stable VT per BHPO

**LBRT Color:**

**WHITE**

**Age Range:**

**4-5 years**

**Weight Range:**

**15-18 kg**

**Approximate kg:**

**15 kg**

**Approximate lbs:**

**30 lbs**

**NG tube size:**

**10 Fr**

**Defib:** 1<sup>st</sup> 30 J 2<sup>nd</sup> 60 J 3<sup>rd</sup> 60 J

**Cardiovert:** 15 J 30 J 30 J

(or clinically equivalent biphasic energy dose)

**Normal vital signs**

**HR: 80-130**

**RR: 20-30**

**SBP: >75 mmHg**

VOL	MEDICATION	DOSE	CONCENTRATION
22 mL	Acetaminophen <b>IV</b> (≥2 years of age)	220 mg	1 gm/100 mL
0.5 mL	Adenosine <b>IV fast 1<sup>st</sup></b>	1.5 mg	6 mg/2 mL
1 mL	Adenosine <b>IV fast 2<sup>nd</sup>/3<sup>rd</sup></b>	3 mg	6 mg/2 mL
6 mL	Albuterol <b>Nebulized</b>	5 mg	2.5 mg/3 mL
1.5 mL <sup>◇</sup>	Amiodarone ( <b>VF/pulseless VT<sup>◇</sup></b> ) <b>IV/IO</b>	75 mg	150 mg/3mL
3 mL	Atropine ( <b>Bradycardia</b> ) <b>IV/IO</b>	0.3 mg	1 mg/10 mL
0.8 mL	Atropine ( <b>Organophosphate</b> ) <b>IV/IO</b>	0.3 mg	8 mg/20 mL
3 mL	Calcium Chloride <b>IV/IO</b>	300 mg	1 gm/10 mL
70 mL*	Charcoal <b>PO</b>	15 gm	50 gm/240 mL
75 mL	Dextrose <b>10% IV</b>	7.5 gm	25 gm/250 mL
0.3 mL	Diphenhydramine <b>IV/IM</b>	15 mg	50 mg/1 mL
0.2 mL*	Epinephrine <b>IM</b>	0.15 mg	<b>1:1,000</b> 1 mg/1 mL
1.5 mL	Epinephrine <b>IV/IO</b>	0.15 mg	<b>1:10,000</b> 1 mg/10 mL
1 mL	Epinephrine ( <b>Push-Dose</b> ) <b>IV slow/IO</b>	0.01 mg	<b>1:100,000</b> 0.1 mg/10 mL
5 mL	Epinephrine <b>Nebulized</b>	5 mg	<b>1:1,000</b> 1 mg/1 mL
0.5 mL	Fentanyl <b>IN</b>	25 mcg	100 mcg/2 mL
0.3 mL	Fentanyl <b>IV</b>	15 mcg	100 mcg/2 mL
0.8 mL*	Glucagon <b>IM</b>	0.75 mg	1 unit (mg)/1 mL
2.5 mL	Ipratropium Bromide <b>Nebulized</b>	0.5 mg	0.5 mg/2.5 mL
0.8 mL <sup>◇</sup>	Lidocaine <b>2% IV slow/IO</b>	15 mg	100 mg/5 mL
0.6 mL	Midazolam <b>IN/IM</b>	3 mg	5 mg/1 mL
0.3 mL	Midazolam <b>IV slow</b>	1.5 mg	5 mg/1 mL
0.2 mL*	Morphine Sulfate <b>IV/IM</b>	1.5 mg	10 mg/1 mL
1.5 mL	Naloxone <b>IN/IM/IV</b>	1.5 mg	2 mg/2 mL
15 mL	Naloxone <b>IV titrated increments</b>	1.5 mg	Diluted to 1 mg/10 mL
300 mL	Normal Saline Fluid Bolus		Standard
1 mL	Ondansetron <b>IM/IV</b> (6 months - 3 years)	2 mg	4 mg/2 mL
½ tablet	Ondansetron <b>ODT</b> (6 months - 3 years)	2 mg	4 mg tablet
2 mL	Ondansetron <b>IM/IV</b> (>3 years of age)	4 mg	4 mg/2 mL
1 tablet	Ondansetron <b>ODT</b> (>3 years of age)	4 mg	4 mg tablet
15 mL	Sodium Bicarbonate <b>IV</b>	15 mEq	50 mEq/50 mL

- To assure accuracy be sure the designated **concentration** of medication is used.
- \* Volume rounded for ease of administration
- ◇ Dosing for stable VT per BHPO

LBRT Color:

BLUE

**Age Range:**

**6-8 years**

**Weight Range:**

**19-23 kg**

**Approximate kg:**

**20 kg**

**Approximate lbs:**

**40 lbs**

**NG tube size:**

**12-14 Fr**

**Defib:** 1<sup>st</sup> 2<sup>nd</sup> 3<sup>rd</sup>  
 40 J 80 J 80 J

**Cardiovert:** 20 J 40 J 40 J

(or clinically equivalent biphasic energy dose)

Normal vital signs	HR: 70-120	RR: 15-30	SBP: >80 mmHg
--------------------	------------	-----------	---------------

VOL	MEDICATION	DOSE	CONCENTRATION
30 mL	Acetaminophen <b>IV</b>	300 mg	1 gm/100 mL
0.7 mL *	Adenosine <b>IV fast 1<sup>st</sup></b>	2 mg	6 mg/2 mL
1.3 mL *	Adenosine <b>IV fast 2<sup>nd</sup>/3<sup>rd</sup></b>	4 mg	6 mg/2 mL
6 mL	Albuterol <b>Nebulized</b>	5 mg	2.5 mg/3 mL
2 mL <sup>◇</sup>	Amiodarone ( <b>VF/pulseless VT <sup>◇</sup></b> ) <b>IV/IO</b>	100 mg	150 mg/3 mL
4 mL	Atropine ( <b>Bradycardia</b> ) <b>IV/IO</b>	0.4 mg	1 mg/10 mL
1 mL	Atropine ( <b>Organophosphate</b> ) <b>IV/IO</b>	0.4 mg	8 mg/20 mL
4 mL	Calcium Chloride <b>IV/IO</b>	400 mg	1 gm/10 mL
100 mL *	Charcoal <b>PO</b>	20 gm	50 gm/240 mL
100 mL	Dextrose <b>10% IV</b>	10 gm	25 gm/250 mL
0.4 mL	Diphenhydramine <b>IV/IM</b>	20 mg	50 mg/1 mL
0.2 mL	Epinephrine <b>IM</b>	0.2 mg	<b>1:1,000</b> 1 mg/1 mL
2 mL	Epinephrine <b>IV/IO</b>	0.2 mg	<b>1:10,000</b> 1 mg/10 mL
1 mL	Epinephrine ( <b>Push-Dose</b> ) <b>IV slow/IO</b>	0.01 mg	<b>1:100,000</b> 0.1 mg/10 mL
5 mL	Epinephrine <b>Nebulized</b>	5 mg	<b>1:1,000</b> 1 mg/1 mL
0.6 mL	Fentanyl <b>IN</b>	30 mcg	100 mcg/2 mL
0.4 mL	Fentanyl <b>IV</b>	20 mcg	100 mcg/2 mL
1 mL	Glucagon <b>IM</b>	1 mg	1 unit (mg)/1 mL
2.5 mL	Ipratropium Bromide <b>Nebulized</b>	0.5 mg	0.5 mg/2.5 mL
6 mL	Levalbuterol <b>Nebulized</b> (≥6 – <12 years)	0.62 mg	0.31 mg/3 mL
1 mL <sup>◇</sup>	Lidocaine <b>2% IV slow/IO</b>	20 mg	100 mg/5 mL
0.8 mL	Midazolam <b>IN/IM</b>	4 mg	5 mg/1 mL
0.4 mL	Midazolam <b>IV slow</b>	2 mg	5 mg/1 mL
0.2 mL	Morphine Sulfate <b>IV/IM</b>	2 mg	10 mg/1 mL
2 mL	Naloxone <b>IN/IM/IV</b>	2 mg	2 mg/2 mL
20 mL	Naloxone <b>IV titrated increments</b>	2 mg	Diluted to 1 mg/10 mL
400 mL	Normal Saline Fluid Bolus		Standard
2 mL	Ondansetron <b>IM/IV</b> (>3 years of age)	4 mg	4 mg/2 mL
1 tablet	Ondansetron <b>ODT</b> (>3 years of age)	4 mg	4 mg tablet
20 mL	Sodium Bicarbonate <b>IV</b>	20 mEq	50 mEq/50 mL

- To assure accuracy be sure the designated **concentration** of medication is used.
- \* Volume rounded for ease of administration
- ◇ Dosing for stable VT per BHPO



LBRT Color:

ORANGE

Age Range:

8-10 years

Weight Range:

24-29 kg

Approximate kg:

25 kg

Approximate lbs:

50 lbs

NG tube size:

14-18 Fr

(or clinically equivalent biphasic energy dose)

	1 <sup>st</sup>	2 <sup>nd</sup>	3 <sup>rd</sup>
Defib:	50 J	100 J	100 J
Cardiovert:	25 J	50 J	50 J

Normal vital signs	HR: 70-110	RR: 15-30	SBP: >85 mmHg
--------------------	------------	-----------	---------------

VOL	MEDICATION	DOSE	CONCENTRATION
37 mL	Acetaminophen <b>IV</b>	370 mg	1 gm/100 mL
0.8 mL *	Adenosine <b>IV fast 1<sup>st</sup></b>	2.5 mg	6 mg/2 mL
1.7 mL *	Adenosine <b>IV fast 2<sup>nd</sup>/3<sup>rd</sup></b>	5 mg	6 mg/2 mL
6 mL	Albuterol <b>Nebulized</b>	5 mg	2.5 mg/3 mL
2.5 mL <sup>◇</sup>	Amiodarone ( <b>VF/pulseless VT <sup>◇</sup></b> ) <b>IV/IO</b>	125 mg	150 mg/3 mL
5 mL	Atropine ( <b>Bradycardia</b> ) <b>IV/IO</b>	0.5 mg	1 mg/10 mL
1.3 mL *	Atropine ( <b>Organophosphate</b> ) <b>IV/IO</b>	0.5 mg	8 mg/20 mL
5 mL	Calcium Chloride <b>IV/IO</b>	500 mg	1 gm/10 mL
120 mL	Charcoal <b>PO</b>	25 gm	50 gm/240 mL
125 mL	Dextrose <b>10% IV</b>	12.5 gm	25 gm/250 mL
0.5 mL	Diphenhydramine <b>IV/IM</b>	25 mg	50 mg/1 mL
0.25 mL	Epinephrine <b>IM</b>	0.25 mg	<b>1:1,000</b> 1 mg/1 mL
2.5 mL	Epinephrine <b>IV/IO</b>	0.25 mg	<b>1:10,000</b> 1 mg/10 mL
1 mL	Epinephrine ( <b>Push-Dose</b> ) <b>IV slow/IO</b>	0.01 mg	<b>1:100,000</b> 0.1 mg/10 mL
5 mL	Epinephrine <b>Nebulized</b>	5 mg	<b>1:1,000</b> 1 mg/1 mL
0.7 mL	Fentanyl <b>IN</b>	35 mcg	100 mcg/2 mL
0.5 mL	Fentanyl <b>IV</b>	25 mcg	100 mcg/2 mL
1 mL	Glucagon <b>IM</b>	1 mg	1 unit (mg)/1 mL
2.5 mL	Ipratropium Bromide <b>Nebulized</b>	0.5 mg	0.5 mg/2.5 mL
6 mL	Levalbuterol <b>Nebulized</b> (≥6 – <12 years)	0.62 mg	0.31 mg/3 mL
1.3 mL *, <sup>◇</sup>	Lidocaine <b>2% IV slow/IO</b>	25 mg	100 mg/5 mL
1 mL	Midazolam <b>IN/IM</b>	5 mg	5 mg/1 mL
0.5 mL	Midazolam <b>IV slow</b>	2.5 mg	5 mg/1 mL
0.3 mL *	Morphine Sulfate <b>IV/IM</b>	2.5 mg	10 mg/1 mL
2 mL	Naloxone <b>IN/IM/IV</b>	2 mg	2 mg/2 mL
20 mL	Naloxone <b>IV titrated increments</b>	2 mg	Diluted to 1 mg/10 mL
500 mL	Normal Saline Fluid Bolus		Standard
2 mL	Ondansetron <b>IM/IV</b> (>3 years of age)	4 mg	4 mg/2 mL
1 tablet	Ondansetron <b>ODT</b> (>3 years of age)	4 mg	4 mg tablet
25 mL	Sodium Bicarbonate <b>IV</b>	25 mEq	50 mEq/50 mL

- To assure accuracy be sure the designated **concentration** of medication is used.
- \* Volume rounded for ease of administration
- ◇ Dosing for stable VT per BHPO

LBRT Color:

GREEN

Age Range:

10-12 years

Weight Range:

30-36 kg

Approximate kg:

35 kg

Approximate lbs:

70 lbs

NG tube size:

18 Fr

Defib: 1<sup>st</sup> 2<sup>nd</sup> 3<sup>rd</sup>  
 70 J 140 J 140 J  
 Cardiovert: 35 J 70 J 70 J

(or clinically equivalent biphasic energy dose)

Normal vital signs	HR: 60-100	RR: 15-20	SBP: >90 mmHg
--------------------	------------	-----------	---------------

VOL	MEDICATION	DOSE	CONCENTRATION
52 mL	Acetaminophen <b>IV</b>	520 mg	1 gm/100 mL
1.2 mL *	Adenosine <b>IV fast 1<sup>st</sup></b>	3.5 mg	6 mg/2 mL
2.3 mL *	Adenosine <b>IV fast 2<sup>nd</sup>/3<sup>rd</sup></b>	7 mg	6 mg/2 mL
6 mL	Albuterol <b>Nebulized</b>	5 mg	2.5 mg/3 mL
3 mL <sup>◇</sup>	Amiodarone ( <b>VF/pulseless VT <sup>◇</sup></b> ) <b>IV/IO</b>	150 mg	150 mg/3 mL
5 mL	Atropine ( <b>Bradycardia</b> ) <b>IV/IO</b>	0.5 mg	1 mg/10 mL
1.8 mL *	Atropine ( <b>Organophosphate</b> ) <b>IV/IO</b>	0.7 mg	8 mg/20 mL
5 mL <sup>‡</sup>	Calcium Chloride <b>IV/IO</b>	500 mg	1 gm/10 mL
170 mL *	Charcoal <b>PO</b>	35 gm	50 gm/240 mL
175 mL	Dextrose <b>10% IV</b>	17.5 gm	25 gm/250 mL
0.7 mL	Diphenhydramine <b>IV/IM</b>	35 mg	50 mg/1 mL
0.3 mL	Epinephrine <b>IM</b>	0.3 mg	<b>1:1,000</b> 1 mg/1 mL
3.5 mL	Epinephrine <b>IV/IO</b>	0.35 mg	<b>1:10,000</b> 1 mg/10 mL
1 mL	Epinephrine ( <b>Push-Dose</b> ) <b>IV slow/IO</b>	0.01 mg	<b>1:100,000</b> 0.1 mg/10 mL
5 mL	Epinephrine <b>Nebulized</b>	5 mg	<b>1:1,000</b> 1 mg/1 mL
1.0 mL	Fentanyl <b>IN</b>	50 mcg	100 mcg/2 mL
0.7 mL	Fentanyl <b>IV</b>	35 mcg	100 mcg/2 mL
1 mL	Glucagon <b>IM</b>	1 mg	1 unit (mg)/1 mL
2.5 mL	Ipratropium Bromide <b>Nebulized</b>	0.5 mg	0.5 mg/2.5 mL
6 mL	Levalbuterol <b>Nebulized</b> (≥6 – <12 years)	0.62 mg	0.31 mg/3 mL
6 mL	Levalbuterol <b>Nebulized</b> (≥12 years)	2.5 mg	1.25 mg/3 mL
1.8 mL <sup>*,◇</sup>	Lidocaine <b>2% IV slow/IO</b>	35 mg	100 mg/5 mL
1 mL	Midazolam <b>IN/IM</b>	5 mg	5 mg/1 mL
0.7 mL	Midazolam <b>IV slow</b>	3.5 mg	5 mg/1 mL
0.4 mL	Morphine Sulfate <b>IV/IM</b>	3.5 mg	10 mg/1 mL
2 mL	Naloxone <b>IN/IM/IV</b>	2 mg	2 mg/2 mL
20 mL	Naloxone <b>IV titrated increments</b>	2 mg	Diluted to 1 mg/10 mL
500 mL	Normal Saline Fluid Bolus		Standard
2 mL	Ondansetron <b>IM/IV</b> (>3 years of age)	4 mg	4 mg/2 mL
1 tablet	Ondansetron <b>ODT</b> (>3 years of age)	4 mg	4 mg tablet
35 mL	Sodium Bicarbonate <b>IV</b>	35 mEq	50 mEq/50 mL

- To assure accuracy be sure the designated **concentration** of medication is used.

\* Volume rounded for ease of administration

◇ Dosing for stable VT per BHPO

Length Exceeds LBRT

**TURQUOISE**

**Patients up to age 15 who are longer than the LBRT are treated with the following doses.  
 Use estimated weight in kilograms to calculate doses.**

Approximate kg: >36 kg Defib and cardioversion:  
 Approximate lbs: >70 lbs Energy dose per manufacturer's  
 guidelines  
 NG tube size: 18 Fr

Normal vital signs	HR: 60-100	RR: 15-20	SBP: >90 mmHg
--------------------	------------	-----------	---------------

VOL	MEDICATION	DOSE	CONCENTRATION
100 mL	Acetaminophen <b>IV</b>	1,000 mg	1 gm/100 mL
2 mL	Adenosine <b>IV fast 1<sup>st</sup></b>	6 mg	6 mg/2 mL
4 mL	Adenosine <b>IV fast 2<sup>nd</sup>/3<sup>rd</sup></b>	12 mg	6 mg/2 mL
6 mL	Albuterol <b>Nebulized</b>	5 mg	2.5 mg/3 mL
3 mL <sup>◇</sup>	Amiodarone ( <b>VF/Pulseless VT<sup>◇</sup></b> ) <b>IV/IO</b>	150 mg	150 mg/3 mL
5 mL	Atropine ( <b>Bradycardia</b> ) <b>IV/IO</b>	0.5 mg	1 mg/10 mL
5 mL	Atropine ( <b>Organophosphate</b> ) <b>IV/IO</b>	2 mg	8 mg/20 mL
5 mL	Calcium Chloride <b>IV/IO</b>	500 mg	1 gm/10 mL
240 mL	Charcoal <b>PO</b>	50 gm	50 gm/240 mL
250 mL	Dextrose <b>10% IV</b>	25 gm	25 gm/250 mL
1mL	Diphenhydramine <b>IV/IM</b>	50 mg	50 mg/1 mL
0.3 mL	Epinephrine <b>IM</b>	0.3 mg	1:1,000 1 mg/1 mL
10 mL	Epinephrine <b>IV/IO</b>	1 mg	<b>1:10,000</b> 1 mg/10 mL
1 mL	Epinephrine ( <b>Push-Dose</b> ) <b>IV slow/IO</b>	0.01 mg	<b>1:100,000</b> 0.1 mg/10 mL
5 mL	Epinephrine <b>Nebulized</b>	5 mg	<b>1:1,000</b> 1 mg/1 mL
1 mL	Fentanyl <b>IN</b>	50 mcg*	100 mcg/2 mL
2 mL	Fentanyl <b>IV</b>	100 mcg*	100 mcg/2 mL
1 mL	Glucagon <b>IM</b>	1 mg	1 unit (mg)/1 mL
2.5 mL	Ipratropium Bromide <b>Nebulized</b>	0.5 mg	0.5 mg/2.5 mL
6 mL	Levalbuterol <b>Nebulized</b>	2.5 mg	1.25 mg/3 mL
‡,◇	Lidocaine <b>2% IV slow/IO</b>	1 mg/kg‡	100 mg/5 mL
1 mL	Midazolam <b>IN/IM/IV</b>	5 mg	5 mg/1 mL
0.4 mL	Morphine Sulfate <b>IV/IM</b>	4 mg	10 mg/1 mL
2 mL	Naloxone <b>IN/IM/IV</b>	2 mg	2 mg/2 mL
20 mL	Naloxone <b>IV titrated increments</b>	2 mg	Diluted to 1 mg/10 mL
500 mL	Normal Saline Fluid Bolus		Standard
2 mL	Ondansetron <b>IM/IV</b>	4 mg	4 mg/2 mL
1 tablet	Ondansetron <b>ODT</b>	4 mg	4 mg tablet
	Sodium Bicarbonate <b>IV</b>	1 mEq/kg	50 mEq/50 mL

- To assure accuracy be sure the designated **concentration** of medication is used.
- Ketamine only for 15 years of age or older
- \* First dose of fentanyl up to 100 mcg IV or 50 mcg IN
- ‡ Administer 1 mg/kg (note this differs from 1.5 mg/kg in adults)
- ◇ Dosing for stable VT per BHPO